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general introduction and 
aim of the thesis
Based on ‘Clinical and pathophysiological aspects of narcolepsy’. 





Narcolepsy with cataplexy is a chronic sleep disorder caused by hypocretin deficiency, that 
affects approximately 25–50 per 100,000 people.1 The first symptoms usually appear from 
childhood to midlife with a large peak around 15 years of age and a smaller one around 36.2 
It has a profound effect on the quality of life3 that might exceed the burden of other serious 
chronic diseases like epilepsy.4 Narcolepsy is associated with reduced vigilance,5 severe 
fatigue,6 anxiety and mood disorders7 and a higher rate of car accidents.8-10 In addition the 
unemployment rate among patients is higher than in controls.11
SIgnS and SymptomS of narcolepSy
Excessive daytime sleepiness
The excessive daytime sleepiness (EDS) may come in various forms, with a continuous feeling 
of sleepiness at one end of the spectrum, and sudden involuntary and irresistible “sleep 
attacks” at the other. Narcolepsy patients often experience a combination of these. Daytime 
sleep episodes are brief, often < 20 min, and are typically reported to be refreshing. Although 
sleep episodes may occur several times a day, the total amount of sleep is not or only slightly 
increased over a 24-h period due to nocturnal sleep fragmentation.12
Nocturnal sleep disturbances
Fragmented nocturnal sleep is a major and common problem in narcolepsy. While patients 
fall asleep very quickly numerous awakenings may follow. These awakenings are usually short 
but can sometimes last for hours, forcing patients to get out of bed. Importantly, fragmented 
night-time sleep is not the cause of EDS; while improving nocturnal sleep may sometimes 
alleviate daytime sleepiness, EDS will never disappear.13
Cataplexy
The most specific symptom of narcolepsy is cataplexy, derived from the Greek word 
καταπλησσω meaning “to strike down”. Cataplexy is defined as a sudden bilateral loss of 
muscle tone with preserved consciousness, usually triggered by emotions. The combination 
of cataplexy and EDS is pathognomonic for narcolepsy. Cataplexy can be triggered by a 
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diversity of emotions. The most often reported triggers are laughter, hearing a joke, or 
feeling excited. Although most cataplectic attacks do have a trigger, 40% of the patients 
have experienced attacks without an identified trigger. Most cataplectic attacks are partial, 
resulting for example in sagging of the jaw with blurred speech or buckling of the knees. 
Partial attacks may evolve into a complete loss of skeletal muscle tone leading to a fall but, 
because of its gradual onset, patients can usually support themselves preventing injury.14
Hypnagogic hallucinations
Hypnagogic hallucinations are vivid dreamlike experiences that occur upon falling asleep. 
The auditory, visual, or tactile sensations are usually felt to be real, and are often bizarre 
and frightening. The perception of intruders, with people or animals standing over or lying 
under the bed is a common reported phenomenon.15
Sleep paralysis
Sleep paralysis is the inability to move at sleep onset or, more commonly, when awakening.16 
While the patient is awake, it is impossible for them to move their arms or legs or sometimes 
even open their eyes, and it can be extremely distressing, especially when occurring for the 
first time. It often occurs in combination with hypnagogic hallucinations. About half of the 
patients experience sleep paralysis. This phenomenon is much less common where it only 
affects 5% of the population.17
addItIonal SIgnS and SymptomS of narcolepSy
In addition of the above mentioned symptoms, there are various other features, frequently 
seen in narcolepsy patients. A few of them, most relevant for this thesis will be discussed.
Obesity
It has long been known that the majority of the narcolepsy patients tend to be overweight. 
This was usually attributed to inactivity due to EDS and received little attention. However, 
more recent epidemiological studies have clearly shown that overweight is a major symptom 
of narcolepsy.18-20 Obesity (body mass index [BMI] ≥ 30 kg/m2) occurs more than twice as 
often in patients with narcolepsy as among the general population. The cause of weight gain 
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in narcolepsy is unknown. Some patients complain about a tendency to binge eat, especially 
during waking periods at night. However, in a study using cross-checked dietary histories, it 
was shown that over a period of 24 h individuals with narcolepsy tended to consume fewer 
calories than controls, particularly carbohydrates.21;22 Patients with idiopathic hypersomnia 
have been shown to have a lower BMI than narcoleptics, indicating that inactivity due to 
EDS is not likely to account for the obesity.18 It seems possible that mechanisms such as a 
lowered metabolic rate underlie the increase in body weight seen in subjects with narcolepsy.
Temperature differences
Narcolepsy patients have an altered thermoregulatory profile with warmer hands and feet 
and lower proximal skin temperature than controls, a state in which sleep propensity is high.23 
Temperature manipulation studies offsetting these temperature changes show improvement 
in narcolepsy symptoms.24;25
Memory complaints
Many narcolepsy patients have memory complaints. Interestingly, when formally tested, they 
do not always show objective memory deficits.26;27 The reason for this is unclear; patients 
may, for example, be more vigilant in a testing situation than in everyday life. 
Delusional confusion of dreaming and reality 
Narcolepsy patients may report difficulty distinguishing between dreams and reality. 
However, although frequently heard in the consulting room, it is rarely mentioned in the 
literature. So far just a few case reports have described more severe examples of memory 
source confusion in patients suffering from narcolepsy, in which false accusations of sexual 
assault occurred when patients mistook a dreamed assault for the memory of an actual 
event.28;29
Endocrine alterations 
The most prominent hormonal disturbances in human narcolepsy were found in leptin, 
and the somatotropic axis. Serum concentrations of the adipocyte-derived hormone leptin 
were found to be significantly lower, and the daily fluctuations in leptin levels were absent 
in narcolepsy.30;31 However, others found normal leptin levels in a single sample study in a 
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larger group of narcolepsy patients.32;33 For the somatotropic axis, the circadian secretion 
of GH appears to be altered, so that a relatively large fraction of total production occurs 
during daytime in narcoleptics.34 In addition, 24-h thyrotropin (TSH) levels were reduced in 
narcolepsy patients. In contrast, thyroxin (T4) and triiodothyronin (T3) were normal, so the 
clinical relevance of these findings remains to be elucidated.35 A blunted total and basal 
adrenocorticotropic hormone (ACTH) production was found in narcolepsy patients whereas 
the pulsatile secretion was normal35 which seemed to indicate that hypocretins are involved 
in the basal but not pulsatile secretion of ACTH. The circadian rhythm of cortisol and ACTH 
was normal, showing that the circadian timekeeper is intact in narcolepsy. Finally, a role 
for hypocretin-1 in luteinizing hormone (LH) release was observed in rats.36 Accordingly, 
a decreased 24-h mean LH concentration and pulsatile secretion was found in human 
hypocretin deficiency.37 A high prevalence of precocious puberty is found in children with 
narcolepsy.38
Diabetes
In the sixties and eighties some reports have been published on a higher incidence of insulin 
resistance and type II diabetes mellitus (T2DM) in narcolepsy.39-41 Another study confirmed 
a higher risk of metabolic syndrome independent of BMI by comparing narcolepsy patients 
to idiopathic hypersomnia patients.22 However, in a recent study where a large group of 
patients were compared to healthy matched controls, no differences in insulin resistance 
were found by calculating pro-insulin to insulin ratio and using homeostatic model assessment 
method (HOMA).42 Unfortunately in the last study, patients were medicated. This might 
have influenced the results. Anticataplectic drugs e.g. imipramine may produce a significant 
increase of fasting blood glucose levels.43
pathophySIology of narcolepSy
Hypocretin deficiency 
The finding that hypocretin (orexin) knockout mice had symptoms of narcolepsy44 and the 
nearly simultaneous report that genetically narcoleptic canine narcolepsy was caused by a 
mutation in the Hypocretin-2 receptor45 led to the hypothesis that human narcolepsy might be 
due to a malfunction of the hypocretin system. This hypothesis was supported by the finding 
of greatly reduced levels of hypocretin in the cerebrospinal fluid of human narcoleptics.46 
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Two simultaneously published papers from different laboratories then reported a loss of 
hypocretin cells in brains of human narcolepsy patients.47;48 Peyron et al. also reported a 
single case of early onset narcolepsy associated with by a hypocretin mutation. Thannickal 
et al. reported elevated levels of gliosis in the hypothalamic region where hypocretin cells 
had been lost, consistent with the autoimmune hypothesis.48;49 Further work showed that the 
number of hypothalamic neurons containing dynorphin and Narp, both substances known 
to be localized to hypocretin cells, were reduced by 90% in narcoleptics with cataplexy.50;51 
This finding suggests that hypocretin cells are lost, rather than simply being unable to 
produce hypocretin.  
Autoimmune hypothesis
Several lines of evidence point to an autoimmune origin for most cases of human narcolepsy. 
Honda discovered that nearly all Japanese narcoleptics had an HLA type (DR2, in the then 
standard terminology), whereas only 20–30% of the non-narcoleptic population had this 
haplotype.52 Since the HLA molecules function to present antigen to the immune system, 
this finding suggested that the immune system was involved in the genesis of narcolepsy. A 
narcolepsy linkage to HLA-DQA1*01:02 and -DQB1*06:02 was demonstrated.53 An association 
was demonstrated between narcolepsy and polymorphisms in the T-cell receptor alpha locus 
in a genome-wide association study.54 Further evidence for the autoimmune hypothesis 
includes the initially disputed report that streptococcal antibodies were often elevated 
in narcoleptics,55;56 with Montplaisir et al.’s initial observations recently replicated.57 An 
anecdotal report of rapid onset of narcolepsy with cataplexy after an anaphylactic reaction 
to an insect bite58 further supports this hypothesis. Additionally, the discovery of circulating 
TRIB2-specific antibodies reactive to hypocretin neurons in individuals with narcolepsy,59-61 
strongly suggest an autoimmune nature. Although this is a major breakthrough in narcolepsy 
research, the role of TRIB2 antibodies remains unclear and there is no direct proof that 
these antibodies actually damage hypocretin neurons.62 Recent reports of an association 
of narcolepsy onset with immunization for the H1N1 flu63 or H1N1 flu infection64 supports 
the autoimmune hypothesis as well, although some of this evidence is disputed.65 The 
latest paper demonstrates CD 4 T cell involvement and seemed to get closer to prove the 
autoimmune hypothesis.66 Unfortunately the paper got retracted because the results could 
not get replicated. Although there are very strong indications for an autoimmune cause of 
narcolepsy, the exact mechanism of disease onset remains to be elucidated. 
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treatment of narcolepSy
Every narcolepsy patient should be advised to live a regular life, trying to have similar 
bedtimes every day. Scheduled naps can alleviate sleepiness for a while, and may be advised.67 
Likewise, a short nap before demanding activities may be helpful. However, in the majority 
of patients, pharmacological treatment is necessary.15;68 In practice, it is recommended to 
start treating the most disabling symptom first, and to tailor drug schedules and dosages 
individually. Combination therapy is often necessary.68 It must be emphasized that drug 
therapy is purely symptomatic. While cataplectic attacks can often be completely abolished, 
EDS will never completely disappear. Drugs to treat narcolepsy are usually divided into 
two groups; stimulant drugs to treat EDS and anti-cataplectic drugs that also tackle dream 
related symptoms.
Stimulants
Examples of wake promoting agents are amphetamines, and amphetamine like drugs e.g. 
methylphenidate. The mode of action of these drugs is complex, but the central mechanism 
entails the enhancement of the release of catecholamines (dopamine and noradrenaline) 
as well as uptake inhibition.69;70 A frequently prescribed non-amphetamine like substance is 
modafinil. Its mode of action is still a matter of debate. Several studies indicate that modafinil, 
like other stimulants, inhibits the reuptake of dopamine (DA) via the DA transporter (DAT).71 
However in vitro studies show that modafinil binds to the DAT with lower affinity than 
methylphenidate and other psychostimulants drugs.71 Recent research identified several 
non-dopaminergic effects of modafinil, such as the increase of electrical neuronal coupling, 
or the enhancement of histamine and orexin neurotransmission that might be of primary 
importance to explain its efficacy as a wake-promoting and cognitive-enhancing medication.71
Anticataplectic drugs
In general, the amelioration of cataplexy is associated with a reduction of hypnagogic 
hallucinations and sleep paralysis. Tricyclic antidepressants are among the most effective 
agents, often in even very low doses.68 Those most commonly used include imipramine, and 
clomipramine. In contrast to the tricyclics, SSRIs usually require a relatively high-dose, which 
can sometimes negate their more favorable side-effect profile. Venlafaxine, a noradrenalin/
serotonin reuptake inhibitor, might have some beneficial effect on cataplexy too, although 
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publications on its efficacy are scarce. Acute withdrawal from antidepressants may severely 
aggravate cataplexy, sometimes leading to a status cataplecticus (sequential cataplexy attacks 
that may last for hours or even longer).
Sodium oxybate
A more recently approved compound to treat narcolepsy is sodium oxybate (SXB,γ-
hydroxybutyrate; GHB). SXB is a hypnotic and is taken twice a night (at bedtime, and a second 
dose 3–4 hours later). Interestingly, despite the short half-life of the drug and its nighttime 
administration, the effects on daytime cataplexy are already obvious when using low dosages 
(3–6 gr/night).72 Additional studies show that the use of higher doses of SXB (up to 9 gr/
night) has additional positive effects on the excessive daytime sleepiness, and the quality of 
nocturnal sleep.73 Moreover SXB may reduce weight, a side effect that could be beneficial 
to an overweight patient.74 GHB occurs naturally in the brain, but its mechanism of action 
in narcolepsy is not precisely known. In healthy subjects, it was shown that administration 
of SXB has a slow wave sleep (SWS) promoting effects associated with an increase in GH 
secretion.75 Its effects are thought to be mediated through γ-aminobutyric acid B receptor 
(GABAB) and has an impact on dopamine and serotonin release.76;77 The existence of a 
specific GHB receptor is still under debate. 
aIm of the theSIS
The first part of the thesis consists of a number of endocrine studies in hypocretin deficient 
male narcolepsy with cataplexy patients. Hypocretins are, besides their crucial function in the 
regulation of the sleep-wake cycle, involved in food intake, glucose sensing and homeostasis, 
and in virtually all endocrine axes.78 Accordingly metabolic and hormonal disturbances are 
increasingly recognized as important features of narcolepsy.22;30;35;37;38 Therefore, it may be 
very important to find treatment options that also deal with these aspects. SXB may very 
well be a suitable candidate, as the drug activates dopaminergic circuits in the brain where 
diminished dopamine (D2) receptor mediated signal transduction appears to induce insulin 
resistance, the metabolic syndrome and diabetes mellitus type 2.79 If SXB is indeed able to 
reduce insulin resistance, it may also have an important impact on metabolic disturbances 
in obese patients without narcolepsy. In addition, more and more evidence suggests 
that GHRH, the hypothalamic hormone controlling the release of GH, simultaneously 
promotes the occurrence of non-REM sleep as well as GH release.80 On the basis of these 
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data, it has been hypothesized that SXB may act by stimulating the GHRH secretion in 
the central nervous system and thereby promoting SWS and the release of GH.75 When 
administered during nocturnal sleep in narcoleptics, it may again confine GHRH secretion 
to the night and decrease possible sleep inducing effects of GHRH as a consequence of 
daytime release.
Part I Endocrine studies in narcolepsy
The objective is to investigate whether the secretion of Prolactin (PRL) (chapter 2), Growth 
Hormone (GH) (chapter 3), Leptin and Ghrelin (chapter 4), and Melatonin (chapter 5) is altered 
in narcolepsy patients compared with individually matched healthy controls. In addition, the 
effect of short term administration of SXB on the aforementioned substances is described. 
Earlier reports on PRL secretion in narcolepsy patients have been inconclusive, showing 
either increased, decreased or normal levels.81-83 Discrepancies seemed to be due to 
methodological issues. The major physiological regulator of PRL release is dopamine.84 
Alterations in the dopaminergic system in the post-mortem brains of narcoleptics have 
been described making changes in PRL release in narcolepsy conceivable.85 Although the 
exact mode of action is still unclear, SXB acts on gamma-aminobutyric acid type B (GABAB) 
and has an impact on dopamine and serotonin release.77 Therefore, SXB treatment may be 
expected to alter PRL secretion. We hypothesised that changes in hypothalamic hypocretin 
signaling in narcoleptic patients may give rise to altered PRL secretion. In addition, we aimed 
to determine the effect of SXB administration on PRL secretion and sleep, both in a healthy 
and in a hypocretin-deficient state.
In healthy subjects, there is a clear association between GH secretion and SWS. This is 
especially clear in young males, in which the majority of 24-h GH is secreted during the first 
period of SWS at night.75 It has been shown previously that GH secretion was less strictly 
confined to the night in narcolepsy patients.34 As the relation between SWS and GH secretion 
was preserved, it was suggested that a shift of SWS episodes to the day was paralleled by a 
daytime shift of GH secretion. In contrast to other hypnotics, SXB is one of the few compounds 
that increases rather than decreases SWS. This led to the hypothesis that it may also act as 
a GH secretagogue. Indeed, it has been shown that single-dose SXB administration leads to 
an increase in GH secretion in healthy young men, paralleled by an increase in SWS.75 Here 
we explore whether SXB administration leads to an increase in nocturnal GH secretion in 
both patients and controls, paralleled by an increase in SWS. 
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Leptin and ghrelin are both strong regulators of energy homeostasis, and their relationship 
with hypocretin has been shown to be of importance. Receptors for leptin are found on 
hypocretin cells,86 and leptin can directly inhibit the expression of isolated hypocretin 
neurons.87 Indirectly, leptin can affect the activity of hypocretin cells via energy-regulating 
neurons in the arcuate nucleus of the hypothalamus.88 Ghrelin is an important endogenous 
regulator of energy balance and it excites hypocretin neurons. An interaction between 
these two systems has been shown to be involved in ingestive behavior.87 Its expression is 
complex89 and influenced by sympathetic nervous system activity.90 Across the wake period, 
plasma concentrations wax and wane episodically, providing an appetite-stimulating signal 
to the brain.91 Hypocretin neurons directly sense ghrelin and leptin but it is unknown if these 
connections are uni-or-bidirectional.92 Therefore a study of hypocretin deficient narcolepsy 
patients provides a unique opportunity to explore the nature of these relationships. In 
addition we hypothesized that SXB administration would alter total ghrelin levels, which 
might be involved in its GH-promoting effects.
Melatonin is a modulator of sleep and high levels induce sleepiness.93 Animal models indicate 
that the hypocretinergic innervation of the pineal gland could be important for the regulation 
of diurnal melatonin synthesis and secretion.94 It is therefore conceivable that melatonin 
secretion is hampered in narcolepsy. Here we describe a study in which hourly melatonin 
levels are compared between narcolepsy patients and controls.
Part II Metabolic studies in narcolepsy
Hypocretins have a major role in glucose sensing and homeostasis78 and therefore it is 
conceivable that hypocretin deficiency may lead to problems in glucose regulation and 
diabetes. Conflicting reports on the risk of diabetes in narcolepsy have been published. 
Several studies reported a higher prevalence of type 2 diabetes in narcolepsy.22;39;41;95 More 
recent studies reported no difference in diabetes prevalence between narcolepsy patients and 
matched controls.42;96 In chapter 6 we describe the first study to compare insulin sensitivity in 
nine narcolepsy with cataplexy patients compared with matched healthy controls, measured 
with the gold standard, the hyperinsulinemic euglycemic clamp technique. In addition, the 
effect of long term sodium oxybate treatment on insulin sensitivity is evaluated.
Sleep onset is preceded by an increase in skin temperature and a decline in core body 
temperature.97 An altered thermoregulatory profile, resembling this sleep promoting pattern, 
has been observed in narcolepsy patients.23 SXB is the sodium salt of GHB and may have 
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a positive effect on the sleep disturbances in narcolepsy.73 The effect of both compounds 
are the same but the exact mechanisms are still unclear.98 Altered thermoregulation is one 
of the effects of GHB described in animal studies and human case reports. Rodent studies 
demonstrate a slight increase in core body temperature after administration of a low dose 
of GHB and a clear decrease in core body temperature in higher doses.99 In addition several 
studies describe hypothermia in humans with GHB intoxication.100;101 Given the impact of 
GHB on temperature regulation, the altered pattern of skin temperature in narcolepsy and 
the positive effects of SXB on sleep in narcolepsy patients, the treatment effect of SXB may 
be, at least in part, mediated by restoring the physiological temperature regulation. Chapter 
7 aims to determine the effect of short term Sodium Oxybate administration on the 24-hour 
temperature and sleep-wake profile in narcolepsy patients and controls.
Part III Other aspects of narcolepsy
Hypnagogic hallucinations are frequently described dream related experiences in narcolepsy. 
Confusions between dreams and reality are an often heard issue in narcolepsy, however so 
far no systematic studies have been published about these confusions. Here we describe an 
explorative study on delusional confusion of dreaming and reality in narcolepsy (chapter 8). 
There are strong indications for an autoimmune cause of narcolepsy but there is no definite 
proof yet. One way to demonstrate an autoimmune cause involves studying the distribution 
of births over the months of the year. Several studies have addressed seasonal birth patterns 
in narcolepsy, suggesting an autoimmune involvement. Analysis methods in published studies 
varied, but no study corrected completely for possible changes in seasonal birth pattern over 
time in the appropriate control population. Therefore we describe the distribution of births 
over the months of the year of 307 narcolepsy patients compared to the general population 
in The Netherlands taking geographical and temporal criteria fully into account (chapter 9).
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Objective: Hypocretin deficiency causes narcolepsy and may affect neuroendocrine 
systems, including TSH, ACTH and LH secretion. Symptoms can be treated effectively 
with sodium oxybate (SXB) in many patients. This study was performed to compare 
prolactin (PRL) secretion in patients and matched controls and establish the effect of 
SXB administration on PRL and sleep in both the groups.
Design: Open label intervention. Blood was sampled before and after 5 days of SXB 
treatment. The study was performed at the Leiden University Medical Centre, Leiden, 
The Netherlands.
Methods: Subjects were admitted to the clinical research centre on both occasions.
Patients or participants: Eight male hypocretin-deficient narcolepsy with cataplexy 
patients and eight controls matched for sex, age, body mass index, waist-to-hip ratio 
and fat percentage were enrolled.
Interventions: SXB two times 3 g per night for five consecutive nights.
results: Patients and controls underwent 24 h blood sampling at 10 min intervals for 
measurement of PRL concentrations. The PRL concentration time series was analysed 
with a new deconvolution programme, approximate entropy (ApEn) and Cosinor analysis. 
Sleep was polygraphically recorded. Basal and pulsatile PRL secretion, as well as pulse 
regularity and frequency, ApEn and diurnal parameters were similar in patients and 
controls. SXB treatment caused similar nocturnal increase in PRL secretion, advance 
of the acrophase and decrease in ApEn in patients and controls. Slow wave sleep was 
increased to a similar extent in patients and controls.
conclusion: This detailed study did not demonstrate altered PRL secretion in hypocretin-
deficient narcolepsy patients during the basal state or during SXB administration. 
Therefore, hypocretin signalling is unlikely to be a regulator of the lactotrophic system.
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IntrODuctIOn
Narcolepsy is a debilitating disorder characterised by excessive daytime sleepiness (EDS), 
cataplexy, hypnagogic hallucinations, sleep paralysis and nocturnal sleep disturbances.102 In 
recent years, obesity and hormonal alterations have been recognised as additional features of 
the narcoleptic syndrome.35 Interest in energy homeostasis in narcolepsy increased after the 
discovery of hypocretin deficiency as the cause of this disorder since hypocretins (orexins) are 
known to influence feeding behaviour, wakefulness and energy expenditure.46-48;103 Hypocretins 
are also involved in the control of the secretion of various hormones.104-108 Prolactin (PRL) is 
a polypeptide hormone, which is primarily produced in the anterior pituitary gland.109 Apart 
from its role in lactation and reproduction, PRL also takes part in the regulation of body energy 
homeostasis.109;110 Prolonged hyperprolactinaemia is often accompanied by weight gain in 
humans, which can be ameliorated by normalisation of serum PRL.110 The major physiological 
regulator of PRL release is dopamine from tubero-infundibular origin. Hypothalamic dopamine 
inhibits the basally high secretory tone of pituitary lactotrophs by binding to D2 receptors 
expressed in their cell membranes.84;111 Hence, alterations in the dopaminergic system, as 
described previously in the post-mortem brains of narcoleptic humans, may cause changes in 
PRL secretion.85 However, earlier reports on PRL secretion in narcolepsy patients have been 
inconclusive, showing either increased, decreased or normal levels.35;81-83 These discrepancies are 
likely due to the use of only few baseline measurements of hormone levels, small sample size, 
relatively poor matching or too long blood sampling intervals, which are not adequate to assess 
either the pulsatile nature of PRL secretion or its total daily production rate. Sodium oxybate 
(SXB) or gamma-hydroxybutyrate (GHB) is effective in the treatment of narcolepsy. It reduces 
cataplexy, improves nocturnal sleep quality and higher doses of SXB may also reduce EDS.73 
Although the exact mode of action is still unclear, SXB acts on gamma-aminobutyric acid type B 
(GABAB) and has an impact on dopamine and serotonin release.
77;112 Therefore, SXB treatment 
may be expected to alter PRL secretion. Indeed, there are reports that SXB administration may 
increase PRL secretion.75;113 Several reports have been published on PRL and sleep; however, 
the precise association between PRL release and sleep still remains to be elucidated.75;113-117 
We hypothesised that changes in hypothalamic hypocretin signalling in narcoleptic patients 
may give rise to altered PRL secretion. In addition, we aimed to determine the effect of SXB 
administration on PRL secretion and sleep, both in a healthy and in a hypocretin-deficient state. 
Therefore, using a combination of polysomnography and state-of-the-art endocrine techniques, 
we compared PRL secretion between hypocretin-deficient narcoleptic subjects and matched 





Eight male narcolepsy patients with definite cataplexy were included, who fulfilled the 
diagnostic criteria of the 2nd edition of the International Classification for Sleep Disorders.118 
All narcolepsy patients were hypocretin-1 deficient and free of medication for at least 2 
weeks before the study. Only one of the patients received prolonged SXB administration in 
advance. He did stop taking SXB 20 days prior to the study. One patient took SXB in the past 
for a short period of time and took stimulants on demand. Another patient was tapered 
off antidepressants. Five patients were not taking any drugs at the time of enrolment. All 
consecutive male patients eligible for the study were asked to participate. Eight healthy 
controls, matched for sex, age, body mass index (BMI), waist-to-hip ratio (WHR) and fat 
percentage, were included for comparison. Bioelectrical impedance analysis (Bodystat, 
Douglas, Isle of Man, UK) was used to estimate fat percentage. Subjects were eligible 
for study after exclusion of hypertension, any known history of pituitary, psychiatric or 
neurological disease (other than narcolepsy), alcohol or drug abuse, recent weight change 
(>3 kg weight change within the last 3 months), a sleep disorder history assessed through 
clinical interview (controls) and endurance sports. Routine laboratory tests were performed 
to rule out diabetes (fasting plasma glucose >6.9 mmol/l), anaemia, as well as hepatic and 
renal failure. The study was performed at Leiden University Medical Centre, Leiden, The 
Netherlands. The study was approved by the ethics committee of the Leiden University 
Medical Centre. Written informed consent was obtained from all subjects.
Protocol
Subjects were admitted to the Clinical Research Centre for 24 h blood sampling. A cannula 
was inserted into the antecubital vein 45 min before the start of blood sampling at 1200 h. 
Blood samples were collected with S-monovetten (Sarstedt, Etten-Leur, The Netherlands) 
from a three-way stopcock attached to a 0.9% NaCl and heparin (1 U/ml) infusion (750 ml/24 
h) to keep the cannula from clotting. Sampling was performed through a long line to prevent 
sleep disruption by investigative manipulations. For PRL measurements, blood was collected 
in serum tubes at 10 min intervals. After clotting, the blood was centrifuged within 30 min of 
sampling (1250 g at 4 °C for 20 min). Subsequently, plasma was divided into separate aliquots 
in Sarstedt tubes and stored at K80 °C until assay. Three standardised meals were served at 
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0830, 1300 and 1800 h (Nutridrink, Nutricia, Zoetermeer, The Netherlands; 1.5 kcal/ml, 2100 
kcal/day; macronutrient composition per 100 ml: protein, 6 g; fat, 5.8 g; carbohydrate, 18.4 
g). Subjects remained (semi)supine except for bathroom visits. Daytime naps were allowed. 
Lights were switched off at 2300 h and turned on at 0730 h the next day. Twenty-four hour 
sampling was performed at baseline and on the 5th day of SXB administration in two night-
time doses of 3 g at 2300 h and 0300 h. This starting dose, higher than the usual of 2.25 g, 
permitted to elicit some effect in a few days of administration. To monitor side effects, the 
first night of administration was done clinically.
sleep analysis
Sleep was polygraphically recorded throughout both sampling occasions, using an Embletta 
X100 recorder (Embla, Broomfield, CO, USA). The recordings were scored visually by an 
experienced sleep technician at 30 s intervals according to the AASM criteria.119 To allow 
assessment of the association between changes in serum PRL levels (measured every 10 
min) and sleep stages (scored every 30 s), sleep profiles were divided into 10 min segments, 
separating consecutive PRL measurements as described previously.120 These segments were 
condensed from the 30 s scoring intervals by calculating the percentage of time spent in 
stages I and II non-rapid eye movement (REM) sleep, slow wave sleep (SWS) and REM sleep.
Assays
Serum PRL concentrations were measured with a sensitive time-resolved immunofluorometric 
assay with a detection limit of 0.04 µg/l (Delfia, Wallac Oy, Turku, Finland). The assay was 
calibrated against the 3rd WHO standard 84/500, 1 ng/mlZ36 mU/l. The intra-assay coefficient 
of variation varied from 3.0 to 5.2%, while the inter-assay coefficient of variation was between 
3.4 and 6.2% (in the 0.1–250 µg/l concentration range). In order to minimise inter-assay 
variability, samples from each patient and matched control were analysed in the same run. 
Calculations and statistics
Deconvolution analysis
PRL concentration time series were analysed using a recently developed automated 
deconvolution method, which was mathematically verified by direct statistical proof and 
empirically validated using hypothalamopituitary sampling and simulated pulsatile time 
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series.121 For PRL, the fast half-life was represented as 3.5 min constituting 37% of the decay 
amplitude and the slow half-life was represented as an unknown variable between 20 and 50 
min.122;123 All candidate pulse-time sets were deconvolved. Statistical model selection was then 
performed to distinguish among the independently framed fits of the multiple candidate pulse-
time sets using the Akaike information criterion.124 The parameters (and units) are frequency 
(number of bursts per total sampling period, l of the Weibull distribution), regularity of inter-
pulse intervals (unitless g of Weibull), slow half-life (min), basal and pulsatile secretion rates 
(concentration units/session), mass secreted per burst (concentration units) and wave form 
shape (mode or time delay to maximal secretion after objectively estimated burst onset, min). 
Approximate entropy
Approximate entropy (ApEn) (1, 20%), was used as a scale- and model-independent regularity 
statistic to quantify the orderliness (regularity) of PRL release. Higher ApEn denotes greater 
disorderliness (irregularity) of the secretion process. Mathematical models and clinical 
experiments have established that greater irregularity signifies decreased feedback control 
with high sensitivity and specificity (both >90%).125
Diurnal variation
The wave form of individual PRL profiles was quantified by a best-fit curve obtained using 
a locally weighted regression procedure with a regression window of 4 h and a Gaussian 
kernel.126 The values (and timings) of the acrophase and the nadir were defined as the 
levels (the timings) corresponding to the maximum and the minimum of the best-fit curve 
respectively. The amplitude was defined as 50% of the difference between the acrophase 
and the nadir values. 
Statistical analysis
Data are presented as mean ± SEM, unless otherwise specified. Statistical comparisons were 
made with either Student’s t-test or repeated measures ANOVA when appropriate. Pearson’s 
correlation coefficient was applied to assess all correlations. Cross-correlation analysis was 
applied to assess the association between PRL levels and the percentage of time spent in 
various sleep stages in the preceding 10 min sampling interval, taking into account all of 
the sampling intervals during sleep.127 Statistical calculations were performed using Systat 
software (version 11, Systat Software, Inc., San Jose, CA, USA) and SPSS (release 17.0, SPSS, 
Inc., Chicago, IL, USA). All tests were two-tailed and significance level was set at 0.05.
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results
Narcoleptic patients and controls did not differ with respect to gender (male), age (38.0 ± 4.7 
vs 37.9 ± 4.1, P = 0.984 respectively), BMI (28.1 ± 1.6 vs 27.4 ± 1.4, P = 0.742), fat percentage 
(23.6 ± 2.1 vs 23.4 ± 1.7, P = 0.946) and WHR (0.92 ± 0.03 vs 0.90 ± 0.02, P = 0.579). As 
expected, in narcolepsy patients the mean BMI was in the overweight range. Ingestion of 
SXB was well tolerated and apart from mild drowsiness no other side effects were reported. 
The mean 24 h PRL concentration in narcolepsy patients was 5.13 ± 0.47 µg/l at baseline 
and 5.65 ± 0.52 µg/l during the SXB administration (P < 0.001, see Figure 2.1). In controls, it 
was 6.78 ± 1.68 and 7.40 ± 1.66 µg/l respectively (P < 0.001). The PRL concentration strongly 
increased shortly after the administration of each dose of SXB. In patients, an increase from 
4.56 ± 0.26 to 12.08 ± 1.61 µg/l occurred (P < 0.001), and in controls PRL increased from 6.28 
± 1.72 to 14.07 ± 2.85 µg/l (P < 0.001) during the first SXB administration. After the second 
Figure 2.1 Mean 24 h plasma prolactin concentration ± SEM, before and after the SXB administration 
in narcolepsy patients (n = 8) and controls (n = 8). The downward arrows indicate ingestion of SXB 
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dose, serum PRL increased from 5.12 ± 0.36 to 12.26 ± 2.74 µg/l in patients (P < 0.001) 
and from 7.28 ± 1.94 to 13.82 ± 1.86 µg/l in controls. The effect of SXB was not statistically 
different between patients and controls.
Deconvolution analysis
At baseline, there were no significant differences in basal, total or pulsatile PRL secretion 
between narcolepsy patients and controls (Table 2.1). However, there was a clearly stimulatory 
effect of SXB on PRL secretion. Basal secretion increased slightly after SXB administration, 
whereas total PRL secretion increased with 20% in patients and nearly 25% in controls, most likely 
resulting from an increase of more than 60% in mean pulse mass in both the groups (Table 2.1). 
Diurnal variation
The acrophase of serum PRL concentrations shifted after SXB administration to 1.5 h earlier 
in controls and 3 h earlier in narcolepsy patients (Table 2.2). Similarly, the nadir advanced 
in both the groups after the SXB administration. The amplitude increased significantly in 
both the groups indicating a greater degree of diurnal variation in PRL secretion after SXB 
treatment. Intergroup differences as well as group x treatment interaction effects were not 
significant, indicating a similar effect of SXB on both narcolepsy and control subjects.
Approximate entropy
The ApEn values decreased in both the groups after the SXB administration, reflecting greater 
regularity of PRL release. There were no differences in baseline ApEn values nor was the 
group x treatment interaction effect significant (Figure 2.2). 
table 2.2 Diurnal variation in prolactin concentrations
Baseline SXB
Treatment effect
(P)Controls Patients Controls Patients
Acrophase 5:05 ± 51 5:45 ± 84 3:37 ± 43 2:34 ± 44 0.01*
Nadir 15:53 ± 48 14:06 ± 38 13:19 ± 47 13:33 ± 42 0.02*
Amplitude (μg/L) 2.19 ± 0.17 2.08 ± 0.30 3.35 ± 0.47 2.71 ± 0.49 0.015*
Data are shown as mean clock time ± SEM in minutes. Statistical comparisons were performed with ANOVA for 




On average, compared with controls, narcolepsy patients spent significantly less time awake 
both during basal conditions and SXB treatment (Table 2.3). During the day (defined as the 
lights on period between 0730 and 2300 h), narcolepsy patients spent significantly less time 
awake, while significantly more time was spent in non-REM sleep, regardless of treatment 
(Table 2.3). The SXB administration resulted in a significant decrease in stages I and II non-
REM and REM sleep over 24 h in both the groups (P = 0.011 and 0.009 respectively), while 
it significantly increased the time spent in SWS (P = 0.001). During the day, SXB treatment 
reduced the time spent in stages I and II non-REM and REM sleep (P = 0.038 and 0.041 
respectively), while it tended to increase wakefulness (P = 0.098). The percentage of SWS 
during the night more than doubled in both the groups in response to SXB treatment 
(narcolepsy: 6.5 ± 1.9 vs 16.5 ± 3.0%; controls: 7.1 ± 1.9 vs 18.5 ± 2.4%; P = 0.001 for treatment 
effect), whereas there were trends for decreases in the percentages of stages I and II non-
REM and REM sleep. The cross-correlation between SWS and PRL release strongly increased 
after SXB treatment in both narcolepsy patients (-0.03 ± 0.03 vs 0.47 ± 0.12) and controls 
(0.09 ± 0.06 vs 0.50 ± 0.07), P ≤ 0.001 for treatment effect (Figure 2.3). However, the SXB 
administration did not significantly affect the cross-correlation between PRL release and 
REM sleep in either narcolepsy patients (0.12 ± 0.05 vs 0.04 ± 0.03) or controls (0.22 ± 0.04 
vs 0.10 ± 0.07), P = 0.070 for treatment effect. Similarly, the cross-correlation between PRL 
Figure 2.2 Approximate entropy of serum prolactin concentration series in patients and controls 
before (left column) and during the SXB (right column) administration. The horizontal black bar 
indicates the mean.
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table 2.3 Sleep patterns before and after sodium oxybate administration
Baseline Sodium oxybate
Patients Controls P Patients Controls P
Wake total (%) 60.8 ± 2.9 68.7 ± 2.0 0.044* 60.8 ± 2.2 70.1 ± 2.4 0.013*
Wake day (%) 79.4 ± 4.2 95.6 ± 2.1 0.004* 82.9 ± 3.2 97.3 ± 1.0 0.001*
Wake night (%) 25.8 ± 5.7 18.4 ± 4.0 0.310 19.2 ± 4.3 19.2 ± 5.8 0.999
Stage I/II total (%) 29.1 ± 1.4 25.0 ± 2.4 0.155 26.3 ± 1.4 21.1 ± 2.2 0.063
Stage I/II day (%) 14.6 ± 3.0 2.5 ± 1.6 0.003* 11.1 ± 2.5 1.6 ± 1.0 0.005*
Stage I/II night (%) 55.1 ± 2.5 65.6 ± 5.7 0.114 53.5 ± 3.7 56.4 ± 5.3 0.647
SWS total (%) 3.7 ± 0.7 2.5 ± 0.7 0.239 7.6 ± 1.2 6.6 ± 0.9 0.534
SWS day (%) 2.1 ± 0.6 0.03 ± 0.03 0.005* 2.7 ± 1.1 0.05 ± 0.05 0.041*
SWS night (%) 6.5 ± 1.9 7.1 ± 1.9 0.843 16.5 ± 3.0 18.5 ± 2.4 0.611
REM total (%) 6.3 ± 1.8 3.7 ± 0.8 0.191 4.7 ± 1.0 2.1 ± 0.8 0.070
REM day (%) 2.9 ± 1.4 0.8 ± 0.5 0.203 1.2 ± 0.5 0.0 ± 0.0 0.032*
REM night (%) 12.6 ± 3.0 8.8 ± 1.8 0.305 10.8 ± 2.1 5.8 ± 2.3 0.127
Data are shown as mean ± SEM. The data are presented as percentages of sleep stages during the 24 h of study, 
before and after the SXB administration. Unpaired t-tests were used to assess the differences between the two 
groups. *P < 0.05.
Figure 2.3 Cross-correlation coefficients between PRL levels and SWS. Sodium oxybate administration 
resulted in a substantial increase in the coupling between PRL release and SWS as evidenced by a 
significant increase in the cross-correlation (P < 0.001 for treatment effect).
secretion and the percentage of time spent in stages I and II non-REM sleep did not change 
after SXB treatment (0.10 ± 0.09 vs 0.19 ± 0.07 in narcolepsy patients and 0.47 ± 0.06 vs 




This is the first study in which advanced endocrinological modelling has been applied to 
accurately assess the secretory dynamics of PRL secretion and its response to SXB challenge in 
narcolepsy patients. As PRL secretion dynamics was similar in hypocretin-deficient narcolepsy 
patients and healthy controls, our findings indicate that hypocretin is unlikely to be a major 
physiological regulator of PRL secretion. We showed that the SXB administration markedly 
increased PRL secretion and that it enhanced the association between PRL release and SWS. 
As SXB is known to modulate dopamine release, the major regulator of PRL secretion, these 
findings suggest that changes in the tubero-infundibular dopaminergic output could underlie 
the effect of SXB on PRL release. These effects of SXB are unlikely to involve the hypocretin 
system, since SXB treatment-stimulated PRL release did not significantly differ between 
narcolepsy patients and controls. PRL secretion is under inhibitory control of dopamine 
released from the tubero-infundibular dopaminergic neurons (TIDA).109 Other inhibitors of 
PRL release include somatostatin and neuropeptide Y (NPY), while TRH, serotonin, oestrogen, 
oxytocin, as well as stress and light stimulate PRL secretion.109 GABA has a dual effect on 
PRL secretion: by inhibiting TIDA neurons it stimulates PRL secretion whereas it inhibits PRL 
release via a non-dopaminergic pathway.109 The effect of hypocretins on PRL release is still 
subject to debate. A study in male rats showed that i.c.v. administration of hypocretin-1 
(orexin A) reduces plasma PRL through a pathway that appears to be partly independent 
of the dopaminergic system.108 Fasting upregulates hypocretin-1 and NPY, which in turn 
stimulates TIDA neuronal activity and inhibits PRL secretion.128 This effect of hypocretin-1 
on dopamine, however, seems to be indirect and mediated through NPY.78 As we found no 
indications for altered PRL secretion in a hypocretin-deficient state, our findings do not 
support a role of hypocretin in the regulation of PRL secretion. Conversely, our data also 
do not provide evidence for the possibility that disrupted PRL release contributes to sleep 
disturbance in narcolepsy.
In contrast to earlier reports in the late seventies we did not find any evidence for decreased 
PRL secretion in narcolepsy patients.82;83 This discrepancy is likely due to the application 
of suboptimal analytical techniques in previous studies. Moreover, it is important to note 
in this context, that, for obvious reasons, hypocretin deficiency was not established in 
patients included in these early studies. A more recent study reported elevated levels of 
PRL in 13 narcolepsy patients (7 with typical cataplexy) compared with controls. However, 
in this study, which included predominantly women, the groups were not matched for 
BMI, and PRL levels were measured only on a single time point.81 As PRL secretion exhibits 
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a marked circadian variation, is more variable in women, and is positively associated with 
body weight, differences in these factors may have been responsible for the differences in 
PRL levels between narcoleptics and controls in this study.109 SXB administration resulted 
in a marked increase in PRL secretion in both narcoleptics and controls. This finding is 
well in line with previous reports. A nearly threefold increase in PRL within 15 min of 
a 2.5 g GHB injection and a fivefold increase after 1 h were reported in healthy young 
men.113 Likewise, van Cauter et al. reported a dose-dependent increase in PRL secretion 
after the SXB administration in healthy humans.75 The mechanism through which SXB 
stimulates PRL secretion is still unclear. SXB can influence dopaminergic, serotonergic and 
GABAB signalling, and activation of these systems could initiate PRL release.
77;112 Systemic 
administration with low amounts of SXB generally induces hyperpolarisation of dopaminergic 
structures with a reduction in dopamine release, thereby enhancing PRL secretion.112 In 
addition, SXB increases the turnover of serotonin, a PRL-releasing factor, most likely due 
to an increase in available tryptophan, a precursor of serotonin.84;112 Additionally, GABAB 
receptor stimulation may also have a stimulatory effect on serotonin and PRL release.112 
Moreover, GHRH increases GH and PRL secretion.129 It is conceivable that SXB stimulates 
GHRH release and thereby promotes both GH and PRL. However, since dopamine is the 
major regulator of PRL secretion, the potentiating effect of SXB on PRL release is most likely 
due to its action on the hypothalamic TIDA neurons. In accordance with a previous study, 
we did not find an association between PRL release and SWS during the basal state.114 
However, after SXB administration the cross-correlation between PRL levels and SWS 
substantially increased. As the effect of SXB administration on PRL release is likely due to 
its inhibition of the activity of TIDA neurons, this finding suggests that the suppression of 
the hypothalamic dopaminergic system may also be responsible for the enhancing effect of 
SXB on SWS. Alternatively, a mechanism upstream of the TIDA system with effects on both 
sleep regulation and hypothalamic dopaminergic activity may be involved. In any case, this 
mechanism is unlikely to include the hypocretinergic system since the facilitating effect of 
SXB on the cross-correlation between PRL and SWS was similar in narcoleptics and controls. 
Further studies are needed to elucidate the exact nature of this novel regulatory circuit. A 
potential limitation of this study is the relatively small number of participants. However, this 
limitation is partly offset by the application of accurate assessment of hormone secretory 
dynamics, which would have been unfeasible in a larger group of subjects due to both the 




In conclusion, we found no evidence for altered PRL secretion in hypocretin-deficient 
narcolepsy patients either during the basal state or after the SXB administration. Therefore, 
hypocretin signalling is unlikely to be a major regulator of the lactotrophic system. Moreover, 
our findings suggest that the marked stimulatory effect of SXB on PRL release and SWS is 
mediated through its influence on the hypothalamic dopaminergic system.
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Hypocretin deficiency causes narcolepsy and may affect neuroendocrine systems and 
body composition. Additionally growth hormone (GH) alterations may influence weight 
in narcolepsy. Symptoms can be treated effectively with sodium oxybate (SXB, gamma-
hydroxybutyrate) in many patients. This study compared growth hormone secretion in 
patients and matched controls and established the effect of SXB administration on GH 
and sleep in both groups. Eight male hypocretin deficient narcolepsy with cataplexy 
and eight controls matched for sex, age, BMI, waist-to-hip ratio, and fat percentage 
were enrolled. Blood was sampled before and on the 5th day of SXB administration. 
SXB was taken 2 times 3g per night for 5 consecutive nights. Both groups underwent 
24-h blood sampling at 10-min intervals for measurement of GH concentrations. The 
GH concentration time series were analyzed with AutoDecon, and approximate entropy 
(ApEn). Basal and pulsatile GH secretion, pulse regularity and frequency, as well as ApEn 
values were similar in patients and controls. Administration of SXB caused a significant 
increase in total 24 hour GH secretion rate in narcolepsy patients, but not in controls. 
After SXB, slow wave sleep (SWS) and, importantly, the cross-correlation between 
GH levels and SWS more than doubled in both groups. In conclusion, SXB leads to a 
consistent increase in nocturnal GH secretion and strengthens the temporal relation 
between GH secretion and SWS. These data suggest that SXB may alter somatotropic 
tone in addition to its consolidating effect on nighttime sleep in narcolepsy. This could 
explain the suggested non-sleep effects of SXB, including body weight reduction.
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IntroductIon
Classically, narcolepsy is defined as a sleep disorder with excessive daytime sleepiness and 
cataplexy as the main symptoms.130 However, in recent years, there is increasing attention 
to other core features of the syndrome. For example, fragmented nighttime sleep is a 
prominent symptom in many narcoleptic patients, and often warrants treatment.131 In 
addition, patients are frequently overweight, storing excess fat in abdominal depots.18 The 
increasing interest for the broad symptomatology of narcolepsy was further fuelled by 
new insights in the pathophysiology of the disease. In the last decade, it has been shown 
that deficiencies in hypothalamic hypocretin (orexin) neurotransmission are the primary 
cause of narcolepsy both in humans and in several animal models of the disease.44;45;132 
The hypocretin system is involved in a broad range of functions, including autonomic and 
hormonal regulation. Recent research therefore focused on consequences of the hypocretin 
deficiency in narcolepsy beyond disordered sleep regulation, such as metabolic and endocrine 
changes.22;133 
Given the relation between sleep and the somatotropic axis, changes in growth hormone 
(GH) dynamics have received particular attention in narcolepsy.34;106;134;135 In healthy subjects, 
there is a clear association between GH secretion and sleep. This is especially clear in young 
males, in which the majority of 24-hour GH is secreted during the first period of slow wave 
sleep (SWS) at night.82;120 In a previous study, we showed that GH secretion was less strictly 
confined to the night in hypocretin-deficient narcolepsy.34 As the relation between SWS and 
GH secretion was preserved, it was suggested that a shift of SWS episodes to the day was 
paralleled by a daytime shift of GH secretion.
Sodium oxybate (SXB) has evolved into a first-line treatment for narcolepsy.72;73;136;137 SXB 
is a short-acting hypnotic which is dosed twice at night, at bedtime and 2.5-4 hours later. 
It significantly consolidates nighttime sleep, ameliorates cataplexy and in higher doses it 
may decrease excessive daytime sleepiness. In contrast to other hypnotics, SXB is one of 
the few compounds that increases rather than decreases SWS. This led to the hypothesis 
that it may also act as a GH-secretagogue. Indeed, it has been shown that single-dose SXB 
administration leads to an increase in GH secretion in healthy young men, paralleled by an 
increase in SWS.75
In the present study, we assessed the effect of repeated, twice-a-night administration of SXB 
on 24-hour GH secretion patterns in both patients with hypocretin-deficient narcolepsy, and 
matched healthy controls. GH secretion was assessed during a 24-hour sample occasion with 
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concomitant sleep registrations at baseline, and after 5 nights of SXB. We hypothesized that 
SXB administration would lead to a persistent increase in nocturnal GH secretion in both 
patients and controls, paralleled by an increase in SWS.
MAterIAls And MetHods
subjects
We included 8 male narcolepsy patients who fulfilled the diagnostic criteria for narcolepsy 
with cataplexy according to the 2nd edition of the International Classification for Sleep 
Disorders.118 All patients were hypocretin-1 deficient, using a standardized cerebrospinal 
fluid assay.132 All patients were free of medication for at least 2 weeks before study. Eight 
male control subjects were individually matched for age, body mass index (BMI), waist-to-
hip ratio (WHR) and body fat percentage. Medical exclusion criteria were hypertension, 
any known (history of) pituitary, psychiatric or neurological disease, and any other chronic 
conditions except narcolepsy as assessed by clinical examination. Routine laboratory tests 
were performed to rule out diabetes (fasting plasma glucose > 6.9 mmol/L), anaemia, as 
well as hepatic and renal failure. Furthermore, we excluded recent weight change (> 3 kg 
weight gain or loss within the last 3 months), a sleep disorder history assessed through 
clinical interview (controls), endurance sports and alcohol or drug abuse. The study was 
approved by the ethics committee of the Leiden University Medical Center. All subjects 
provided written informed consent to participate. 
study design
All subjects underwent two 24-hour blood sampling studies, with a 5-day interval. After the 
baseline sampling study, subjects received SXB for 5 consecutive nights (see below). The 
second sampling occasion took place on the 5th day of SXB use. 
Medication protocol
The first night of SXB administration took place in the hospital to provide instruction for 
proper usage and to monitor for possible side effects. Subjects received 3 grams of SXB in 
the evening (23:00 h) and during the night (3:00 h). Subjects were fasted at least 2.5 hours 
before drug intake, as food reduces the bioavailability of SXB. When no significant adverse 
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effects occurred, subjects were allowed to continue the study protocol and take SXB at home 
during the next three nights. The 5th night on SXB took place at the Clinical Research Center 
during the next sampling occasion. 
clinical protocol 
Subjects were admitted to the Clinical Research Center for 24-hour blood sampling. A cannula 
was inserted into an antecubital vein 45 minutes before the start of blood sampling at 12:00 
h. Blood samples were collected with S-Monovette (Sarstedt, Etten-Leur, The Netherlands) 
from a three-way stopcock attached to a 0.9% NaCl and heparin (1 U/ml) infusion (500 ml/24 
h) to keep the cannula from clotting. Sampling was performed through a long line to prevent 
sleep disruption by investigative manipulations. Samples for IGF-1 and IGFBP-3 were both 
taken just before breakfast at 8:30 on each day of study. For GH measurements, blood was 
collected at 10-minute intervals. After clotting, the blood was centrifuged within 30 minutes 
of sampling (20 minutes, 1250 g, 4°C). Serum was then stored at -80°C until hormonal assays. 
Bioelectrical impedance analysis (Bodystat, Douglas, Isle of Man, UK) was used to assess 
lean body mass and fat percentage at 8:25 (just before breakfast). 
Subjects remained sedentary except for bathroom visits. Lights were switched off at 23:00 
and switched on at 07:30 the next morning. Three standardized meals were served at 08:30, 
13:00, and 18:00 (Nutridrink, Nutricia, Zoetermeer, The Netherlands; 1.5 kcal/ml, 2100 
kcal/d; macronutrient composition per 100 ml protein, 6 g; fat, 5.8 g; carbohydrate, 18.4 
g). Subjects were asked to complete each meal provided. Water and caffeine free redbush 
tea were the only drinks available during the study.  
sleep analysis
Sleep was polygraphically recorded throughout both sampling occasions, using an Embletta 
X100 recorder (Embla, Broomfield, CO, USA). The recordings were scored visually at 30-second 
intervals according to the AASM criteria119 by an experienced sleep technician. To allow 
assessment of the associations between changes in serum GH levels (measured every 10 
minutes) and sleep stages (scored every 30 seconds), sleep profiles were divided into the 
10 minute segments separating consecutive GH measurements, as described previously.120 
Every segment was condensed from the 30-second sleep epochs into percentage of time 




Serum GH was measured by a time-resolved fluoroimmunoassay (DELFIA® hGH, PerkinElmer 
Life and Analytical Sciences, Turku, Finland). The detection limit of the assay was 0.03 
mU/L, and the interassay variation ranged from 1.6 to 8.4%. Samples from each patient 
and matched control were handled in the same run. Total serum insulin-like growth factor 
IGF-1 and insulin-like growth factor binding protein IGFBP-3 concentrations were measured 
by radioimmunoassay (Serono, Biomedica, Milan, Italy; and Nichols, San Juan Capristano, 
CA, respectively). Glycosylated hemoglobin (HbA1c) levels were measured with a high 
performance liquid chromatography (HPLC) system (Variant, Biomed, Hercules, CA, USA). 
Urinary epinephrine, norepinephrine and dopamine concentrations were assessed by HPLC 
with electron capture detection (ESTA-Coulochem, Chelmsford, MA, USA). 
Deconvolution analysis
A recently developed, fully automatic, multi-parameter deconvolution procedure, AutoDecon, 
was used to estimate various specific measures of secretion and serum disappearance rate of 
GH, considering all serum hormone concentrations and their dose-dependent intra-sample 
variance simultaneously.138;139 The AutoDecon process is a statistically based algorithm 
to test the significance of hormone secretion events, obviating the subjective nature of 
previously used deconvolution methods. Apart from the initial concentration and the basal 
secretion rate, which both were initialized to zero, the AutoDecon algorithm requires only 
two approximations of the parameter values that are to be estimated: 1) The standard 
deviation of the Gaussian-shaped secretion events (SecretionSD) which is generally initialized 
as half of the data-sampling interval, and 2) a starting value for the elimination parameter, 
or hormone half-life. Thus, for 10-minute sampled data, the SecretionSD was initialized to 
5-minutes together with a starting value for the GH half-life of 16-minutes. To account for 
intrinsic errors in the estimates of hormone secretion and clearance rates, the AutoDecon 
algorithm was then used to find the best fits for both parameters. The following parameters 
of the serum GH concentration time series were estimated: number of secretory bursts, 
secretory burst half-duration (duration at half-maximal amplitude), mean mass secreted per 
burst, hormone half-life, basal secretion rate, pulsatile secretion rate, and total secretion 
rate. Finally the first GH peak after SXB administration was defined as the first peak after 
medication intake detected by AutoDecon as described earlier.139 
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Approximate entropy (Apen)
ApEn is a model-independent statistic used to quantify the regularity of a time series, which 
estimates, within a predefined tolerance r given a pattern of window length m, the likelihood 
of a similar pattern in the next incremental window.140 Greater regularity yields smaller ApEn 
values, whereas greater independence among sequential values of a time series yields larger 
ApEn values. ApEn parameters of m = 1 and r = 20% of the intra-series standard deviation 
were used, the statistical suitability of which has been established previously.140
Statistical analyses
Results are expressed as mean ± standard error (SE), unless otherwise specified. Unpaired 
t-tests were used to assess differences in means between the two groups. In order to account 
for the two repeated measurements within each individual, mixed-effects models were used 
to assess the effects of SXB treatment and potential interaction effects. Cross-correlation 
analysis was applied to assess the association between serum GH concentrations and the 
percentage of time spent in slow wave sleep in the preceding 10 min sampling interval, taking 
into account all of the sampling intervals during sleep. Because of the individual matching of 
patients and controls and small number of subjects in each group , paired parametric (paired 
samples t-test) and non-parametric tests were also performed (Wilcoxon signed rank test). 
All tests were two-tailed and significance level was set at P < 0.05. Statistical calculations 
were performed using Systat software (version 11, Systat Software, Inc, San Jose, CA) and 
SPSS (release 17.0, SPSS, Inc., Chicago, IL).
results
Patients and controls were well-matched for age, BMI, waist-to-hip ratio and body fat content 
(Table 3.1). Serum HbA1c and glucose concentrations were similar in narcolepsy patients 
and controls (5.3 ± 0.08 vs. 5.3 ± 0.03, P = 0.80 , and 4.9 ± 0.21 vs. 5.1 ± 0.12, mmol/L P = 
0.47 respectively ) SXB was well tolerated by all participants. Apart from mild drowsiness, no 
other side-effects were reported during the study. After 5 days of SXB, mean concentrations 
of IGF-1 remained similar in both patients (16.1 ± 1.4 vs. 16.5 ± 0.9 nmol/L) and controls 
(20.7 ± 2.5 vs. 21.7 ± 3.1 nmol/L ), P = 0.14 and P = 0.30 for group and treatment effect, 
respectively. However, after SXB administration IGFBP-3 levels significantly decreased in both 
patients (4.05 ± 0.46 vs. 3.9 ± 0.3 mg/L), and controls (4.06 ± 0.31 vs. 3.84 ± 0.28 mg/L), P = 
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0.62 and P = 0.035 for group and treatment effect, respectively. (Wilcoxon signed rank test: 
P for intergroup difference = 0.58, P for treatment effect in patients = 0.48; P for treatment 
effect in controls = 0.024).
sleep analysis
On average, compared to controls, narcolepsy patients spent significantly less time awake 
both during basal conditions and after SXB (Table 3.2); paired t-tests and Wilcoxon signed-
rank tests yielded similar results (all P ≤ 0.039) During the day (defined as the lights-on 
period between 07:30 h-23:00 h), narcolepsy patients also spent significantly less time 
awake, while the time spent in non-REM sleep was significantly higher regardless of 
treatment; paired t-tests and Wilcoxon signed-rank tests yielded similar results (all P ≤ 
0.047). SXB administration resulted in a significant decrease in stages I/II non-REM and 
REM sleep over 24 hours in both groups (P = 0.011 and P = 0.009, respectively), while the 
time spent in SWS significantly increased (P = 0.001). During the day, SXB administration 
also reduced the time spent in stages I/II non-REM and REM sleep (P = 0.038 and P = 
0.041, respectively), while there was a trend for a longer period of wakefulness as well (P 
= 0.098). The percentage of SWS during the night more than doubled in both groups after 
SXB administration (narcolepsy: 6.5 ± 1.9 % vs.16.5 ± 3.0 %, controls: 7.1 ± 1.9 % vs. 18.5 
± 2.4 %; P = 0.001 for treatment effect), whereas there were trends for a decline in the 
percentages of stages I/II non-REM and REM sleep. During the night, SXB administration 
also significantly reduced the number of awakenings (P = 0.002), while sleep efficiency was 
not affected (P = 0.082) (Table 3.2).
table 3.1 Deconvolution of serum prolactin concentration profiles in narcolepsy patients and 
healthy controls
Patients Controls P-value
Age (yrs) 38.0 ± 4.7 37.9 ± 4.1 0.98
BMI (kg/m2) 28.1 ± 1.6 27.4 ± 1.4 0.74
Waist/hip ratio 0.92 ± 0.03 0.90 ± 0.02 0.58
Body fat (%) 23.6 ± 2.1 23.4 ± 1.7 0.95
Data are shown as mean ± SEM.
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Deconvolution analysis of GH time series
The deconvolution-derived GH secretory kinetics in patients and controls at baseline and 
after SXB are shown in Table 3.3. At baseline and after SXB administration, there were no 
significant differences between the groups. However, SXB resulted in a significant increase 
in total 24 hour GH secretion rate in narcolepsy patients (73 ± 21 vs. 112 ± 36 mU/Ldv), but 
not in controls (120 ± 19 vs. 102 ± 12 mU/Ldv), P = 0.047 for treatment × group interaction.
Regularity of serum GH concentration time series
The ApEn values of the GH time series were not significantly different between narcolepsy 
patients and controls, either during basal conditions (0.31 ± 0.06 vs. 0.45 ± 0.07, P = 0.17) or 
following SXB (0.23 ± 0.03 vs. 0.27 ± 0.05, P = 0.47). SXB administration, however, increased 
the regularity of GH secretion as indicated by lower ApEn values during the second study 
occasion in both patients and controls (P = 0.002 for treatment effect). 
GH release and sleep association
After SXB, the ratio between GH released at night to total GH secretion significantly increased 
in both narcolepsy patients (0.72 ± 0.06 vs. 0.84 ± 0.03) and controls (0.55 ± 0.06 vs. 0.79 ± 
0.05); P < 0.001 and P = 0.456 for treatment and group effect, respectively (Figure 3.1). We 
also compared the first GH secretory burst right after SXB administration (at 23:00 and 3:00 
h). Compared to the baseline condition, the first dose of SXB at 23:00 h led to a significant 
GH secretory burst in both patients and controls (P = 0.005 for treatment effect; Table 3.3). 
However, the effect of SXB administration on the first GH secretory burst was not different 
between patients and controls (P = 0.063) (paired t-test: P = 0.071; Wilcoxon signed-rank 
test: P = 0.093). After the second dose the increase in GH secretion was less pronounced 
(Table 3.3). 
During basal conditions, the mean cross-correlation between GH levels and the percentage 
of time spent in SWS in the previous 10 min equaled 0.24 ± 0.10 in narcolepsy patients and 
0.28 ± 0.09 in controls (P = 0.76 for the difference in the means). SXB more than doubled 
the cross-correlation between GH levels and SWS in both groups (narcolepsy: 0.49 ± 0.10, 
controls: 0.63 ± 0.07; P = 0.002 for treatment effect, Figure 3.2). 
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Figure 3.1 Mean serum growth hormone concentrations and slow-wave sleep in narcolepsy and 
matched control subjects. Blood sampling started at 1200 and was continued at 10-min intervals 
for 24 h, whereas sleep electroencephalogram was recorded continuously. Sodium oxybate (SXB) 
administration induced an immediate rise in growth hormone levels in both narcolepsy patients (A) 
and controls (b). Similarly, after 5 consecutive days of SXB treatment (including the 2nd sampling 
occasion), the percentage of slow-wave sleep had significantly increased in both narcolepsy patients 
(c) and controls (d). The black bar on the abscissa indicates the dark period (2300–0730). The gray 
arrows indicate the timings of the lunch, dinner, and breakfast at 1300, 1800, and 0830, respectively. 
The black arrows indicate the timings of SXB administration during the 2nd occasion at 2300 and 
0300. Error bars show means ± SEM.
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dIscussIon
We have shown that twice-a-night administration of SXB for 5 consecutive days consistently 
increases nocturnal GH secretion in both healthy controls and hypocretin-deficient narcolepsy 
patients. This was paralleled by a concomitant increase in SWS. Both the increase in GH 
and SWS were most prominent after the first dose of SXB at sleep onset. SXB reinforced 
the relation between GH and SWS, as evidenced by an almost doubled cross-correlation 
between the two. 
GH secretion in narcolepsy has been the topic of a number of studies. Several groups found 
diminished or even unmeasurable GH concentrations around sleep onset.82;83;134 In contrast, 
we did not find lowered total 24-hour concentrations of GH in a previous study, but rather a 
more dispersed pattern with a shift towards daytime secretion.34 However, in both scenarios, 
SXB may partly restore the nocturnal GH ‘deficit’, by increasing nighttime GH secretion. 
The potency of SXB as a GH-secretagogue was previously shown in two daytime studies 
without sleep recordings,113;141 and more recently in a controlled single-dose study using 
repeated sampling together with sleep registrations in healthy young males.75 Even at the 
Figure 3.2 Cross-correlation coefficient between growth hormone (GH) levels and slow-wave sleep 
(SWS). SXB administration resulted in a substantial increase in the coupling between GH release 
and SWS, as evidenced by a significant increase in the cross-correlation (P = 0.002 for treatment 




lowest dose (2.5 grams) a twofold increase in sleep-related GH secretion was observed. We 
confirmed and extended these observations, showing that a second nighttime dose may 
further enhance GH secretion, albeit to a lesser extent than the first dose. Furthermore, 
stimulation of GH secretion persists after repeated use, at least after 5 consecutive days. 
However, in controls we did not find a difference in 24 h GH secretion before and during 
SXB administration. Van Cauter, Gerra, and Takahara did find an increase in GH secretion 
after administration of a single dose of SXB in healthy controls as well as in narcoleptic 
patients.75;113;141 As a putative explanation of our findings, we believe that subchronic 
administration of SXB may elevate GH levels to induce feedback inhibition in controls, but 
not in narcoleptic patients, suggesting that narcolepsy does indeed disrupt normal control 
of GH release. Obviously, a single dose of SXB will not evoke such feedback inhibition, which 
explains the fact that other authors did not report a reduction of GH release in healthy 
humans. As SXB was well tolerated by subjects, this indeed suggests a potential for SXB as 
a strategy to counteract the relative growth hormone deficiency and sleep disturbances 
in the elderly, as was previously suggested.75;80
The close relation between sleep and the activity of the somatotropic axis has been known 
for a long time.142;143 There is a wealth of data supporting the hypothesis that this relation 
is brought about by the simultaneous promotion of sleep and GH release by GHRH.80;144;145 
The mechanism through which SXB promotes GH secretion is unknown.75 Some researchers 
claim that SXB may exert its central nervous system effects through dedicated GHB-receptors 
in the brain, but the existence of these receptors has been disputed.146;147 There is clear 
evidence that SXB does modulate GABAergic tone through agonism of GABAB receptors, 
also in sleep-promoting regions of the hypothalamus.80;146 Our data showed that SXB further 
strengthened the relation between SWS and GH secretion, so its effect may be mediated 
by an increase in GHRH activity. SXB increased the regularity of GH secretion as well. This 
may imply that sodium oxibate simultaneously promotes endogenous somatostatin release, 
as negative feedback has been shown to increase secretory regularity.148 Although animal 
studies showed that hypocretin administration induced a dose-dependent reduction of GH 
concentrations in rats,106 the effects of SXB on GH secretion are unlikely to be mediated by 
altering hypocretin tone, as results were not different between controls and hypocretin-
deficient patients. 
Influencing somatotropic activity in narcolepsy may have clinical relevance regarding body 
composition. Narcolepsy is associated with an increase in body weight. The BMI in the 
majority of patients is in the overweight range, as has been shown in several population based 
53
Sodium oxybate and GH secretion in narcolepsy
3
studies.18;19;149 In fact, there often is a clear increase in body weight around the first onset 
of symptoms of narcolepsy, especially excessive daytime sleepiness. Obesity in narcolepsy 
is not due to decreases in motor activity throughout the day.22;150 Furthermore, the total 
amount of calories consumed is not increased in narcolepsy.21 Basal metabolic rate has been 
studied by several groups, but inconsistent results have been reported.151;152 The same holds 
true for well-known endocrine factors regulating bodyweight, such as leptin.30-33 Obesity 
in narcolepsy is notoriously difficult to treat. This lends particular interest to a recent case 
series suggesting that SXB may decrease body weight in patients with narcolepsy.74 In 54 
treated patients, the average reduction in body weight amounted to 3.4 kg. In the patients 
with cataplexy, the mean weight reduction was even larger: 5.1 kg. GH has a potent lipolytic 
activity, while GH deficiency leads to decreases in lean body mass and an increased fat 
mass.153;154 It is therefore tempting to speculate that the putative weight reducing effect of 
SXB is mediated by its stimulatory effect on the somatotropic axis. 
We report a relatively low sleep efficiency in controls. It is conceivable that the laboratory 
setting disrupts sleep more than a natural environment. However the percentages of SWS 
and awekenings are comparable with earlier studies.75;155 
Proper assessment of the secretion pattern of hormones that fluctuate during the day, 
requires repeated blood sampling over longer periods of time. Obviously, this complicates 
study design, and limits the number of subjects that can be included. Furthermore, five 
nights of SXB administration may not correctly reflect the long-term effects of SXB. Our 
results therefore need confirmation in future long-term studies. Nevertheless, our results 
suggest that future prospective long-term studies should especially focus on the effects 
of SXB on body weight, as this would provide a major improvement in the treatment of 
narcolepsy. 
In conclusion, repeated administration of SXB leads to a consistent increase in nocturnal 
GH secretion in both healthy controls and hypocretin-deficient narcoleptic patients. SXB 
also strengthens the temporal relation between GH secretion and slow wave sleep. These 
data suggest that SXB may alter somatotropic tone in addition to its consolidating effect on 
nighttime sleep in hypocretin-deficient narcolepsy. This could explain the suggested non-
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Plasma total ghrelin and leptin 
levels in human narcolepsy and 
matched healthy controls: 
basal concentrations and 
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study objectives: Narcolepsy is caused by a selective loss of hypocretin neurons and is 
associated with obesity. Ghrelin and leptin interact with hypocretin neurons to influence 
energy homeostasis. Here, we evaluated whether human hypocretin deficiency, or the 
narcolepsy therapeutic agent sodium oxybate (SXB), alter the levels of these hormones.
Methods: Eight male, medication free, hypocretin deficient, narcolepsy with cataplexy 
patients, and 8 healthy controls matched for age, sex, body mass index (BMI), waist-to-
hip ratio, and body fat percentage were assessed. Blood samples of total ghrelin and 
leptin were collected over 24 hours at 60 and 20-min intervals, respectively, during 
2 study occasions: baseline, and during the last night of 5 consecutive nights of SXB 
administration (2 × 3.0 g/night).
results: At baseline, mean 24-h total ghrelin (936 ± 142 vs. 949 ± 175 pg/mL, P = 0.873) 
and leptin (115 ± 5.0 vs. 79.0 ± 32 mg/L, P = 0.18) levels were not different between 
hypocretin deficient narcolepsy patients and controls. Furthermore, SXB did not 
significantly affect the plasma concentration of either one of these hormones.
conclusions: The increased BMI of narcolepsy patients is unlikely to be mediated by 
hypocretin deficiency-mediated alterations in total ghrelin or leptin levels. Thus, the 
effects of these hormones on hypocretin neurons may be mainly unidirectional. Although 
SXB may influence body weight, the underlying mechanism is unlikely to involve changes 
in total ghrelin or leptin secretion.
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IntroductIon
The hypocretin system, also known as the orexin system, is of major importance in the 
regulation of sleep and sustained wakefulness. Moreover, hypocretin neurons are responsive 
to metabolites and hormones helping to translate signals of metabolic state into adaptive 
levels of activity and consciousness.156;157 Hypocretin deficiency leads to narcolepsy, a sleep-
wake disorder characterized by excessive daytime sleepiness, cataplexy, and disrupted 
nocturnal sleep. Obesity is associated with the disorder,18 yet the cause of the increased 
body weight has been challenging to discern due to inconsistent findings on the hormonal 
and metabolic characteristics of this population.22;30;31;33;81;151 However, altered ingestive 
behavior has been observed in these patients,81;158-160 suggesting hypocretin deficiency may 
dysregulate feeding behavior, and possibly energy homeostasis.
Ghrelin is a peptide hormone mainly produced by endocrine cells in the stomach and 
gastrointestinal tract, and is an important endogenous regulator of energy balance and growth 
hormone (GH) secretion.161 Its expression is complex89 and influenced by sympathetic nervous 
system activity.90 Across the wake period, plasma concentrations wax and wane episodically, 
providing an appetite-stimulating signal to the brain.91 During sleep, ghrelin levels rise sharply 
in the early part of the night and decrease gradually toward morning. During sleep deprivation, 
however, levels gradually rise toward a plateau in the morning.162 Hypocretin neurons directly 
sense and are excited by ghrelin, and an interaction between these two systems has been 
shown to be involved in ingestive behavior.87 A study by Toshinai et al. first identified this 
connection.92 In that study, ghrelin-induced feeding was attenuated in rats pretreated with 
anti-hypocretin-1 IgG and anti-hypocretin-2 IgG, and suppressed in hypocretin knockout mice. 
Later, it was demonstrated that ghrelin plays a key role in the rewarding aspects of eating, 
but it requires the presence of intact hypocretin signaling to impart this effect.163 
Leptin is another peptide hormone involved in energy homeostasis, the dominant role of 
which is to signal energy deficiency to the brain.164 It is an adipokine produced primarily by 
subcutaneous white adipose tissue, and its expression is stimulated by various hormones, 
sympathetic outflow, energy intake, and output.164;165 Under normal conditions, blood 
levels display circadian variation as levels rise across the day and peak in the middle of 
the night.166 During sleep deprivation, blood leptin levels show a reduced and flattened 
profile.167 Receptors for leptin are found on hypocretin cells,86 and leptin can directly 
inhibit the expression of isolated hypocretin neurons.87 Indirectly, leptin can affect the 
activity of hypocretin cells via energy regulating neurons in the arcuate nucleus of the 
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hypothalamus.88 Conversely, because the hypocretin system greatly influences autonomic 
control,156 it is plausible that hypocretin deficiency may alter leptin expression via inhibited 
sympathetic activity. Indeed, obese hypocretin deficient mice have lowered sympathetic 
vasoconstrictor outflow, while greater heart rate variability has been observed in hypocretin 
deficient narcolepsy patients.168;169 Thus, leptin and hypocretin may interact to affect levels 
of physical activity and wakefulness in response to energy needs, and the loss of hypocretin 
neurons may dysregulate leptin expression and signaling. While ghrelin levels have not 
been previously reported in hypocretin-deficient narcoleptic patients, abnormal leptin 
levels have been observed.30;31 It is unknown if the associations between hypocretin and 
total ghrelin or leptin are uni-or bi- directional. Because hypocretin influences sympathetic 
outflow and sympathetic nervous system activity affects the expression of both leptin and 
ghrelin, hypocretin deficiency may lead to altered levels of these hormones. This study of 
hypocretin deficient narcoleptic patients provides a unique opportunity to further explore 
the nature of these relationships. We hypothesized that both total ghrelin and leptin levels 
would be abnormal in hypocretin-deficient narcolepsy patients, which might help explain 
the increased BMI and abnormal ingestive behavior seen in this population.22;30;81;149;170;171
Additionally, we explored if the narcolepsy therapeutic agent, sodium oxybate (SXB), has an 
effect on these hormones. In a narcolepsy population, SXB improves disrupted nocturnal 
sleep, impaired wakefulness, and cataplexy, and promotes weight loss.74;172 Like ghrelin, SXB 
administration also stimulates GH release.75 We hypothesized that its administration would 
alter total ghrelin levels, the effect of which might be involved in its GH-promoting effects. 
Here, we investigate whether total blood ghrelin or leptin levels are altered in hypocretin-
deficient narcoleptic patients compared to controls, and whether total ghrelin or leptin 
levels are influenced by SXB.
MAterIAls And Methods
subjects
We included 8 medication-free, male hypocretin-deficient narcolepsy with cataplexy patients 
and 8 healthy male controls, matched for age, BMI, and body fat percentage. Hypocretin 
measurement was performed according to international standards.46 Body fat percentage 
was measured with bioelectrical impedance analysis (Bodystat, Douglas, Isle of Man, UK). 
Two patients were drug naive, one patient was tapered from antidepressants ≥ 2 weeks prior 
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to the study, and 2 patients had prior history with SXB; however, no subject took sodium 
oxybate within 20 days of study initiation. The other patients did not take any medication 
for at least several months prior to beginning the study.
Subjects were eligible for participation after exclusion of chronic conditions, with particular 
attention to the absence of sleep disorders in control subjects, hypertension, pituitary 
disease, and weight change (> 3 kg weight gain or loss within the last 3 months) as assessed by 
structured clinical interview. None of the participants had previously undergone gastrectomy. 
Written informed consent was obtained from all subjects. The study was approved by the 
ethics committee of the Leiden University Medical Center.
clinical protocol
All subjects were admitted to the Clinical Research Center for 24-h blood sampling before and 
after 5 days of SXB administration. A cannula was inserted into an antecubital vein ≥ 45 min 
before the start of blood sampling at 12:00. Blood samples were collected with S-Monovette 
(Sarstedt, Etten-Leur, The Netherlands) from a 3-way stopcock that was attached to a 0.9% 
NaCl and heparin (1 U/mL) infusion (750 mL/24 h) to keep the cannula from clotting. For 
total ghrelin measurements, blood was collected in EDTA tubes at 60-min intervals, and 
these tubes were immediately put on ice. Ghrelin samples were acidified with 50 μL of 1 
N HCL. Within 5 min of sampling, tubes were centrifuged at 1,250 g at 4°C for 20 minutes. 
For leptin measurements, blood was collected at 20-min intervals. After clotting, the blood 
was centrifuged within 30 min of sampling (20 min, 1,250 g, 4°C). Serum was then stored 
at -80°C until hormonal assays. Three standardized meals were served at 08:30, 13:00, and 
18:00 (Nutridrink, 1.5 kcal/mL, 2,100 kcal/d; macronutrient composition per 100 mL: protein, 
6 g; fat, 5.8 g; carbohydrate, 18.4 g; Nutricia, Zoetermeer, The Netherlands). Subjects were 
asked to complete each meal provided. Food-induced suppression of total ghrelin release 
was defined as the ratio between total ghrelin levels one hour post- prandially to the levels 
immediately before the meal (lunch and dinner) or 30 min postprandially to 30 min before 
the meal (breakfast). Subjects remained sedentary except for bathroom visits. In both study 
occasions, lights were switched off (dark period) at 23:00 and then switched on at 07:30.
sodium oxybate
In the drug-intervention study occasion, SXB was administered in a total nightly dose of 6 
grams/night for 5 consecutive nights in both the narcoleptic patients and the controls. Each 
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night, 3 grams of SXB were administered orally at 23:00 and 03:00. Lights were turned off 
after ingestion of the first dose.
Assays
Plasma total ghrelin and leptin levels were measured by radioimmunoassay (LINCO Research, 
St. Charles, MO, USA) with a detection limit of 93 pg/mL, and an interassay variation ranging 
from 14.7% to 17.8% for total ghrelin and a detection limit of 0.5 μg/L and an interassay 
variation ranging from 3.0% to 5.1% for leptin. Samples from each patient and matched 
control were handled in the same run.
Deconvolution analysis
Leptin concentration time series were analyzed via a recently developed automated 
deconvolution method, empirically validated using hypothalamo-pituitary sampling and 
simulated pulsatile time series.121 The Matlabbased algorithm first detrends the data and 
normalizes concentrations to the unit interval [0, 1]. Second, the program creates multiple 
successive potential pulse-time sets, each containing one fewer burst via a smoothing 
process (a nonlinear adaptation of the heat-diffusion equation). Third, a maximum-likelihood 
expectation estimation method computes all secretion and elimination parameters 
simultaneously conditional on each of the multiple candidate pulse-time sets. The fast half-
life was represented as 3.4 min constituting 19% of the decay amplitude. The slow half-life 
was estimated as an unknown variable between 6 and 70 min. Here we present only results 
for pulse frequency (pulses per 24 h), basal secretion, pulsatile secretion, and total secretion 
per 24 h, all expressed as µg per liter distribution volume.
Data analysis and statistics
Results are expressed as mean ± SD unless otherwise specified. Unpaired t-tests were used 
to assess differences in means between the 2 groups, while paired t-tests were applied to 
assess changes in means within each group. All tests were 2-tailed, and significance level 
was set at P < 0.05. Statistical analyses were performed using SPSS for Windows (release 
17.0, SPSS, Inc., Chicago, IL).
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Patients and controls did not differ with respect to age, BMI, waist-to-hip ratio, and body fat 
percentage (Table 4.1). SXB was well tolerated by all participants. Apart from mild drowsiness, 
no other side effects were reported during the study. 
Sleep and wakefulness differences
When compared to controls, during baseline conditions and after SXB administration, 
narcolepsy patients spent significantly less time awake across a 24 h period, and during 
the day (defined as the lights-on period between 07:30-23:00) they spent less time 
awake and more time in slow wave sleep ([SWS] P = 0.004 and P = 0.005, respectively; 
Table 4.2).
Effect of sodium oxybate administration on sleep and wakefulness
In both groups, administration of SXB resulted in a significant decrease in stages I/II NREM 
and REM sleep over 24 h (P = 0.011 and P = 0.009, respectively), while at night, awakenings 
were significantly reduced (P = 0.002) and the percentage of SWS more than doubled 
(narcolepsy: 6.5% ± 5.5% vs.16.5% ± 8.4%, controls: 7.1% ± 5.5% vs. 18.5% ± 6.4%; P = 0.001 
for administration effect). During the day, time spent in stages I/II NREM and REM sleep (P 
= 0.038 and P = 0.041, respectively) was reduced, while there was a trend towards longer 
periods of wakefulness (P = 0.098).
table 4.1 Demographics, body composition, baseline parameters
Patients Controls p-value
Age (yrs) 38.0 ± 4.7 37.9 ± 4.1 0.98
BMI (kg/m2) 28.1 ± 1.6 27.4 ± 1.4 0.74
Waist/hip ratio 0.92 ± 0.03 0.90 ± 0.02 0.58
Body fat (%) 23.6 ± 2.1 23.4 ± 1.7 0.95
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baseline total ghrelin levels
Mean 24-h total ghrelin levels at baseline were virtually identical between narcolepsy patients 
and controls (P = 0.873; Figure 4.1A). Mean total ghrelin levels were also not different 
between the 2 groups when the analyses were restricted to the dark period (P = 0.973). 
In fact, at no single time-point an intergroup difference could be detected (all P ≥ 0.232). 
Food induced suppression of total ghrelin concentration (expressed as the ratio between 
postprandial to preprandial total ghrelin concentration) was similar in the 2 groups (lunch: 
P = 0.413, dinner: P = 0.301, breakfast: P = 0.437, and mean postprandial total ghrelin levels 
averaged over the 3 occasions [P = 0.540]) (Table 4.3).
Effect of sodium oxybate on total ghrelin levels
Twenty-four hour mean total ghrelin levels during SXB administration were not different 
between narcolepsy patients and controls (P = 0.642; Figure 4.1B). Similar to baseline, mean 
Figure 4.1 Mean 24-h ghrelin levels in narcolepsy patients and matched controls. The diurnal plasma 
ghrelin levels, as well as food induced suppression of ghrelin release were not significantly different 
between narcolepsy patients and matched controls, either during basal conditions (A) or after five 
days of sodium oxybate administration (b). Hourly blood sampling started at noon and continued 
for 24 hours. The black bar on the abscissa indicates the dark period (23:00-7:30 h). The grey arrows 
indicate the timings of the lunch, dinner and breakfast at 13:00 h, 18:00 h and 08:30 h, respectively. 
The black arrows indicate the timings of sodium oxybate administrations during the second occasion 
at 23:00 h and 03:00 h. Error bars show the means ± SD.
12:00             20:00              04:00             12:00










12:00             20:00              04:00             12:00












total ghrelin levels during the dark period did not differ between the 2 groups (P = 0.449), 
and at no single time-point a difference could be detected between groups (all P ≥ 0.05). 
Postprandial total ghrelin suppression, as defined above, was also similar between the 2 
groups after SXB administration: lunch (P = 0.920), dinner (P = 0.261), and breakfast (P = 
0.880); mean postprandial total ghrelin levels averaged over the 3 occasions (P = 0.428) 
(Table 4.3). The average change in 24-h total ghrelin levels between the second and first 
occasion amounted to -15 ± 72 pg/mL in narcolepsy patients and -63 ± 87 pg/mL in controls, 
but was not significantly different from zero in either group (paired t-tests: P = 0.56 and P 
= 0.078, respectively).
table 4.3 Plasma ghrelin concentrations and deconvolution of leptin levels before and after 
administration of sodium oxybate in both narcoleptic patients and controls
Baseline Sodium oxybate
Patients Controls p Patients Controls p 
Ghrelin
24-h total integrated 
concentration (pg/mL)
936 ± 142 949 ± 175 0.873 920 ± 142 886 ± 150 0.642
Dark perioda (pg/mL) 1012 ± 156 1009 ± 196 0.973 983 ± 163 910 ± 211 0.449
Food induced suppression 
of ghrelin concentrationb 
(pg/mL)
Lunch 0.83 ± 0.10 0.86 ± 0.09 0.413 0.87 ± 0.08 0.88 ± 0.16 0.920
Dinner 0.93 ± 0.16 0.83 ± 0.17 0.301 0.89 ± 0.20 0.80 ± 0.10 0.261
Breakfast 1.05 ± 0.10 1.01 ± 0.09 0.437 0.98 ± 0.12 0.98 ± 0.06 0.880
Postprandial total ghrelinc 
(pg/mL)     
0.93 ± 0.08 0.90 ± 0.11 0.540 0.91 ± 0.08 0.88 ± 0.06 0.428
Leptin
Total 24-h secretion (µg/
Lx24h)
115 ± 98 79.0 ± 88 0.18 100 ± 113 64.0 ± 35 0.58
Basal 24-h secretion (µg/
Lx24h)
64.7 ± 63 37.9 ± 30 0.96 56.0 ± 70 47.6 ± 63 0.94
Pulsatile 24-h secretion (µg/
Lx24h)
50.3 ± 36 25.6 ± 11 0.11 43.8 ± 46 31.0 ± 27 0.29
Pulse frequency (no/24h) 18.5 ± 2.7 15.3 ± 4.8 0.04 19.8 ± 2.4 19.0 ± 3.0 0.04
a In both study occasions, lights were switched off (dark period) at 2300 h and then switched on at 0730 h.
b Expressed as the ratio between post- to preprandial ghrelin concentration.
c Averaged over three occasions.
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Baseline leptin levels
Mean 24-h total leptin levels at baseline were not significantly different between narcolepsy 
patients and controls (P = 0.18; Figure 4.2A). Mean pulse frequency was different between 
the 2 groups (P = 0.04), but mean 24-h basal and pulsatile secretion levels were not different 
(P = 0.96; P = 0.11, respectively; Table 4.3). 
Figure 4.2 Mean 24-h plasma leptin concentration ± SD, before (A) and during sodium oxybate 
administration (b) in narcolepsy patients and matched controls. The black horizontal bar on the 
abscissa indicates the lights off period. The grey arrows indicate the timing of meals and the black 
arrows indicate timing of sodium oxybate administration (b).
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Effect of sodium oxybate on leptin levels
Mean 24-h total leptin levels during SXB treatment were not significantly different between 
narcolepsy patients and controls (P = 0.58; Figure 4.2B); neither were mean 24-h basal and 
pulsatile secretion rates (P = 0.94; P = 0.29, respectively). Mean pulse frequency was different 
between the 2 groups (P = 0.04; Table 4.3).
dIscussIon
We found no differences in mean 24-h total plasma ghrelin levels or food-induced suppression 
of ghrelin concentrations between narcolepsy patients and controls, nor any influence of 
5 days of SXB administration in both groups. In view of the capacity of ghrelin to stimulate 
growth hormone secretion, it is worth noting that a report from this same research protocol 
showed no differences in mean hourly GH levels between patients and controls, supporting 
our conclusion that total ghrelin levels are not altered with hypocretin deficiency.173
Despite the excitatory influence of ghrelin on hypocretin neurons and the interaction of 
the ghrelin-hypocretin systems to influence food reinforcement, our finding did not show 
the total ghrelin level to be influenced by hypocretin deficiency, suggesting a unidirectional 
relationship. These findings also suggest that disturbed ingestive behavior is unlikely mediated 
by an altered total ghrelin level in narcolepsy patients. Notably, we measured total ghrelin 
levels and not the biologically active, octanoylated-ghrelin fraction. While there is a high 
correlation between the total and octanoylated fraction ghrelin level,174 it remains possible 
that the active fraction may be altered in this population.
In contrast to earlier reports,30;31 more recent, larger, controlled studies have not demon-
strated an abnormal leptin level in humans with hypocretin deficiency.32;33 Similar to the 
recent research on this subject, we found that the mean 24-h total leptin level, and basal and 
pulsatile secretion levels were not significantly different between narcolepsy patients and 
controls. The mean leptin pulse frequency was slightly but significantly higher in narcolepsy 
patients in both conditions, but the clinical relevance of this finding is unclear. Because sleep 
disruption and insulin resistance have been shown to affect leptin levels,175 it is plausible 
that previous investigations showing decreased leptin in narcolepsy may have resulted from 
a study sample of narcoleptic patients with relatively poor sleep or a difference in insulin 
sensitivity compared to the control group.
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There were several limitations to the study. The small number of patients and controls raise 
the possibility of a type II statistical error. However, the intergroup differences were very 
small; therefore, a large sample size would be needed to detect a difference if present. As 
with many chronic diseases, compensatory mechanisms are likely involved in narcolepsy as 
the condition progresses from onset into the chronic stage. Studying narcoleptic patients 
only during the chronic stage challenges the interpretation that loss of hypocretin cells in 
the hypothalamus does not alter leptin and ghrelin levels since compensatory adaptation 
may have already taken place. However, alterations in appetite and weight regulation 
remain present and clinically relevant in the chronic stage of the disease, and therefore our 
findings remain relevant despite putative compensations. Additionally, since sleep-wake state 
instability is intrinsic to hypocretin deficiency, standardizing research parameters such as 
study environment, meal timing and composition, and predefined bedtimes may have created 
a setting not representative of real-life conditions for these patients. Therefore, although 
we did not find alterations in total ghrelin and leptin concentrations in this controlled and 
standardized environment, it remains possible that the release of these hormones is affected 
by the altered sleep, wake, and eating patterns described in this population.
As expected, in both groups nighttime administration of SXB increased SWS and reduced 
awakenings, and the narcoleptic patient group showed a trend towards increased wakefulness 
the following day. As demonstrated in other studies, acute SXB administration corresponds 
with a significant increase in GH release.75;173 However, we found no evidence that the GH-
elevating effect is mediated through an influence on total ghrelin secretion. Various treatment 
effects of SXB exhibit discrete temporal dynamics with some effects occurring acutely and 
other effects taking place only after chronic exposure. Although the difference in total 
ghrelin levels between patients and controls after SXB administration was not significant, it 
is possible that significant differences would be seen with higher doses, prolonged periods 
of nightly administration, or in a larger group of subjects. Lastly, we did not see an effect 
of SXB on the leptin level, and to our knowledge, an interaction between this drug and 
hormone has not been reported elsewhere. Therefore, mechanisms underlying increased 
BMI and altered ingestive behavior in narcolepsy and the effects of SXB administration on 
GH release and weight loss are unlikely to involve changes in total plasma ghrelin or leptin 
concentrations. Future investigations should further evaluate if the sleep-wake instability 
intrinsic to hypocretin deficient narcolepsy promotes ingestive and activity patterns that 
promote positive energy balance.

Altered circadian rhythm of 
melatonin concentrations in 
hypocretin-deficient men













Hypocretin deficiency causes narcolepsy. It is unknown whether melatonin secretion 
is affected in this sleep disorder. Therefore, in both narcolepsy patients and matched 
controls we measured plasma melatonin levels hourly for 24 h before and after five 
days of sodium oxybate (SXB) administration. Although mean melatonin concentrations 
were similar between patients and controls, in narcoleptics the percentage of 24-h 
melatonin secreted during the daytime was significantly higher, and melatonin secretion 
exhibited a weaker coupling to sleep. SXB did not affect melatonin secretion. These 
findings suggest that hypocretin deficiency might disturb both the circadian control of 
melatonin release and its temporal association with sleep. 
73
Plasma melatonin in hypocretin deficiency
5
IntroductIon
Narcolepsy in humans is caused by hypocretin deficiency due to loss of hypocretin-producing 
neurons in the hypothalamus by an as yet unknown mechanism.47;48 An autoimmune cause is 
assumed but has not been proven yet.62 Hypocretins play an important role in the regulation 
of various homeostatic functions, most notably the consolidation of the sleep/wake cycle.176 
Therefore, it is not surprising that the inability to stay awake during the day and asleep during 
the night are among the major symptoms of narcolepsy.102 Another potential modulator of 
sleep is melatonin, high levels of which have been associated with sleepiness.93 The synthesis 
and secretion of melatonin in the pineal gland is under the influence of the circadian clock 
genes in the suprachiasmatic nucleus (SCN) of the hypothalamus.93 Apart from its circadian 
control, melatonin production is also regulated by the light/dark cycle and primarily occurs 
at night.93 Specialized melanopsin-containing cells in the retina detect a narrow band of blue 
wavelengths and subsequently signal the SCN, resulting in melatonin suppression during 
exposure to (day)light.177 Furthermore, accumulating evidence derived from experiments 
on various animal models indicates that the hypocretinergic innervation of the pineal gland 
could also be important for the regulation of diurnal melatonin synthesis and secretion.94;178-181
Sodium oxybate (SXB), or γ-hydroxybutyrate, has been shown to be highly effective in the 
treatment of narcolepsy-associated sleep disturbances.73 It reduces cataplexy, improves 
nocturnal sleep fragmentation, and, at higher doses, it may also reduce excessive daytime 
sleepiness (EDS). The mechanisms of action of SXB are poorly understood. It is known to act 
on the GABAB receptor, whereas the existence of a special GHB receptor is still a matter of 
debate. SXB might act via modulation of melatonin release, which is known to affect sleep. 
Indeed, previously we have shown that GABAergic mechanisms affect melatonin release.182-184 
Several papers have delineated melatonin secretion in narcolepsy patients, primarily focusing 
on whether altered melatonin secretion could contribute to EDS and nocturnal sleep 
disturbances.185-187 Although most of these studies found melatonin levels within the normal 
range in narcolepsy patients, in a more recent study Blazejova et al. discovered elevated saliva 
melatonin levels during the day in almost half of the patients.188 These patients had a shorter 
sleep onset on the Multiple Sleep Latency Test (MSLT) compared to those without elevated 
daytime melatonin levels. However, the MSLT and melatonin sampling were performed on 
separate occasions. Therefore, as comparison of findings from these previous studies is 
hampered by significant methodological differences, it remains to be elucidated whether, 
how, and to which extent melatonin secretion is altered in narcolepsy patients.
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Given the recent indications for a hypocretinergic innervation of the pineal gland, we 
hypothesized that melatonin secretion and/or its circadian rhythmicity might be altered in 
hypocretin-deficient narcolepsy patients, and that SXB might reverse these alterations.94;178-181 
To evaluate this hypothesis we performed 24-h blood sampling studies in combination with 
polysomnography on a group of hypocretin-deficient narcolepsy patients and rigorously 
matched healthy controls, both before and after SXB administration.
subjects And methods
subjects
Seven male narcolepsy patients with definite cataplexy, who fulfilled the diagnostic criteria 
of the second edition of the International Classification for Sleep Disorders were included.118 
All narcolepsy patients had hypocretin levels under the detection limit using a standardized 
cerebrospinal fluid assay132 and were free of medication for at least 2 weeks before study. 
Seven healthy controls, matched for sex, age, body mass index (BMI), waist-to-hip ratio 
(WHR) and fat percentage were included for comparison (see Table 5.1 for subjects’ 
characteristics). Subjects were eligible for study after exclusion of hypertension, any known 
(history of) pituitary, psychiatric or neurological disease (other than narcolepsy), alcohol or 
drug abuse, recent weight change (> 3 kg weight change within the last 3 months), a sleep 
disorder history (controls), and endurance sports. Routine laboratory tests were performed 
to rule out diabetes, anaemia, hepatic, and/or renal disease. The study was approved by 
the ethics committee of the Leiden University Medical Centre and adhered to the ethical 
standards outlined in the Helsinki Declaration.189 Written informed consent was obtained 
from all subjects. 
table 5.1 Group characteristics
Narcolepsy Controls p-value
Age (yrs) 34.3 ± 3.4 34.7 ± 3.0 0.93
BMI 28.2 ± 1.8 27.8 ± 1.6 0.89
Fat % 22.9 ± 2.3 23.9 ± 1.9 0.76
WHR 0.90 ± 0.04 0.90 ± 0.01 0.99
Data are shown as mean ± SEM. Comparisons were made using independent  t-test.
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Protocol
Subjects were admitted to the Clinical Research Centre for 24-h blood sampling. A cannula 
was inserted into an antecubital vein 45 min before the start of blood sampling at 12:00 h. 
Blood samples were collected with S-Monovette (Sarstedt, Etten-Leur, The Netherlands) from 
a three-way stopcock attached to a 0.9% NaCl and heparin (1 U/ml) infusion (750 ml/24 h) to 
keep the cannula from clotting. Sampling was performed through a long line to prevent sleep 
disruption by investigative manipulations. For melatonin measurements, blood was collected 
in EDTA tubes at 60-min intervals, except the sample at 23:30 h which was taken 30 min after 
the previous sample. Blood was put on ice immediately after sampling and centrifuged within 
5 min (1250 g at 4°C for 20 min). Subsequently, plasma was divided into separate aliquots in 
Sarstedt tubes and stored at -80°C until assay. Three standardized meals were served at 08:30, 
13:00, and 18:00 h (Nutridrink, Nutricia, Zoetermeer, The Netherlands; 1.5 kcal/ml, 2100 kcal/d; 
macronutrient composition/100 ml: protein, 6 g; fat, 5.8 g; carbohydrate, 18.4 g). A 24-h urine 
sample was collected for the determination of catecholamine concentrations. Patients and 
controls were always studied in the same room, mostly in parallel to keep circumstances equal 
and rule out seasonal differences. Subjects remained (semi)supine except for bathroom visits. 
Daytime naps were allowed. Light intensity was between 300 and 400 lux during L and < 10 lux 
during D. Lights were switched off at 23:00 h and turned on at 07:30 h the next day. Twenty-
four hour sampling was performed at baseline and on the fifth day of SXB administration.
sodium oxybate
SXB was administered in two nighttime doses of three grams each, at 23:00 h and 03:00 
h. To monitor for possible side effects, the first night of administration was done on the 
neurology ward.
sleep analysis
Sleep was polygraphically recorded throughout both sampling occasions, using an Embletta 
X100 recorder (Embla, Broomfield, CO, USA). The recordings were scored visually by an 
experienced sleep technician at 30-s intervals according to AASM criteria.190 To allow 
assessment of the association between changes in plasma melatonin levels (measured 
every 60 min) and sleep stages (scored every 30 s), sleep profiles were divided into 30-min 
segments as described previously.120 These segments were condensed from the 30-s scoring 
intervals by calculating the percentage of time spent in stages I and II non-REM sleep, slow 
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wave sleep (SWS), and REM sleep in the 30 min immediately preceding each melatonin 
measurement. The temporal relation between melatonin levels and the conjoining sleep 
segments was subsequently assessed by cross-correlation analysis.
melatonin assay
Melatonin levels were measured by radioimmunoassay after extraction from plasma with 
dichloromethane.191 Duplicate aliquots each containing 100 μl of extracted plasma were 
assayed by adding 100 μl of a specific rabbit antiserum (R19540, INRA, Nouzilly, France) and 
300 μl of labelled [125I]-2-iodomelatonin. The mixture solution was incubated overnight at 
4°C. Then 800 μl of an anti-rabbit gamma globulin was added, and the tubes were put on ice 
for 1 h. Tubes were then centrifuged and the supernatant discarded. The pellet was counted 
using a γ-ray counter. The detection limit of the assay was 1 pg/tube (10 pg/ml plasma). 
Statistical analysis
Results are expressed as mean ± standard error (SEM), unless otherwise specified. Statistical 
comparisons were made with either the Student’s t-test or repeated-measures ANOVA, 
as appropriate. The area under the curve (AUC) of the melatonin versus time plots was 
calculated as a measure of the total 24-h melatonin secretion. As there was considerable 
interindividual heterogeneity in absolute melatonin concentrations, diurnal variations in 
melatonin secretion were assessed by calculating the percentage of the 24-h AUC during 
the lights-on period (i.e., 07:30 - 23:00 h). Cross-correlation analysis was applied to assess 
the association between melatonin levels and the percentage of time spent in various sleep 
stages in the preceding 30 min.127 Cross-correlation analysis is a standard method of assessing 
the degree of correlation between two time series, and was defined here as:
Where t = 0,1,2,...,24, and  = the melatonin concentration at each time point,  = the 
mean 24-h melatonin concentration,  = the percentage of time spent in various sleep 
stages in the preceding 30 min at each time point, and  = the 24-h mean of each . For 
cross-correlations during nighttime only, t ranged from 0 to 9. Statistical calculations were 
performed using SPSS (release 17.0, SPSS, Inc., Chicago, IL). All tests were two-tailed, and 
the significance level was set at 0.05.
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Narcolepsy patients and controls did not differ with respect to age, BMI, fat percentage, 
and WHR (all p ≥ 0.76, Table 5.1). There were also no differences in urinary epinephrine, 
norepinephrine, and dopamine levels either at baseline (all p ≥ 0.70) or after SXB 
administration (all p ≥ 0.16). Ingestion of SXB was well-tolerated; apart from mild drowsiness, 
no other side-effects were reported. 
Melatonin profiles
Mean 24-h melatonin concentrations did not differ between narcolepsy patients and controls, 
either before (39.2 ± 16.4 vs. 28.6 ± 4.6 pg/mL, p = 0.56) or after SXB administration (39.8 
± 9.2 vs. 31.0 ± 5.1 pg/mL, p = 0.43) (Figure 5.1). Similarly, differences in mean melatonin 
levels were not significant between the two groups when analyzed for day- and nighttime 
separately, either during the basal condition or after SXB treatment (all p ≥ 0.11). As 
expected, with repeated-measures ANOVA, we found a significant effect of Circadian Time 
on melatonin levels in both groups (p < 0.005). However, the effect of Circadian Time on 
melatonin levels differed between narcolepsy patients and controls (p = 0.042 for Time × 
Group interaction effect). The percentage of total 24-h melatonin secreted during the day 
was significantly higher in narcolepsy patients compared to controls, both during the basal 
condition (46.6 ± 4.1 vs. 32.5 ± 5.8%) and after SXB intake (51.5 ± 3.5 vs. 34.4 ± 4.0%), (p 
= 0.007 for Group effect; Figure 5.2). Administration of SXB did not significantly affect the 
percentage of melatonin secreted during the daytime (p = 0.415 for the Treatment effect 
and p = 0.718 for Group × Treatment interaction effect). 
sleep recordings
Compared to controls, narcolepsy patients spent significantly less time awake both during 
basal conditions and SXB treatment (Table 5.2). During the day (defined as the lights-on 
period between 07:30 - 23:00 h), narcolepsy patients spent significantly less time awake, 
while significantly more time was spent in non-REM sleep, regardless of treatment (Table 
5.2). SXB administration resulted in a significant decrease in stages I/II non-REM and REM 
sleep over the 24 h in both groups (p = 0.011 and p = 0.009, respectively), while it significantly 
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increased the time spent in SWS (p = 0.001). During the day, SXB treatment reduced the time 
spent in stages I/II non-REM and REM sleep (p = 0.038 and p = 0.041, respectively), while it 
tended to increase wakefulness (p = 0.098). The percentage of SWS during the night more 
than doubled in both groups in response to SXB treatment (narcolepsy: 6.5 ± 1.9 vs.16.5 ± 
3.0%, controls: 7.1 ± 1.9 vs. 18.5 ± 2.4%; p = 0.001 for treatment effect), whereas there were 
trends for decreases in the percentages of stages I/II non-REM and REM sleep.
Figure 5.1 Mean melatonin concentrations plus standard error of the mean in narcolepsy patients 
and controls at baseline (A) and during SXB administration (b). No difference in mean concentrations 
was found between groups in both conditions. Black bar on the abscissa indicates the dark period 
(23:00–07:30 h). Downward arrows (b) ) indicate ingestion of SXB (23:00 h and 03:00 h). Time is 
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Figure 5.2 Fraction of melatonin secreted during the day in narcolepsy patients and controls, both 
at baseline and during sodium oxybate administration (lights-on period 07:30-23:00 h). Fraction of 
melatonin secreted during daytime is higher in narcolepsy patients compared to matched controls 
(p = 0.007 for group effect, p = 0.415 for treatment effect, and p = 0.718 for group × treatment 
interaction effect). Bars represent standard errors of the mean.
table 5.2 Sleep patterns before and after sodium oxybate administration
Baseline Sodium oxybate
Patients Controls p Patients Controls p
Wake total (%) 60.8 ± 2.9 68.7 ± 2.0 0.044* 60.8 ± 2.2 70.1 ± 2.4 0.013*
Wake day (%) 79.4 ± 4.2 95.6 ± 2.1 0.004* 82.9 ± 3.2 97.3 ± 1.0 0.001*
Wake night (%) 25.8 ± 5.7 18.4 ± 4.0 0.310 19.2 ± 4.3 19.2 ± 5.8 0.999
Stage I/II total (%) 29.1 ± 1.4 25.0 ± 2.4 0.155 26.3 ± 1.4 21.1 ± 2.2 0.063
Stage I/II day (%) 14.6 ± 3.0 2.5 ± 1.6 0.003* 11.1 ± 2.5 1.6 ± 1.0 0.005*
Stage I/II night (%) 55.1 ± 2.5 65.6 ± 5.7 0.114 53.5 ± 3.7 56.4 ± 5.3 0.647
SWS total (%) 3.7 ± 0.7 2.5 ± 0.7 0.239 7.6 ± 1.2 6.6 ± 0.9 0.534
SWS day (%) 2.1 ± 0.6 0.03 ± 0.03 0.005* 2.7 ± 1.1 0.05 ± 0.05 0.041*
SWS night (%) 6.5 ± 1.9 7.1 ± 1.9 0.843 16.5 ± 3.0 18.5 ± 2.4 0.611
REM total (%) 6.3 ± 1.8 3.7 ± 0.8 0.191 4.7 ± 1.0 2.1 ± 0.8 0.070
REM day (%) 2.9 ± 1.4 0.8 ± 0.5 0.203 1.2 ± 0.5 0.0 ± 0.0 0.032*
REM night (%) 12.6 ± 3.0 8.8 ± 1.8 0.305 10.8 ± 2.1 5.8 ± 2.3 0.127
* p < 0.05. Percentages of sleep stages during the 24 h of study, before and after SXB administration. Data are
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melatonin and sleep
The cross-correlations between melatonin levels and the percentages of time spent in 
either SWS, phase I/II non-REM sleep, or time awake were significantly weaker in narcolepsy 
patients compared to controls during the 24-h period (all p < 0.023; Table 5.3). Although SXB 
treatment did not influence the association between melatonin levels and sleep during the 
total 24-h period, restriction of the analyses to the lights-off period showed that, in both 
groups, SXB treatment inverted the association between melatonin concentrations and 
REM-sleep, while it attenuated the negative association between melatonin concentrations 
and time spent awake (Table 5.3).
dIscussIon
Recent publications have suggested an association between altered temporal patterning of 
melatonin secretion in persons complaining of poor sleep and medical conditions linked with 
disordered sleep.192-194 However, to our knowledge, this is the first study which combines 
measurements of diurnal plasma melatonin concentration profiles and polysomnography in 
hypocretin-deficient narcolepsy patients and matched controls. Although mean 24-h levels 
of plasma melatonin were similar between narcolepsy patients and controls, the circadian 
distribution of melatonin release was altered in narcolepsy, since the proportion of melatonin 
secreted during daytime was substantially higher in narcolepsy patients. Moreover, our 
findings indicate that the temporal coupling between sleep and plasma melatonin levels is 
diminished in narcolepsy patients, suggesting that hypocretin deficiency differently affects 
the circadian distribution of sleep and melatonin release because otherwise, despite an 
altered diurnal pattern of sleep and melatonin secretion, their cross-correlation would have 
been expected to remain unchanged. 
In agreement with earlier reports, we did not find differences in mean melatonin levels 
between narcolepsy patients and controls.185;188;195 Moreover, we were able to detect daytime 
melatonin secretion in all our patient and control subjects. This is in line with an earlier study 
in which daytime melatonin secretion was established in less than half of the narcolepsy 
patients.188 Two reasons are likely to account for the fact that we did find an increase in all 
patients and Blazejova in less than half of them: first, we measured (daytime) melatonin 
levels much more frequently, and, second, we assessed melatonin levels in plasma instead 
of saliva in which melatonin concentration is estimated to be only 24% of that in plasma.196
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The proportion of total 24-h melatonin secreted during the daytime was substantially higher 
in narcolepsy patients. This finding may reflect disruption of the circadian control of melatonin 
secretion as a consequence of hypocretin deficiency. Several studies – on sheep,181 pig,179 
rat,180 and zebrafish94 – have found evidence for hypocretinergic innervation of the pineal 
gland as indicated by the presence of hypocretin fibers and/or receptors in this region. 
Functional evidence for the connection between the hypocretin and melatonin system was 
recently provided in a study on zebrafish by Appelbaum et al.94 Zebrafish have only one 
hypocretin receptor gene (humans have two), and serve as a simplified model for the study 
of the hypocretin system.197 Hcrtr-/- null-mutant fish display the disturbed nocturnal sleep 
phenotype, but not the other symptoms of narcolepsy.94 The mutant fish exhibit reduced 
mRNA expression of arylalkylamine-N-acetyltransferase, a key enzyme in the melatonin 
production pathway, during the night,94 suggesting that melatonin secretion may be stimulated 
by hypocretin signalling during the night. As our data indicate that hypocretin deficiency 
results in a smaller amount of the total diurnal melatonin being released during the nighttime, 
our findings are in line with those of Appelbaum et al. and suggest that hypocretin is mainly 
involved in the consolidation of the diurnal rhythm of melatonin release, confining it mainly 
to the dark phase of the circadian cycle. Indeed, another study on zebrafish demonstrated 
synaptic plasticity of the hypocretinergic projections to the pineal gland that exhibited marked 
circadian rhythmicity, again suggesting that hypocretin signalling may modulate circadian 
variations in melatonin secretion. A recent study byMcGregor et al. provides further clues 
as how hypocretin might be involved in the modulation of circadian rhythms.198 Although 
these authors did not assess melatonin release, they found decreased responsivity to light 
in hypocretin deficient mice. Since light is the major suppressor of melatonin synthesis, it is 
conceivable that defects in hypocretin signalling might disrupt light-induced suppression of 
melatonin secretion, resulting in relatively higher daytime concentrations as described in the 
present study. However, the effect of hypocretin on melatonin secretion in humans is likely 
to be modest as one might expect larger differences in the absence of hypocretin. 
A potential limitation of this study is the relatively small number of participants. However, 
this limitation is partly offset by the large number of melatonin samples and the standardized 
conditions under which the sampling was performed. All subjects were assessed at the 
same location, during the same time of year, and under the same lighting conditions. This 
is essential because these factors have been shown to be major modulators of melatonin 
secretion.93 Furthermore, our subjects were closely matched and all narcolepsy patients 
were proven to be hypocretin deficient. 
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In summary, in narcolepsy patients, melatonin secretion was relatively higher during the 
day and exhibited a weaker coupling to sleep, suggesting that hypocretin deficiency might 
disturb both the circadian control of melatonin release and its temporal association with 
various stages of sleep. Furthermore our findings indicate that SXB does not affect melatonin 
secretion per se but might act to modulate its temporal coupling with sleep.
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Introduction: Narcolepsy is associated with obesity though it is uncertain whether 
this is caused by changes in glucose and fat metabolism. Therefore, we performed a 
detailed analysis of systemic energy homeostasis in narcolepsy patients, and additionally, 
investigated whether it was affected by three months of sodium oxybate (SXB) treatment.
Methods: Nine hypocretin deficient patients with narcolepsy-cataplexy, and nine healthy 
sex, age, and BMI matched controls were enrolled. A hyperinsulinemic-euglycemic clamp 
combined with stable isotopes ([6,6-2H2]-glucose and [
2H5]- glycerol) was performed at 
baseline. In seven patients a second study was performed after three months of SXB 
treatment.
results: Glucose disposal rate (GDR) per unit serum insulin was significantly higher 
in narcolepsy patients compared to matched controls (1.6 ± 0.2 vs. 1.1 ± 0.3 μmol/
kgFFM/min/ mU×L; P = 0.024), whereas β-cell function was similar (P = 0.50). Basal 
steady state glycerol appearance rate tended to be lower in narcolepsy patients (5.2 ± 
0.4 vs. 7.5 ± 1.3 μmol/kgFM/ min; P = 0.058), suggesting a lower rate of lipolysis. SXB 
treatment induced a trend in reduction of the GDR (1.4 ± 0.1 vs. 1.1 ± 0.2 μmol/ kgFFM/
min/ mU×L; P = 0.063) and a reduction in endogenous glucose production (0.24 ± 0.03 
vs. 0.16 ± 0.03 μmol/ kgFFM/ min/ mU×L: P = 0.028) per unit serum insulin. After SXB 
treatment lipolysis increased (4.9 ± 0.4 vs. 6.5 ± 0.6 μmol/kgFM/ min; P = 0.018), and 
body weight decreased in narcolepsy patients (99.2 ± 6.0 vs. 94.0 ± 5.4 kg; P = 0.044).
conclusion: We show that narcolepsy patients are more insulin sensitive and may have 
a lower rate of lipolysis than matched controls. SXB stimulated lipolysis in narcolepsy 
patients, possibly accounting for the weight loss after treatment. While SXB tended to 
decrease systemic insulin sensitivity, it increased hepatic insulin sensitivity, suggesting 
tissue-specific effects.
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IntroductIon
Narcolepsy is a sleep disorder that is characterized by excessive daytime sleepiness, cataplexy, 
hypnagogic hallucinations, sleep paralysis, disturbed nocturnal sleep and obesity.1 Both 
obesity and disturbed nocturnal sleep are important risk factors for the development of type 
2 diabetes mellitus (T2DM).199 Narcolepsy is caused by a loss of hypocretin (orexin) neurons 
in the hypothalamus.47;48 Hypocretins are neuropeptides known to be involved in sleep-
wake regulation, feeding behavior as well as body weight and temperature regulation.103;176 
Furthermore hypocretins are important hypothalamic regulators of glucose homeostasis. 
Disturbed activation of hypocretin neurons during sleep deprivation may lead to increased 
basal endogenous glucose production and a decreased insulin sensitivity in rats.200 Moreover, 
hypocretin deficiency leads to an age-related defective glucose tolerance and insulin 
resistance.201 Intracerebroventricular infusions of hypocretin-1 increase hepatic glucose 
production in rats,202;203 but intracerebral injections of hypocretin-1 in the ventromedial 
hypothalamus increase glucose uptake and promote insulin induced glucose uptake and 
glycogen synthesis in skeletal muscle of mice.204 Taken together, these data imply that the 
absence of hypocretin in human narcolepsy may disturb glucose homeostasis.
In the sixties and eighties of the previous century, some reports suggested a higher incidence 
of T2DM in narcolepsy patients.39;41;95 Another study confirmed a higher risk of metabolic 
syndrome independent of body mass index (BMI) when comparing patients with narcolepsy 
to those with idiopathic hypersomnia.22 However, in a recent study comparing narcolepsy 
patients with healthy controls matched for BMI, no differences in insulin resistance could 
be detected using the homeostatic model assessment (HOMA),42 a method which estimates 
β-cell function and insulin resistance from a single pair of fasting glucose and insulin 
measurements.205 Similarly, another more recent study could not find differences in glucose 
tolerance and β-cell function between 17 narcolepsy patients and healthy controls.96 So far, 
there have been no studies using a hyperinsulinemic-euglycemic clamp to estimate insulin 
sensitivity in narcolepsy patients.
Metabolic syndrome and insulin resistance may lead to T2DM within several years if lifestyle 
is not adapted.206 Under normal circumstances pancreatic islet β-cells compensate for insulin 
resistance by increasing insulin release. However, when these compensatory mechanisms fail 
T2DM will develop.207 The most accurate method available for measuring insulin sensitivity 
is the hyperinsulinemic-euglycemic clamp technique.208 During a clamp a fixed dose of 
insulin is continuously infused along with a variable amount of glucose so as to maintain 
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euglycemia, i.e., the plasma glucose levels are “clamped” at a predefined level. Thus, the 
amount of glucose infused necessary to keep plasma glucose levels constant can be used 
as a measure of peripheral insulin sensitivity since relatively lower amounts of glucose will 
be needed in case of insulin resistance.208 
Sodium oxybate (SXB), also known as γ-hydroxybutyrate (GHB), is an effective treatment 
of narcolepsy. It reduces cataplexy, improves nocturnal sleep fragmentation and in higher 
doses it may also reduce excessive daytime sleepiness.73 SXB activates dopaminergic circuits 
in the brain.77 As diminished dopamine (D2) receptor mediated signal transduction appears 
to induce insulin resistance, the metabolic syndrome and T2DM,79 it is conceivable that SXB 
might be protective against developing T2DM. Additionally, there are indications that SXB 
might reduce body weight,74 which could also decrease the risk of T2DM. 
The abovementioned discrepancies between the findings from earlier reports regarding 
potential disturbances in glucose metabolism in narcolepsy patients may be due to 
suboptimal assessment of insulin sensitivity. Moreover, to our knowledge, fat metabolism, 
which is obviously key to systemic energy homeostasis, has not been scrutinized before 
in narcolepsy patients. Therefore, in the present study we applied the gold standard for 
measuring insulin sensitivity, i.e., the hyperinsulinemic-euglycemic clamp, complemented 
with a stable isotope technique to assess both glucose and fat metabolism in a group of 9 
hypocretin deficient narcolepsy with cataplexy patients and 9 individually matched healthy 
controls. In addition, we assessed the effect of three months of treatment with SXB on 
glucose and fat metabolism in narcolepsy patients.
Methods
subjects
Nine narcolepsy with cataplexy patients and nine, individually age, sex, BMI, fat percentage, 
and waist-to-hip ratio (WHR) matched healthy controls were enrolled. All patients fulfilled 
the ICSD-2 criteria for narcolepsy with cataplexy.118 All were HLA DQB1*06:02positive, and 
CSF hypocretin-1 deficient. None of the controls used medication. Seven patients were drug 
naive, one discontinued methylphenidate 2 weeks prior to the study. The last patient was 
tapered off antidepressants and methylphenidate and did not take any drugs in the 2 weeks 
prior to the start of the study. None of the patients used any other medication. Subjects 
were eligible for study after exclusion of hypertension, any known (history of) pituitary, 
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psychiatric, or neurological disease (other than narcolepsy), alcohol or drug abuse, recent 
weight change (> 3 kg weight change within the last 3 months), or a sleep disorder history 
(controls). Routine laboratory tests were performed to rule out overt diabetes, thyroid 
disease, anemia, and hepatic and/ or renal disease. The study was approved by the ethics 
committee of the Leiden University Medical Centre. Written informed consent was obtained 
from all subjects.
clinical protocol
All studies started at 08:30 after an overnight fast. Alcohol consumption and excessive 
exercise on the day preceding the study was not allowed. Caffeinated drinks were also not 
allowed from 18:00 prior to and on the day of study, and smoking was prohibited until the end 
of the measurements. Height, weight, BMI, and waist-to-hip ratio were measured according 
to the WHO recommendations.209 Bioelectrical impedance analysis (Bodystat, Douglas, Isle of 
Man, UK) was used to estimate lean body mass and fat percentage. Subjects were requested 
to lie down on a bed in a semi-supine position. A polyethylene catheter was inserted into 
an antecubital vein for infusion of test substances. Another catheter was inserted into a 
contralateral dorsal hand vein for blood sampling; this hand was kept in a heated box (60°C) 
throughout the test to obtain arterialized blood.210 Samples were taken for measurement 
of basal levels of glucose, insulin, total cholesterol, LDL cholesterol, HDL-cholesterol, 
triglycerides, glycerol and background enrichment of [6,6-2H2]-glucose and [
2H5]-glycerol. At 
08:30 (t = 0 min), an adjusted primed (17.6 μmol/kg × actual plasma glucose concentration 
(mmol/L)) continuous (0.33 μmol/kg/min) infusion of [6,6-2H2]-glucose (enrichment 99.9%; 
Cambridge Isotopes, Cambridge, Massachusetts, USA) was started and continued throughout 
the study. After 60 min, a primed (1.6 μmol/kg) continuous (0.11 μmol/kg/min) infusion 
of [2H5]-glycerol (Cambridge Isotopes) was started and continued throughout the study. 
Subsequently, a primed continuous infusion of insulin (Actrapid, Novo Nordisk Pharma BV, 
Alphen aan de Rijn, The Netherlands; 40 mU/m2/min) was started (t = 120 min). Exogenous 
glucose 20% enriched with 3% [6,6-2H2]-glucose was infused at a variable rate to maintain 
the plasma glucose level at 5.0 mmol/ L. From t = 210 to 240 min, blood was drawn every 
10 min for determination of [6,6-2H2]-glucose and [
2H5]-glycerol specific activities, glucose, 
insulin, and glycerol. While blood in the serum samples was allowed to clot, plasma samples 
were immediately put on ice. Within 60 min of sampling, all samples were centrifuged at 




Narcolepsy patients started SXB treatment after completion of the first clamp session. SXB 
was given in a regular starting dose of 2 nighttime doses of 2.25 grams. Subsequently, the 
dose was titrated up to an optimum for each individual patient, although never exceeded 
the maximum dose of 9 grams per night. When there was satisfactory symptom control for 
3 months, according to the patient and the treating neurologist, patients were allowed to 
embark on the second clamp session. The same neurologist (GJL) evaluated all cases. No 
other drugs were allowed during these 3 months.
Assays
Serum insulin concentrations were measured by enzyme-labelled chemiluminescent 
immunometric assay (Immulite 2500; Siemens, Munich, Germany) with an intra-assay 
coefficient of variation (CV) of 4%. Enrichment of plasma [6,6-2H2]-glucose was determined 
in a single analytical run using gas chromatography coupled to mass spectrometry, as 
described previously.211 All isotope enrichments were measured on a gas chromatograph 
mass spectrometer (model 6890/5973; Hewlett-Packard, Palo Alto, CA). Serum cholesterol, 
high-density lipoprotein (HDL) and triglycerides (TG) were measured with a fully automated 
P-800 module (Roche, Almere, The Netherlands). For both TG and total cholesterol (TC) 
the CV was less than 2%. For HDL the CV was less than 3%. Low-density lipoprotein (LDL) 
cholesterol was calculated according to the Friedewald equation.212
Calculations
In all clamp sessions a physiological steady state was achieved during the last 30 min of both 
the basal as well as the hyperinsulinemic period; therefore, the rates of appearance and 
disappearance for glucose and glycerol were calculated as the tracer infusion rate divided 
by the tracer to tracee ratio.213 Under steady-state conditions the rate of appearance equals 
the rate of disappearance, or the disposal rate. Glucose flux rates were expressed per kg 
fat free mass (FFM), whereas glycerol flux rates were normalized per kg fat mass (FM). 
Endogenous glucose production (EGP) during the basal steady state is equal to the rate 
of appearance of glucose whereas EGP during the clamp was calculated as the difference 
between the rates of glucose appearance and infusion. Since the fasting plasma insulin 
concentration is a strong inhibitory stimulus for EGP, the basal hepatic insulin resistance 
index (μmol/ min/ kgFFM/ pmol×L) was calculated as the product of fasting EGP and fasting 
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plasma insulin concentration.208 The metabolic clearance rate of insulin was calculated as 
the constant infusion rate of insulin divided by the steady state serum insulin concentration 
corrected for endogenous insulin secretion. β-cell function was estimated using the HOMA 
as described previously.205
Statistical analysis
Results are expressed as mean ± standard error (SEM) unless otherwise specified. The 
nonparametric Mann-Whitney U test was used to assess differences in medians between 
patients and controls, whereas the Wilcoxon signed ranks test was applied to assess 
differences between baseline and SXB conditions. The nonparametric Spearman rank 
correlation coefficient was used to assess correlations between changes in weight and other 
metabolic parameters. A paired-samples t-test was used if applicable. All tests were two-
tailed, and significance level was set at P < 0.05. Statistical analyses were performed using 
SPSS for Windows (release 18.0, SPSS, Inc.).
results
subjects
Narcolepsy patients did not differ from controls with respect to sex, age, BMI, WHR, lean 
body mass, or fat percentage (all P ≥ 0.33, Table 6.1). Moreover baseline glucose, insulin, 
total cholesterol (4.7 ± 0.23 vs. 4.7 ± 0.26 mmol/L), LDL cholesterol (3.1 ± 0.18 vs. 3.0 ± 
0.23 mmol/L), HDL-cholesterol (0.98 ± 0.06 vs. 1.2 ± 0.11 mmol/L), and triglycerides (1.4 ± 
table 6.1 Demographics and body composition
Narcolepsy patients Controls P
Male/Female 7/2 7/2
Age (Y) 35.7 (0.9) 37.1 (1.5) 0.33
BMI 29.1 (1.3) 28.3 (1.1) 0.60
Fat (%) 25.0 (2.6) 24.4 (2.8) 0.95
Lean body mass (kg) 71.4 (3.6) 73.4 (3.6) 0.57
WHR 0.89 (0.2) 0.90 (0.2) 0.57




0.26 vs. 1.0 ± 0.14 mmol/L) did not differ between the 2 groups (all P ≥ 0.10). SXB was well 
tolerated except in one patient who discontinued due to an unacceptable increase in sleep 
paralysis. Another patient with excessive daytime sleepiness as major complaint could not 
be assessed after treatment due to the fact that he insisted on taking stimulants. Thus 9 
patients and controls were measured at baseline, and 7 patients were assessed for a second 
time. Narcolepsy patients lost an average amount of 5.2 kg of their body weight after 3 
months of treatment with SXB (99.2 ± 6.0 vs. 94.0 ± 5.4 kg; P = 0.044). 
Glucose metabolism in narcolepsy patients versus controls
An overview of all metabolic parameters in narcolepsy patients and controls during both the 
basal steady state and the hyperinsulinemic steady state is presented in Table 6.2. During 
the basal steady state there were no significant differences in glucose disposal rate (Glucose 
Rd) between patients and controls. In addition, during the hyperinsulinemic steady state 
the glucose disposal rate was similar in narcolepsy patients and controls (55.9 ± 7.9 vs. 40.2 
± 5.3 μmol/kgFFM/min, P = 0.122), despite significantly lower steady state plasma insulin 
levels (33.9 ± 2.9 vs. 42.6 ± 3.5 mU/L, P = 0.047). When adjusted for the differences in plasma 
insulin levels, the glucose disposal rate (1.6 ± 0.2 vs. 1.1 ± 0.3 μmol/kgFFM/min/mU × L, 
P = 0.024) was significantly higher in patients, whereas the rate of endogenous glucose 
production (0.26 ± 0.03 vs. 0.24 ± 0.07 μmol/kgFFM/min/mU × L, P = 0.085) did not differ 
between both groups. In addition, β-cell function as assessed using the baseline glucose 
and insulin levels was equal in the two groups (8.7 vs. 10.3 Mann-Whitney U = 33, Z = −0.66, 
P = 0.50).
Lipid metabolism in narcolepsy patients versus controls 
During the basal steady state plasma glycerol levels (46.7 ± 2.8 vs. 67.2 ± 11.3 μmol/L, P = 
0.070), as well as the rate of glycerol appearance (5.2 ± 0.4 vs. 7.5 ± 1.3 μmol/kgFM/min, 
P = 0.058) tended to be lower in narcolepsy patients compared to controls, suggesting a 
lower rate of lipolysis in narcolepsy patients. However, these trends disappeared during the 
hyperinsulinemic steady state, indicating an intact insulin mediated suppression of lipolysis 
in narcolepsy patients. These findings remained unchanged when adjusted for plasma insulin 
levels (Table 6.2). 
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Glucose metabolism in narcolepsy patients before and after SXB
β-cell function did not change after SXB treatment (P = 0.61). SXB had no obvious effects on 
the basal steady state glucose metabolism (Table 6.3). After SXB treatment the steady state 
plasma insulin levels were significantly higher during the hyperinsulinemic conditions (33.8 ± 
3.8 vs. 48.9 ± 4.8 mU/L, P = 0.018), perhaps due to a significantly lower metabolic clearance 
rate of insulin (0.11 ± 0.02 vs. 0.06 ± 0.01 mL/m2/min, P = 0.018). When adjusted for these 
differences in plasma insulin levels, SXB treatment induced a trend towards a reduced rate 
of glucose disposal (1.4 ± 0.1 vs. 1.1 ± 0.2 μmol/kgFFM/min/mU × L, P = 0.063). In addition 
there was a significant reduction in endogenous glucose production (0.24 ± 0.03 vs. 0.16 
± 0.03 μmol/kgFFM/min/mU × L, P = 0.028) during the hyperinsulinemic condition. Thus, 
SXB had a tendency to decrease peripheral (primarily muscle) insulin sensitivity, while it 
increased hepatic insulin sensitivity (Table 6.3). 
Lipid metabolism in narcolepsy patients before and after SXB
SXB treatment significantly increased both basal levels of glycerol (47.3 ± 3.7 vs. 62.4 ± 5.3 
μmol/L, P = 0.043) and the rate of glycerol appearance (4.9 ± 0.4 vs. 6.5 ± 0.6 μmol/kgFM/
min, P = 0.018), indicating that SXB treatment increases lipolysis in narcolepsy patients 
(Table 6.3). After SXB treatment the rate of lipolysis became lower during hyperinsulinemic 
conditions as evidenced by a trend towards lower plasma glycerol levels (17.8 ± 1.6 vs. 
14.6 ± 1.9 μmol/L, P = 0.063) and a lower rate of glycerol appearance (1.9 ± 0.2 vs. 1.4 ± 
0.2 μmol/kgFM/min, P = 0.018), suggesting that SXB increases the sensitivity of fat tissue 
to the inhibitory effects of insulin on lipolysis (Table 6.3). These findings remained largely 
unchanged when adjusted for plasma insulin levels (Table 6.3).
Metabolic parameters in relation to weight change
The change in body weight after SXB treatment was strongly associated with alterations in 
glucose disposal rate per unit serum insulin (r = -0.93, P = 0.003; Figure 6.1), but not with 
changes in endogenous glucose production per unit serum insulin (r = 0.29, P = 0.535).
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The aim of this study was to accurately assess both glucose and fat metabolism in narcolepsy 
patients, as well as the metabolic effects of SXB treatment using the most accurate method 
available, i.e. a combination of a hyperinsulinemic-euglycemic clamp and stable isotope 
techniques. Surprisingly, we found increased peripheral insulin sensitivity in narcolepsy 
patients, whereas hepatic insulin sensitivity and β-cell function were not different from 
matched healthy controls. The higher insulin sensitivity in narcolepsy patients was reflected 
by a higher rate of insulin-mediated glucose uptake in peripheral tissues, of which skeletal 
muscle is the most important. Lipolysis tended to be lower in narcolepsy patients, which 
could be due to insulin sensitivity of adipose tissue. This finding may at least partly account 
for comorbid overweight in narcolepsy, which is seen in two thirds of the patients.18 Also 
the higher insulin sensitivity itself might contribute.
Furthermore, we found that SXB treatment increased hepatic but tended to decrease whole 
body insulin sensitivity. Moreover, SXB stimulated lipolysis, which might be one of the 
reasons why patients lose weight while on this drug. In our study, patients lost on average 
5.2 kg of weight after 3 months of SXB treatment which is in line with an earlier report that 
SXB treatment is associated with weight loss.74 The mechanisms through which hypocretin-
Figure 6.1 Correlations in body weight change and glucose disposal rate.
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deficiency and SXB treatment affect glucose and fat metabolism might involve modulation 
of autonomic nervous system activity, which recently has been demonstrated to be critically 
implicated in the regulation of energy homeostasis.214 SXB appears to hamper insulin 
mediated glucose disposal in patients who maintain a stable body weight during treatment, 
but it simultaneously induces weight loss in other patients, which clearly compensates for 
the reduction in insulin sensitivity (Figure 6.1). On average, glucose disposal per unit of 
circulating insulin was reduced by SXB (Table 6.3). The impact of SXB on insulin action appears 
to be tissue specific: while glucose disposal is diminished, the capacity of insulin to suppress 
glucose production is reinforced by SXB (Table 6.3). The mechanism underlying the effects 
of SXB is unknown. As glucose disposal rate is primarily determined by glucose uptake in 
muscle tissue, and given the fact that the capacity of insulin to suppress lipolysis was not 
affected by SXB treatment, our findings suggest that the systemic effects of SXB on insulin 
sensitivity are chiefly mediated by changes in muscle, rather than fat, insulin sensitivity.
Since peripheral insulin sensitivity is increased and pancreatic β-cell function is normal in 
narcolepsy patients, our data do not support the notion that the risk of T2DM is increased 
in narcolepsy, which is in contrast to some earlier reports.22;39;41;95 We found no differences in 
pancreatic β-cell function, which is in line with previous observations.42;96 However, increased 
insulin sensitivity has not been previously reported in narcolepsy. Several explanations 
might account for these differences. Firstly, to our knowledge we are the first to apply the 
hyperinsulinemic-euglycemic clamp to assess insulin sensitivity, whereas previous studies 
used indirect and derived measures of insulin sensitivity such as the homeostasis model 
assessment and minimal model analysis.96 Although the method used by Beitinger et al. 
highly correlates with the clamp technique, it is not the same and less accurate.215 Secondly, 
in both earlier studies patients continued to be on their usual medication which might have 
confounded their results. For example, antidepressants, which are used as anticataplectic 
drugs, may induce insulin resistance.216 Thirdly, all our patients were proven to be hypocretin 
deficient and HLA-DQB1*06:02 positive which makes our group more homogeneous than 
the ones in earlier reports. There is a growing body of evidence that hypocretin plays a 
fundamental role in glucose metabolism.200;214;217 However, the precise role of hypocretin in 
systemic glucose homeostasis is likely to be complex and seems even paradoxical since it can 
have both hyperglycemic202 as well as hypoglycemic effects.214 This dual effect of hypocretin 
in glucose homeostasis is probably related to its decisive role in the control of sleep/ wake 
and circadian rhythms, i.e., at awakening hypocretin not only stimulates arousal but also 
glucose production as well as glucose uptake.218
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One limitation of this study is the relatively small number of subjects. However, this 
limitation is partly offset by the application of very sensitive techniques, which would have 
been unfeasible in larger groups of subjects due to the expensive and arduous nature of 
the experiments. 
In conclusion, our findings show that narcolepsy patients are more insulin sensitive and 
tend to have a lower rate of lipolysis than weight matched controls. SXB stimulated lipolysis 
in narcolepsy patients, possibly accounting for the observed weight loss after treatment. 
While SXB had a tendency to decrease systemic insulin sensitivity, it increased hepatic insulin 
sensitivity, suggesting tissue-specific effects.
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the effects of sodium oxybate on 
core body and skin temperature 
regulation in narcolepsy
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study objectives: Patients suffering from narcolepsy with cataplexy show altered 
skin temperatures, resembling the profile that is conductive to sleep onset in healthy 
controls. Temperature manipulation counteracting the altered temperature profile 
improves both daytime and nocturnal narcoleptic sleep-wake disturbances. The aim of 
the present study is to investigate the effects of Sodium Oxybate, a widely used drug 
to treat narcolepsy, on the 24-hour profiles of temperature and sleep-wakefulness in 
narcolepsy patients and controls. 
Design: Prospective case-control study.
setting: Tertiary narcolepsy referral center in a university hospital.
Patients or participants: Eight hypocretin-deficient, male narcolepsy with cataplexy 
patients and eight healthy matched controls.
Interventions: Temperatures of the core body and proximal and distal skin areas, as well 
as the sleep-wake state were measured twice for 24 hours while participants maintained 
a supine posture. After the baseline assessment, 2 x 3 grams of Sodium Oxybate was 
administered for five nights, immediately followed by the second assessment.
Measurements and results: At baseline, daytime core body temperature and proximal 
skin temperature were significantly lower in narcolepsy patients compared to controls 
(core: 36.78 ± 0.05°C vs. 36.97 ± 0.05°C, F = 8.31, P = 0.01; proximal: 33.4 ± 0.26°C vs. 
34.32 ± 0.26°C, F = 5.66, P = 0.03). In patients, Sodium Oxybate administration increased 
proximal skin temperature during the day (F = 6.46, P = 0.04) to a level similar as 
measured in controls, but did not affect core body temperature, distal temperature or 
distal-proximal temperature gradient (DPG). Sodium Oxybate administration normalized 
the predictive value of DPG for the onset of daytime naps (P < 0.01).
conclusions: Sodium Oxybate improved the symptoms of narcolepsy in concert with a 
partial normalization of the skin temperature profile, by increasing daytime proximal 
skin temperature and by restoring the known relationship between skin temperature 
and daytime sleep propensity.
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IntroDuctIon
Narcolepsy with cataplexy is a sleep disorder characterized by excessive daytime sleepiness, 
cataplexy, hypnagogic hallucinations, sleep paralysis and impaired maintenance of nocturnal 
sleep.131 A decreased level of hypocretin-1 (orexin-A) in the CSF is the hallmark of the disease 
and is considered to explain all narcolepsy symptoms.46 
Skin and core body temperature play an important role in sleep and wake regulation.97;219;220 
Wake is associated with a relatively low skin temperature and a relatively high core body 
temperature, while sleep is associated with a higher skin temperature and a lower core body 
temperature. Sleep onset is preceded by a decline in core body temperature and an increase 
in skin temperature. The decrease in core body temperature is mediated through increased 
skin perfusion, which consequently leads to the increase in skin temperature, and facilitates 
cooling of the body.221;222 These changes are facilitated in part by the postural change from 
an upright to a supine position that commonly occurs during sleep.223 
Previous studies demonstrated an altered diurnal profile of skin temperature in narcolepsy. 
Compared with controls, patients with narcolepsy show an increased distal skin temperature 
and a decreased proximal skin temperature in the waking state.23;25;224 This pattern may be 
considered as characteristic of lowered vigilance225;226 or even ‘sleep promoting’, since it is 
also seen in controls immediately before sleep onset.97;219 Indeed, temperature manipulation 
studies in narcoleptic patients counteracting these changes have shown to improve nocturnal 
sleep and excessive daytime sleepiness.24;25 All together, these findings suggest a relationship 
between hypocretin function, temperature and sleep regulation. 
Gammahydroxybutyrate (GHB) is a hypnotic used to improve nocturnal sleep and EDS in 
narcolepsy.227 GHB has a wide range of effects, but the exact mechanisms are still unclear. 
Altered thermoregulation is one of the effects described in animal studies and human 
case reports. Rodent studies demonstrate a slight increase in core body temperature 
after administration of a low dose of GHB (5-10 mg/kg) and a clear decrease in core body 
temperature in higher doses (< 500 mg/kg).99 Several studies describe hypothermia in humans 
with GHB intoxication.100;101 
Sodium Oxybate (SXB) is the sodium salt of GHB and is registered for the treatment of 
narcolepsy. Its effects are comparable to the effects of GHB. Given the impact of GHB 
on temperature regulation, the altered pattern of skin temperature in narcolepsy and 
the positive effects of SXB on sleep in narcolepsy patients, it may be hypothesized that 
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the treatment effect of SXB may in part be mediated by its possible restorative effect on 
temperature regulation. The aim of the present study is to investigate the effect of SXB on 
core body and skin temperature in relation to its effects on sleep. Therefore, we continuously 
measured sleep, core body temperature and skin temperature for 24 hours in narcolepsy 




8 male narcolepsy patients (18-65 years of age) were included after informed consent. They all 
fulfilled the criteria for narcolepsy with cataplexy according to the International Classification 
of Sleep Disorders-2 (ICDS-2),118 suffered clear-cut cataplexy and were hypocretin-1 deficient. 
Two patients were drug naive, one patient was tapered from antidepressants ≥ 2 weeks 
prior to the study, and 2 patients had prior history with SXB; however, no subject took SXB 
within 20 days of study initiation. The other patients did not take any medication for at 
least several months prior to beginning the study. Eight healthy male controls, free of any 
neurologic, endocrine or psychiatric disease, were individually matched for age and body 
mass index (BMI).
study design (Figure 7.1)
The results of this study originate from an extensive protocol that was described previ-
ously.133;173;228 All subjects stayed overnight in the hospital and underwent a baseline 24h 
temperature measurement and polysomnography. During this measurement subjects 
remained (semi)supine except for bathroom visits. Lights were switched off at 23:00h 
and switched on at 7:30h, and daytime naps were allowed. At 8:30h, 13:00h and 18:00h 
a standardized cold meal was served and during the whole day water and tea (caffeine 
free) were available. Following the baseline study, subjects were treated with SXB for 
five consecutive days, the first and the 5th day in the hospital. A second 24h temperature 
measurement and polysomnography was performed on the 5th day of SXB use.
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To monitor possible side effects, the first SXB administration was done in the hospital. Since 
food reduces the bioavailability of the drug, patients were not allowed to eat for at least 
2.5 hours prior to drug administration. Subjects received 3 grams SXB at 23:00h and 3:00h. 
When no adverse-effects were experienced, subjects were allowed to continue the study 
and used this dosage of SXB for the next 4 nights. The 5th night the subjects spent in the 
hospital again for the second measurement.
temperature measurement
During the baseline measurement and 5th night of SXB use, subjects stayed overnight in the 
hospital and a 24h temperature measurement was performed. 
Figure 7.1 At day 1 subjects underwent a 24h temperature measurement and polysomnography 
without any treatment. Following this baseline study, subjects were treated with SXB for five 
consecutive days, the first and the 5th day in the hospital. A second 24h temperature measurement 
was performed on the 5th day of SXB use. The dots on the man indicate the location of the iButtons 
for skin temperature measurement.
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Core body temperature was measured with a wireless monitoring system: an ingestible and 
biocompatible capsule with Vitalsense monitor (Mini Mitter Company Inc., A Respironics, 
Inc. Company Bend, Oregon, USA).229 
Skin temperature was measured with wireless monitoring systems: Thermochron iButtons 
(type DS1921H-F50; Maxim Integrated products, Inc., Sunnyvale, CA, USA)230 Skin temperature 
was measured at 7 locations: left infraclavicular area, both hands, abdomen (1cm above the 
umbilicus), left midthigh (musculus rectus femoris) and both feet. Distal skin temperature 
was obtained from the temperatures at the thenar area at the palmar side of both hands 
and medial metatarsal area at the plantar sides of both feet.231 Proximal skin temperature 
contained the infraclavicular, the thigh and abdominal temperature. Additionally, the 
distal-proximal temperature gradient (distal minus proximal skin temperature, DPG) was 
calculated.
Both core body temperature and skin temperature were sampled once per minute with a 
temperature resolution of 0.125°C.
sleep analysis
Polysomnographic sleep recordings were performed with a portable, Embletta X100 recorder 
(Embla Broomfield, CO, USA) and scored by an experienced sleep technician according to 
the American Academy of Sleep Medicine criteria.119 
Daytime naps were defined as naps if they fulfilled the following criteria: (1) a period of any 
sleep stage (I, II, III or REM) during the ‘lights on’ period (between 7:30h and 23:00h), (2) 
for at least two consecutive minutes, (3) no sleep was registered at least 10 minutes prior 
to the nap.
Data analysis and statistics
To compare sleep characteristics between patients and controls unpaired t-tests were used. 
Paired t-tests were used to analyze sleep characteristics before and during SXb administration. 
Analysis of differences for the number of daytime naps between patients and controls was 
performed with the Mann Whitney U test and the Related-Samples Wilcoxon Signed Rank 
test because of small group size and skewed distribution. 
To evaluate group differences, group by time of day differences and treatment by time of 
day effects on temperature, the mean temperature of each episode of 30 minutes was 
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calculated. With these data Generalized Linear Model for repeated measures with Huynh-
Feldt corrections were run using IBM SPSS 20 (Illinois) with between factor narcolepsy and 
within factors SXB and time of day. This analysis was performed on the 24 hours data, and 
separately for daytime (7:30h-23:00h) and night time (23:00h-7:00h). Posthoc t-tests were 
used to evaluate the times of day where narcolepsy or SXB related differences reached 
significance. 
To evaluate the effect of temperature on nap probability in patients at baseline and during 
SXB administration, mixed effect logistic regression analysis (MlwiN, Center for Multilevel 
Modeling, Institute of Education, London, UK) was applied to account for the 2-level 
hierarchical dependency of the data structure: temperatures measured each minute (time 
of day), nested within subjects. For all analysis the outcome variable was sleep onset, which 
was binomially coded for every 1 minute epoch (since temperature was measured once per 
minute) as wake = 0 and sleep onset = 1. The predictive value of temperature for the odds of 
sleep onset was evaluated using logistic regression. The equation evaluated was as follows: 
logit(Pij) = β0ij + β1 x Xij (subscripts indicate time of day i for subject j), with P representing 
the sleep onset probability and X representing either proximal skin temperature, distal skin 
temperature, distal-proximal temperature gradient (DPG) or core body temperature. For each 
of these temperatures, this analysis was performed with three different regressors. The first 
regressor evaluated was the temperature during the minute prior to the 1-minute epoch. 
The second and third regressor rather evaluated the predictive value of monotonic changes 
in temperature prior to sleep onset. To this end, the second regressor was the difference 
between the temperature immediately prior to the 1-minute epoch and the temperature 5 
minutes before. The third regressor was the difference between the temperature immediately 
prior to the 1-minute epoch and the temperature 15 minutes before.
results
subjects
Eight patients (mean age 38.0 ± 4.7 years) and eight controls (mean age 37.9 ± 4.1 years) 
were included after informed consent. Mean BMI was 28.1 ± 1.6 kg/m2 for patients and 




Sleep characteristics are given in Table 7.1. During the day, patients were significantly less 
awake compared to controls (P = 0.004). SXB administration, results in significantly less stage 
I/II sleep during the day (P = 0.049), and a trend towards more wake (P = 0.052) was seen. 
SXB intake demonstrated a significantly higher percentage slow wave sleep during the night 
in patients (P = 0.014) and in controls (P = 0.045). 
Daytime napping occurred in all patients at baseline and during SXB administration, 
varying from 3 to 16 naps per patient at baseline and from 3 to11 naps per patient during 
treatment. At baseline three controls took 2 or 3 daytime naps per person, while during SXB 
administration five controls took one nap. Both at baseline and during SXB administration, 
patients had significantly more daytime naps then controls (baseline number of naps for 
patients and controls, respectively: N = 57 and N = 8, P < 0.01; treatment number of naps for 
patients and controls, respectively: N = 46 and N = 5, P < 0.01). No significant improvement 
in the number of daytime naps was seen in controls (P = 0.334) or in patients (P = 0.248) 
during SXB administration.
Temperature in narcolepsy patients vs. controls at baseline 
Temperature profiles are demonstrated in Figure 7.2 and the results of statistical analysis in 
Table 7.2. Patients had a significantly lower core body temperature. Proximal skin temperature 
showed a trend to be lower in patients (F = 4.13, df = 1, P = 0.06), while in distal skin 
temperature and in distal-proximal temperature gradient (DPG) no significant differences 
were found. Analysis of the effect of group by time of day showed a nearly significant effect 
of narcolepsy by time of day for proximal skin temperature (F = 2.24, df = 5.49, P = 0.05). 
Separate analysis of daytime and night time temperatures demonstrated a significantly 
lower proximal skin temperature (F = 5.66, df = 1, P = 0.03) and core body temperature (F = 
8.31, df = 1, P = 0.01) in patients during daytime. Furthermore, a significant effect of group 
by time of day was seen for core body temperature during daytime (F = 2.82, df = 7.11, P = 
0.01) and for distal skin temperature during nighttime (F = 4.34, df = 2, P = 0.02). 
Post-hoc tests indicated a significantly (P < 0.05) lower core body temperature in narcolepsy 
between 16:30 and midnight (00:00) and between 10:00 and 12:00 the next morning. The 
same was found in proximal skin temperature between 15:30 and 23:00 and between 11:00 
and 12:00 the next morning. 
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Figure 7.2 Temperature profiles of narcolepsy patients vs. controls.
table 7.2 Temperatures of controls vs. patients at baseline
df F P-value
Group effect
Proximal skin temperature 1 4.13 0.06
Distal skin temperature 1 0.17 0.69
DPG 1 0.52 0.48
Core body temperature 1 6.46 0.02*
Group by time of day effect
Proximal skin temperature 5.49 2.24 0.05
Distal skin temperature 7.46 1.25 0.28
DPG 8.91 1.75 0.09
Core body temperature 4.83 1.96 0.10
* P < 0.05.
Temperature in narcolepsy patients: baseline vs. SXB (Table 7.3, Figure 7.3)
In patients, a significant main effect of SXB on proximal skin temperature (F = 6.41, df = 1, P 
= 0.04) as well as a nearly significant SXB by time of day effect (F = 2.22, df = 4.80, P = 0.08) 
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Table 7.3 Temperatures at baseline vs. during SXB administration
Controls Patients
df F P-value df F P-value
treatment effect
Proximal skin temperature 1 0.03 0.88 1 6.41 0.04*
Distal skin temperature 1 0.48 0.51 1 2.11 0.19
DPG 1 1.41 0.27 1 0.46 0.52
Core body temperature 1 0.01 0.91 1 2.07 0.19
treatment by time of day effect
Proximal skin temperature 5.06 0.61 0.70 4.80 2.22 0.08
Distal skin temperature 6.48 0.37 0.91 11.05 1.36 0.21
DPG 6.74 0.33 0.93 9.44 1.56 0.14
Core body temperature 5.74 1.65 0.16 7.58 1.56 0.16
* P < 0.05.
Figure 7.3 Temperature profiles of narcolepsy patients at baseline and during SXB administration. 
(A) distal skin temperature in patients at baseline and during treatment with SXB, (b) proximal skin 
temperature in patients at baseline and during treatment with SXB, (c) distal-proximal temperature 
gradient (DPG) in patients at baseline and during treatment with SXB (D) core body temperature in 
narcolepsy patients at baseline and during treatment with SXB. The gray area indicates the lights off 
period and the striped area the period during which the temperature significantly differed according 
the post-hoc tests (* P < 0.05). Data are expressed as mean ± SEM.
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was seen. Additional separate daytime and night time analysis demonstrated that proximal 
skin temperature was higher during the day in the SXB condition (F = 6.46, df = 1, P = 0.04), 
but no difference was found during night time (F = 0.08, df = 1, P = 0.79). In post-hoc tests 
significance (P < 0.05) was reached from 15:00 to 16:00, from 18:00 to 19:30, and from 8:00 
to 9:30 and 10:30 to 12:00 the next morning. 
For core body temperature, distal skin temperature and DPG, no main significant effect was 
found for SXB administration. 
Summarizing, SXB administration in patients increased proximal skin temperature at several 
time points during daytime. There was no effect on core body temperature, distal skin 
temperature and DPG.
Temperature in controls: SXB vs. baseline (Table 7.3)
In controls, no significant effect of SXB or SXB by time of day was found on core body 
temperature, skin temperatures and DPG. 
The predictive value of temperature changes in the onset of daytime naps (Table 7.4).
Since daytime napping was rare in controls, only daytime naps in patients were analyzed. 
Mixed effect logistic regression analysis of sleep onset in patients at baseline revealed no 
predictive value of the four temperature variables for daytime sleep onset. However, during 
SXB administration changes in DPG significantly predicted sleep onset. Change in DPG 15 
minutes prior to sleep onset, 5 minutes prior to sleep onset and DPG one minute prior falling 
asleep significantly predicted daytime napping (respectively O.R. 1.99 (P = 0.009), O.R. 2.23 
(P = 0.042) and O.R. 1.33 (P = 0.029) per degree Celsius change in temperature).
DIscussIon
The aim of this study was to investigate the effects of SXB on core body and skin temperature 
in relation to its effects on sleep in patients suffering from narcolepsy with cataplexy. This is the 
first study in which both core body and skin temperature were measured in combination with 
continuous sleep registration in narcolepsy. At baseline, patients had significantly lower daytime 
core body and proximal skin temperatures compared to controls. In patients, SXB increased 
nocturnal slow wave sleep (SWS), normalized proximal skin temperature, and strengthened 
the relationship between changes in skin temperature and subsequent daytime sleep onset. 
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An altered thermoregulatory profile in narcolepsy
In the present study, core body temperature and proximal skin temperature were lower in 
narcolepsy, mainly caused by significant differences during daytime. No significant differences 
in distal skin temperature were found, although the nocturnal time course of distal skin 
temperature significantly differed between patients and controls.
The finding of a decreased daytime proximal skin temperature in narcolepsy patients 
compared to controls was previously demonstrated as well.23 In contrast to our current 
findings, this previous work also reported a higher distal skin temperature. The combination 
of the increased distal skin temperature and the decreased proximal skin temperature in 
that study resulted a higher distal-proximal temperature gradient (DPG). Comparison of 
the present study with the previous one indicates that the absence of a higher distal skin 
temperature in patients, and subsequently the absence of a higher DPG, is mainly due to 
a higher distal skin temperature in controls in the current study. Since a higher distal skin 
temperature can be a direct consequence of a supine position,232 maintaining this position 
throughout our study can be the explanation of the higher distal skin temperature found 
in controls. Concertedly, these results indicate that narcolepsy patients are likely to attain, 
even in an upright or sitting position, the high distal skin temperature that healthy controls 
reach only when remaining in a supine position. 
We found a lower core body temperature during the day in patients. In the past, core body 
temperature has been more extensively studied than skin temperature. Unfortunately, previous 
studies in narcolepsy are not conclusive at this point; results vary from an elevated core body 
temperature to a lowered core body temperature.25;233-236 Manipulation studies demonstrate a 
minimal effect of manipulation of core body temperature on sleep propensity,25;221;231 however, 
a high core body temperature is associated with higher vigilance.25;222
SXB normalizes temperature profiles in narcolepsy
In patients, SXB administration significantly increased daytime proximal skin temperature, 
reaching levels comparable with healthy controls. Paradoxically, based on previous 
temperature manipulation studies proximal skin warming would result in increased 
sleepiness.24;231;237 This finding is in contradiction with the knowledge that SXB reduces the 
amount of daytime sleep attacks.238 However, warming up the skin by direct manipulation 
as performed in this previous study, may represent a different physiological mechanism 
compared with the intrinsic skin warming resulting from SXB administration. 
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In healthy subjects, sleep onset is preceded by a decline in core body temperature and an 
increase in distal skin temperature.222 In healthy controls, an increased DPG is associated 
with a lower vigilance225;226 and an accelerated sleep onset.97;219 In narcolepsy, a shorter 
sleep onset latency was found to be associated with an increase of proximal and distal skin 
temperatures and, to a lesser extent, an increase of the DPG.23 However, none of these studies 
concerned spontaneous daytime napping in narcolepsy patients. Analysis of spontaneous 
naps in (semi) supine position in the present study revealed an absence of predictive value 
for any of the temperature measurements in narcolepsy patients at baseline. Surprisingly, 
during SXB administration an increase in DPG did become predictive for subsequent daytime 
sleep onset. The relationship between skin temperature and sleep onset that is known to 
exist in controls thus seemed to be restored by the administration of SXB.
Does altered thermoregulation play a role in SXB’s effects on sleep?
An increase in nocturnal SWS, previously reported to be one of the principal effects of SXB 
on sleep,238-241 was confirmed in this study. If this is mediated by an altered temperature 
regulation is questionable, since there were no nocturnal temperature effects seen during 
SXB intake in this study. The relatively high percentage of wake during the night in controls 
is probably due to the laboratory settings. 
Study limitations 
Since body position directly affects skin temperature, the major limitation of this study is 
the setting during which patients were in (semi) supine position for 24 hours. This body 
position differs from the situation in normal daily life, and the setting in previous studies. 
Moreover, the clinical effects of SXB on nocturnal sleep can already be experienced with 
the dose we have used in the first night of its use, but it usually takes several weeks and a 
higher dose to obtain significant improvement of EDS. Subsequently, it is presumable that 
there are some long-term effects, particularly during daytime that may have been missed 
in this study. Furthermore, the present study only included male subjects, while men and 




In conclusion, during a constant routine protocol a decreased daytime core body and proximal 
skin temperature were observed in narcolepsy patients compared to controls. Administration 
of SXB normalized the sleep wake pattern as well as the temperature profiles in narcolepsy 
patients. Furthermore, SXB restored the relationship between skin temperature and 
subsequent sleep onset – that is known to exist in controls – in patients. To further explore 
the role of SXB in temperature regulation and sleep in narcolepsy, studies with patients and 
controls of both sexes have to be performed in normal daily life. 
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Other aspects of narcolepsy

month of birth is not a risk factor 
for narcolepsy with cataplexy
in the netherlands
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The month of birth has been proposed as a risk factor for narcolepsy, suggesting a harmful 
influence during early development. Several authors have described an excess of births 
in March in those developing narcolepsy later. Analysis methods in published studies 
varied, but no study corrected completely for possible changes in seasonal birth pattern 
over time in the appropriate population. The present study describes changes in seasonal 
birth pattern of the entire Dutch population over a 79-year span and compared the 
monthly birth pattern of Dutch narcoleptics with the population data. Month and year 
of birth were noted for 307 patients with non-familial narcolepsy with cataplexy, born 
in the Netherlands between 1923 and 2001. The numbers of live births per month and 
per year from the entire Dutch population for the same period were used to calculate 
a virtual data set of expected births per month with exactly the number of cataplexy 
cases, but with the birth pattern of the Dutch population. Observed and expected 
numbers per month were compared using the chi-square test. In the 1970s the peak 
of births shifted from spring to autumn, confirming the need to correct for changing 
seasonal patterns. There was no significant difference between observed and expected 
birth numbers per month. An effect of birth month on the occurrence of narcolepsy 
with cataplexy was not found in a study of 307 cases after adjusting for changing birth 
patterns in the general population.
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IntroductIon
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy 
and nocturnal sleep disturbances.102 Narcolepsy with cataplexy is associated strongly 
with a loss of hypocretin-producing neurones in the hypothalamus.47 The exact aetiology 
of this cell loss is unknown.242 The strong association of narcolepsy with cataplexy with 
several human leucocyte antigen (HLA) subtypes suggested that autoimmune processes 
play a role in the pathogenesis of narcolepsy.243 However, searches for evidence to support 
the autoimmune hypothesis, for instance the detection of autoantibodies or inoculation 
with immunoglobulins, have failed.242;244 The recent discovery of circulating anti-Tribbles 
homologue 2 (TRIB2) antibodies reactive with hypocretin neurones strongly supports 
the autoimmune nature of narcolepsy.59 Another approach to demonstrate autoimmune 
involvement involves studying the distribution of births over the months of the year. For 
some disorders with a presumed autoimmune origin (multiple sclerosis, type I diabetes and 
inflammatory bowel disease), seasonal birth patterns were found to differ from those of the 
population as a whole.245;246 The underlying concept is that exposure to various environmental 
factors such as viruses may vary during the course of the year. An exposure in early life may 
later set events in motion leading to the development of a specific disease. Several studies 
have addressed seasonal birth patterns in narcolepsy.170;247-251 A relative abundance from 
March to June as well as a relative paucity in September has been described in a study 
of 555 German cases.248 A similar pattern was also described for 886 cases, from French, 
Canadian and Californian sources combined.249 This type of study is not without potential 
problems. First, birth data from the narcolepsy population under study should ideally be 
compared with an appropriate control population, as the putative environmental risk factors 
might depend upon the geographical origin of the populations, as well as on cultural habits 
or racial susceptibility. Secondly, seasonal birth patterns in a population may well differ 
over time under the influence of factors such as changes in contraceptive use or in cultural 
attitudes towards procreation, as these may affect a priori chances of risk exposure. Hence, 
any comparison should correct for changes in birth patterns over years or decades. None 
of the above-mentioned studies corrected completely for both sources of potential error. 
In the present study we first investigated if and how the distribution of births over the 
year changed between 1923 and 2001 in the entire population of the Netherlands. Then, 
we compared the birth pattern of Dutch narcoleptic patients with that of the entire Dutch 





Data from 337 Dutch narcolepsy patients with cataplexy were available from The Leiden 
University Medical Centre narcolepsy database. Diagnostic criteria were those of the 
International Classification of Sleep Disorders.118 Thirty cases were excluded to improve 
the homogeneity of the study group; reasons for exclusion were being born outside the 
Netherlands (n = 9), atypical cataplexy (n = 10) and familial cases (n = 8). Three cases, born 
before 1923, were excluded because complete birth data were not available for the Dutch 
population prior to that year.
Statistical analysis
The month and year of birth were noted for 307 (146 men) patients with narcolepsy with 
typical cataplexy, born 1923–2001. The number of live births for each month in the period 
1923–2001 was obtained from The Dutch Central Bureau of Statistics (Voorburg, The 
Netherlands). We first assessed whether the distribution of births over the months of the 
year changed during the 79 years of study.
To do so, the numbers of births per month in any given year were divided by the total number 
of births of that year, resulting in a series of 12 fractions of that year’s births. The fractions 
were then plotted as a function of month and year, allowing any changes to be visualized. The 
second step of analysis concerned the comparison of birth distribution of narcoleptics with 
that of the population. Two tables were formed containing the absolute number of births 
by month and by year; one table concerned narcoleptics, the other the Dutch population. 
The narcolepsy table was used to add the number of births per month, resulting in 12 totals 
for January–December: this was the observed monthly birth distribution for the narcolepsy 
group. The same table was also used to calculate the number of births of narcoleptics for each 
of the 79 years. Both tables were used to arrive at the expected monthly birth distribution 
for narcoleptics, as follows. For each year, the population table was used to calculate which 
fraction of that year’s births occurred in each of the 12 months. These 12 fractions were 
multiplied by the number of births of narcoleptics of that year, resulting in 12 virtual birth 
numbers. In this way, the number of births per year was the same in the virtual group as in 
the narcolepsy group, but their distribution over the months was exactly that of the general 
population. Adding the calculated virtual birth numbers over all 79 years for each month 
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resulted in 12 numbers: expected monthly birth distribution. The observed and expected 
monthly birth distributions were compared with the chi-square test. This technique was also 
used to study seasonal patterns instead of months, by pooling data from three consecutive 
months, starting with winter (January–March), analogous to the approach taken by other 
authors.248 Finally, odds ratios were calculated per month, comparing the number of births 
in the particular month to the pooled number of births in the other 11 months, with the 
expected number of births as reference category.
results
A total of 16 699 889 live births were recorded in the 79 years of study in the Netherlands. 
The monthly distribution of these births did not remain stable over the years: during the 
1970s the birth peak shifted from spring to autumn (Figure 8.1). The figure also shows a 
profound disruption for the period during World War II, which in the Netherlands lasted 
from May 1940–May 1945. The observed monthly birth distribution of the narcolepsy with 
cataplexy group did not differ significantly from the expected monthly birth distribution (v2 
= 8.350, df = 11, P = 0.681; Figure 8.2). This also held for the secondary analyses when births 
were grouped per season (v2 = 1.229, df = 3, P = 0.745). None of the calculated odds ratios 
per month differed significantly from one.
Figure 8.1 Distribution of births in the Netherlands 1923–2003. The number of births per year and 
month were calculated on a yearly basis to obtain the fractions of each year’s births per month. 
The resulting table of 79 years x 12 months were used to calculate a filled contour plot, in which 
the range of fraction (0–1) was divided into bands of similar colour. Darker colours indicate higher 
fractions of births. Note the shift of birth peak from spring to autumn during the 1970s and the 
abrupt upheavals in birth pattern during World War II (1940–1945) (note also that the statistical 




This is the first study on birth month patterns in narcolepsy that takes geographical and 
temporal criteria fully into account. The method of analysis corrects for changes in birth 
patterns that occurred in the general population. Such corrections were necessary, as shown 
by the shift in peak from spring to autumn occurring in the 1970s, and by the marked changes 
occurring during the World War II. The descriptive nature of the study means that the causes 
of the change in the 1970s cannot be identified, even though social changes and changes 
in methods of contraception may have contributed.
No effect of birth month on the occurrence of narcolepsy was observed, in contrast to some 
earlier reports. Some authors reported a significantly different seasonality of birth month 
compared to that of the general population,248-251 whereas others mentioned a predilection 
for births in March without stating statistical significance.170;247 It is possible that correction 
factors explain the discrepancy, but this remains uncertain. 
A limitation of this study is the relatively small size of the patient group. Despite this, the 
method used in this study has advantages over those used in previous studies. Compared 
to previous studies in this field, the ascertainment percentage of narcolepsy patients in our 
group is the highest. Furthermore, the study was performed on a very homogeneous group 
of narcolepsy patients. In addition, the Netherlands is a relatively small country with a high 
Figure 8.2 Observed versus expected births by month. The total number of births for each month 
over 79 years are shown for the narcolepsy group and the calculated expected number, matched 
for birth year. See the text for an explanation. The distributions did not differ significantly (P = 0.94).
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population density and no pronounced climatic or other geographical differences between 
areas, providing even more uniform conditions. Finally, we suggest that the methods used 
in this study to correct for changing birth patterns may be used also to research birth month 
patterns for other diseases.

Delusional confusion of dreaming 
and reality in narcolepsy










study objectives: We investigated a generally unappreciated feature of the sleep disorder 
narcolepsy, in which patients mistake the memory of a dream for a real experience, 
forming sustained delusions about significant events.  
Design: We interviewed narcolepsy patients and controls to establish the prevalence 
of this complaint and identify its predictors.
setting: Academic medical centers in Boston and Leiden.
Participants: Patients (n = 46) with a diagnosis of narcolepsy with cataplexy, and age-
matched healthy controls (n = 41).
Measurements and results: “Dream delusions” were surprisingly common in narcolepsy 
and were often striking in their severity. As opposed to fleeting hypnagogic and 
hypnopompic hallucinations of the sleep/wake transition, dream delusions were false 
memories induced by the experience of a vivid dream, which led to false beliefs that 
could persist for days or weeks.
conclusions: The delusional confusion of dreamed events with reality is a prominent 
feature of narcolepsy, and suggests the possibility of source memory deficits in this 
disorder that have not yet been fully characterized.
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IntroDuctIon
Each time we recall an event from the past, we are faced with the dual tasks of identifying 
the source of the memory and evaluating its veracity. In general, we can accurately determine 
whether a memory originated in our past experience, as opposed to in our imagination, 
a dream, a film, or a story. However, this process of “source monitoring” sometimes goes 
wrong.252-254 Minor confusions about the source of a memory are common in the general 
population, as when we mistake the source of a quotation, misremember the context in 
which we met an acquaintance, or even believe that we actually experienced an event 
that we only heard about. Recently, case reports have described more severe examples of 
memory source confusion in patients suffering from the sleep disorder narcolepsy, in which 
false accusations of sexual assault occurred when patients mistook a dreamed assault for 
the memory of an actual event.28;29 These reports are remarkable in that dream memories 
were misinterpreted as representing real, highly significant life events, leading to sustained 
delusions that became the basis for serious actions. Narcolepsy is a disorder of excessive 
sleepiness, and is not typically associated with psychotic symptoms.255 The dramatic 
nature of these case reports led us to undertake the first systematic study of these “dream 
delusions” in narcolepsy. In a structured telephone interview, we asked narcolepsy patients 
and controls a series of questions about sleep, dreaming, and memory. Our goals were (1) 
to characterize the incidence of this phenomenon in narcolepsy patients, as compared to 
the general population, and (2) to describe the features of this experience.
MethoDs
Participants
Narcolepsy patients and age-matched controls were recruited at two collaborating sites, Beth 
Israel Deaconess Medical Center in Boston, Massachusetts (n = 18), and Leiden University 
Medical Center in the Netherlands (n = 69). Institutional review boards at both institutions 
approved this research. Patients (n = 46; age 34.2 ± 10.9 [SD], 59% female) had a definite 
diagnosis of narcolepsy with cataplexy for a minimum of 6 months prior to the study, 
according to the standards of the International Classification of Sleep Disorders (ICSD-2) 
Diagnostic and Coding Manual.118 Diagnoses were confirmed by interview and review of 
medical records, including clinic notes, overnight sleep studies, multiple sleep latency tests 
(MSLTs), and Human Leukocyte Antigen testing. At the time of the interviews, patients 
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were under treatment with a variety of medications to manage their narcolepsy, including 
stimulants (72% of patients; includes modafinil, amphetamine, dextroamphetamine, and 
methylphenidate), antidepressants (15% of patients; includes tricyclics, SSRIs, SNRIs and 
SARIs), and sodium oxybate (35% of patients). There were no differences in medication 
usage between those with and without dream delusions (chi-square tests of independence: 
stimulants: P = 0.82, antidepressants: P = 0.64, sodium oxybate: P = 0.69). Controls were 
recruited from the general population (n = 41; age 32.7 ± 11.6 SD, 59% female), and were 
screened (by self-report) to exclude the presence of any diagnosed sleep disorder. There 
were no differences across study sites in participant age, gender, habitual sleep schedule, 
dream recall, or incidence of reported confusion.
Interview procedures
Participants completed a ~30-min structured telephone interview in which they were asked 
a series of questions pertaining to sleep, dreaming, and memory. Following questions about 
their habitual sleep schedule and dream experiences, participants were asked, “Have you 
ever had the experience of being unsure whether something was real, or if it was from a 
dream?” Delusional episodes were defined as incidents in which a fully awake participant 
was uncertain if a memory was dreamed or real, or was convinced that a memory was real, 
only later to discover that it was actually dreamed. To be included, a delusional episode 
was required to clearly persist into the waking state – Fleeting feelings of confusion during 
the transition to wakefulness were excluded because brief confusion is a well-known 
consequence of the hypnagogic and hypnopompic hallucinations characterizing narcolepsy. 
For purposes of analysis, participants were categorized as a “Yes” for having dream delusions 
if they claimed to have experiences that met this definition, and were able to provide at 
least one detailed example of an instance when this had occurred.  
To compare general features of dreaming between narcolepsy patients and controls, 
participants also rated the frequency, emotionality, and intensity of their typical dream 
experiences on a 5-point scale.  
At the conclusion of the interview, two standardized questionnaires were verbally 
admin istered – the Boundary Questionnaire and the Prospective-Retrospective Memory 
Questionnaire. Ernest Hartmann’s Boundary Questionnaire, assesses the personality 
construct of psychological boundaries.256;257 A “thin” boundary score (higher values) is 
associated with frequent and intense dreaming, as well as high interest in dreams, and the 
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report of unusual sleep experiences such as sleep paralysis and sleep-related hallucinations, 
both of which are features of narcolepsy. We administered the 18-item short form of the 
Boundary Questionaire.256 The Prospective-Retrospective Memory Questionnaire (PRMQ) 
assesses subjective complaints of difficulties in remembering to carry out intentions 
(prospective memory), and in remembering the events of the recent past (retrospective 
memory).258;259 Seventeen participants who reported dream/reality confusions meeting our 
criteria additionally reported to the laboratory for a face-to-face interview in which they 
described the qualities of these experiences in greater detail.
results
Dream delusions were extremely common in narcolepsy. Overall, 83% of narcolepsy patients 
reported that they had confused dreams with reality, compared to only 15% of controls (χ2 
= 40.1, P < 10-10; Figure 9.1). The severity of these delusions was striking. One man, after 
dreaming that a young girl had drowned in a nearby lake, asked his wife to turn on the local 
news in full expectation that the event would be covered. Another patient experienced sexual 
Figure 9.1 Prevalence of dream-reality confusion. Patients with narcolepsy were much more likely 




dreams of being unfaithful to her husband. She believed this had actually happened and 
felt guilty about it until she chanced to meet the ‘lover’ from her dreams and realized they 
had not seen each other in years, and had not been romantically involved. Several patients 
dreamed that their parents, children or pets had died, believing that this was true (one 
patient even made a phone call about funeral arrangements) until shocked with evidence to 
the contrary, when the presumed deceased suddenly reappeared. Although not all examples 
were this dramatic, such extreme scenarios were not uncommon.
All narcolepsy patients reporting dream delusions provided multiple examples of such 
occurrences. Two-thirds of patients (65%) who completed the follow-up interview reported 
experiencing dream delusions at least once a week, and all but two (95%) had the experience 
at least once a month. In contrast, of the 6 control participants who reported delusions, only 
2 (5% of all control subjects) had experienced this more than once in their lives.
The classic hypnagogic and hypnopompic hallucinations of narcolepsy are fleeting images and 
feelings linked to the current environment, and patients recognize the hallucinatory nature 
of the experience within seconds of awakening. In contrast, the experiences reported here 
were much longer lasting, persisting into stable wakefulness. In follow-up interviews (see 
Methods), patients reported that although some delusions resolved within minutes after 
awakening, they often persisted for hours, days, or even weeks. 
In line with prior literature,260;261 narcolepsy patients rated their dreams as substantially more 
vivid (t83 = 3.79; P = 0.0003) and more emotional (t82 = 5.25; P < 10
-6) than the age-matched 
controls. They also reported recalling dreams more frequently than controls (t84 = 3.16; P = 
0.002), and scored higher on the BQ than controls (indicating that patients had “thinner” 
boundaries; t85 = 1.98; P = 0.05). However, we found no evidence that dream delusions were 
related to an abnormal quantity or quality of dream experience in narcolepsy. Within the 
narcolepsy sample, neither BQ scores nor any other measure of dreaming differentiated 
between those who did and did not experience confusions (all Ps > 0.1). 
While prior research has largely failed to find objective memory dysfunction in narco-
lepsy,26;262;263 subjective complaints of memory difficulty are common.264 Here, narcolepsy 
patients scored higher than controls on the PRMQ for both retrospective memory problems 
(t85 = 3.71, P = 0.0004) and prospective memory problems (difficulties in remembering to carry 
out intentions; t85 = 4.20, P = 0.00007). However, memory impairment as measured by the 
PRMQ did not discriminate between narcolepsy patients with and without dream delusions.
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DIscussIon
Our data reveal an underappreciated memory problem in narcolepsy, in which patients are 
prone to delusionally believe that dreamed events actually occurred. These “dream delusions” 
are a special case of memory source confusion, a well-described phenomenon in which the 
origin of a particular memory is misattributed.253 The conflation of dream experiences with 
actual events has previously been described in healthy controls.265;266 However, in this sample 
of narcolepsy patients, the incidence and severity of dream delusions was striking, and far 
greater than that seen in controls. These observations suggest that something about the 
pathophysiology of narcolepsy leads to a profound confusion of memory source. Although 
the mechanism of dream delusions cannot be determined at this time, several possibilities 
present themselves. First, on the phenomenological level, our observations confirm previous 
reports of frequent and intense dreaming in narcolepsy. Thus, it is possible that patients 
mistake dream experiences for real events because the vividness of their dreams prevents 
the use of perceptual realism as a cue in discriminating the dreamed from the real. Our data 
did not provide support for this hypothesis, as dream vividness ratings did not discriminate 
between patients with and without delusions. However, the possibility that these delusions 
are caused by an abnormal intensity of dream experience in narcolepsy certainly cannot 
be ruled out. 
Alternatively, dream delusions may be just one manifestation of a more general memory 
deficit in this disorder. Consistent with this possibility, we found evidence of subjective 
memory difficulties in narcolepsy, as assessed by the PRMQ. Again, however, this measure did 
not discriminate between patients with and without delusions. To our knowledge, no prior 
study has examined any form of memory source confusion in narcolepsy. Thus, it cannot be 
said at this time whether the delusions observed here are specific to dreaming, or whether 
narcolepsy patients might be equally prone to confuse the origin of other memories, for 
example mistaking imagined events or stories they have heard as personal experiences. 
Future studies employing standard source monitoring tasks in narcolepsy patients should 
be able to better determine the specificity of this complaint.
Finally, dream delusions could result from an abnormality of memory encoding specific to 
the sleep state. The failure to discriminate memories formed during sleep from waking life 
experiences could be a direct consequence of the well-described neural mechanisms of 
narcolepsy. Narcolepsy is caused by destruction of orexin/hypocretin neurons in the lateral 
hypothalamus. Normally, the orexin system helps stabilize wake/sleep states, and loss of 
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the orexin neurons results in “state dissociation” characterized by frequent transitions 
between states and the intrusion of aspects of rapid eye movement sleep into waking.267 
As monoaminergic and cholinergic neurons involved in the control of sleep states are major 
targets of the orexin neurons, we speculate that abnormal activity in these neurons during 
sleep could alter the encoding of dream content in long-term memory stores, leading to 
its misattribution as waking memory. Disruption of sleep neuromodulation, for example, 
could cause features of wakefulness to bleed into REM sleep, strengthening the typically 
poor memory encoding during this state.
Though the underlying mechanism of dream delusions is unknown, it is clear that many 
people with narcolepsy have a surprising and intense difficulty distinguishing the dreamed 
from the real. In concert, these patients perceive themselves as having more general 
difficulties with both retrospective and prospective memory. These observations highlight the 
possibility of source memory deficits in narcolepsy that have not yet been fully characterized.
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General introduction and aims of the thesis
A short overview of the symptoms, pathophysiology and treatment of narcolepsy is presented 
in chapter 1. Narcolepsy is caused by hypocretin deficiency and characterized by the classical 
symptoms; excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis 
and nocturnal sleep disruption. In addition there are numerous other signs and symptoms 
including increased weight and endocrine disturbances. Sodium oxybate (SXB) is a drug 
that may have a positive effect on all symptoms of narcolepsy. In addition it may influence 
endocrine function and metabolism as well as shown in Part I and II.
Part I EndocrInE studIEs In narcolEPsy
In part I we describe a large endocrine study. Eight male hypocretin-deficient narcolepsy 
with cataplexy patients and eight controls matched for sex, age, body mass index, waist-to-
hip ratio and fat percentage were enrolled in this study. All narcolepsy patients were free 
of medication for at least 2 weeks before the study. None of the controls took medication. 
Patients and controls underwent 24 h blood sampling at 10 minute intervals for measurement 
of prolactin (PRL) and growth hormone (GH) concentrations, at 20 minute intervals for 
leptin, and at hourly intervals for ghrelin and melatonin. This was done at baseline and on 
the fifth consecutive day of SXB administration. Three grams of SXB was taken two times per 
night for 5 consecutive nights. Subjects remained (semi)supine except for bathroom visits. 
Three standardized meals were served, and non-caffeinated tea and water were provided 
ad libitum. Daytime naps were allowed, and lights were switched off between 2300 h and 
0730 h the next day. In addition to the blood samples, sleep was polygraphically recorded 
throughout both sampling occasionsperiod. Skin temperature was measured using I-buttons 
and core body temperature using the Jonah capsule as is described in Part II of this thesis.
sodium oxybate increases prolactin secretion in narcolepsy patients and healthy 
controls 
Chapter 2 addresses the question whether plasma PRL concentrations are different between 
hypocretin deficient narcolepsy patients and controls. In addition we explored the effect of 
sodium oxybate on PRL release pattern in both groups. The PRL concentration time series was 
analysed with a new deconvolution programme, approximate entropy (ApEn) and with cosinor 
analysis. ApEn is a model-independent statistic used to quantify the regularity of a time series, 
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here PRL release. Basal and pulsatile PRL secretion, as well as pulse regularity and frequency, 
ApEn and diurnal parameters were similar in patients and controls. SXB treatment caused 
similar nocturnal increase in PRL secretion, advance of the acrophase and decrease in ApEn 
in patients and controls. Slow wave sleep was increased to a similar extent in patients and 
controls. This detailed study did not demonstrate altered PRL secretion in hypocretin-deficient 
narcolepsy patients during the basal state or during SXB administration. Therefore, hypocretin 
signalling is unlikely to be a regulator of the lactotrophic system. SXB administration resulted 
in a marked increase in PRL secretion in both narcoleptics and controls. This finding is well 
in line with previous reports and might be mainly due to hyperpolarisation of dopaminergic 
structures with a reduction in dopamine release, by neurons regulating PRL secretion.
Effect of sodium oxybate on growth hormone secretion in narcolepsy patients 
and healthy controls
In chapter 3 we describe growth hormone (GH) secretion in patients and matched controls 
and the effect of SXB administration on GH and sleep in both groups. GH alterations may 
influence weight in narcolepsy. The GH concentration time series were analysed with 
AutoDecon and approximate entropy (ApEn). Basal and pulsatile GH secretion, pulse 
regularity, and frequency, as well as ApEn values, were similar in patients and controls. After 
SXB, slow-wave sleep (SWS) and, importantly, the cross correlation between GH levels and 
SWS more than doubled in both groups. In addition SXB administration caused a significant 
increase in total 24-h GH secretion rate in narcolepsy patients, but not in controls. GH has 
a potent lipolytic activity, whereas GH deficiency leads to decreases in lean body mass and 
increased fat mass.153;154 These data suggest that SXB may alter somatotropic tone in addition 
to its consolidating effect on night-time sleep in narcolepsy. Therefore, it is tempting to 
speculate that the putative weight-reducing effect of SXB is partly mediated by its stimulatory 
effect on the somatotropic axis.  
PRL secretion is not altered in hypocretin-deficient narcolepsy patients. 
SXB administration increases prolactin secretion in narcolepsy patients and controls.
GH secretion characteristics were not different in patients and controls. 
SXB increases total 24-h GH secretion in narcolepsy patients only.
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Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy 
controls: basal concentrations and response to sodium oxybate
In chapter 4 we describe a study in which we investigate whether total blood ghrelin or leptin 
levels are altered in hypocretin-deficient narcolepsy patients compared to controls, and 
whether ghrelin or leptin levels are influenced by sodium oxybate. No differences in mean 
24-h total plasma ghrelin levels or food-induced suppression of ghrelin concentrations were 
found between narcolepsy patients and controls, or any influence of 5 days of sodium oxybate 
administration in both groups. We found that the mean 24-h total leptin concentration, 
and basal and pulsatile secretion rates were not significantly different between narcolepsy 
patients and controls. While the mean leptin pulse frequency was slightly but significantly 
higher in narcolepsy patients in both conditions, the clinical relevance of this finding is unclear. 
Mechanisms underlying increased BMI and altered ingestive behaviour in narcolepsy, and 
the effects of sodium oxybate administration on weight loss, are unlikely to involve changes 
in plasma ghrelin or leptin concentrations.
altered circadian rhythm of melatonin concentrations in hypocretin deficient men
In chapter 5, we assessed whether melatonin secretion differs between narcolepsy 
patients and controls, and whether SXB affects melatonin secretion. Mean 24-h melatonin 
concentrations did not differ between narcolepsy patients and controls, either before 
or after SXB administration. However, the percentage of 24-h melatonin concentrations 
during daytime was significantly higher in narcolepsy patients, both before and after SXB 
administration. As a recent study demonstrated decreased responsivity to light in hypocretin 
deficient mice,198 it is conceivable that hypocretin signalling might be involved in the light-
induced suppression of melatonin secretion. However, the effect of hypocretin on melatonin 
secretion in humans is likely to be modest as one might expect larger differences in the 
absence of hypocretin. Our findings indicate that daytime plasma melatonin concentrations 
(as a percentage of average 24-h concentration) are elevated in narcolepsy patients. SXB 
does not affect melatonin concentrations.
Leptin secretion and ghrelin concentrations are not altered in narcolepsy.
Daytime plasma melatonin concentrations (as a percentage of average 24-h concentra-
tion) are elevated in narcolepsy patients.
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Part II mEtabolIc studIEs In narcolEPsy
Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a 
hyperinsulinemic-euglycemic clamp study
In chapter 6 we addressed the question whether narcolepsy patients are more insulin 
resistant than healthy controls. To investigate this we enrolled nine narcolepsy with cataplexy 
patients and nine, individually age, sex, BMI, fat percentage, and waist to hip ratio (WHR) 
matched healthy controls. All narcolepsy patients fulfilled the ICSD II criteria118 and were all 
HLA DQB1*06:02 positive. All patients were hypocretin deficient. None of the controls used 
medication and if patients were on medication, they stopped doing so at least two weeks 
prior to the study. All studies started at 08:30 after an overnight fast. A hyperinsulinemic-
euglycemic clamp combined with stable isotopes ([6,6-2H2]-glucose and [2H5]- glycerol) was 
performed at baseline. In seven patients a second study was performed after three months 
of SXB treatment. Glucose disposal rate per unit serum insulin was significantly higher in 
narcolepsy patients compared to matched controls, whereas β-cell function was similar. Basal 
steady state glycerol appearance rate tended to be lower in narcolepsy patients, suggesting 
a lower rate of lipolysis. SXB treatment induced a trend in reduction of the GDR and a 
reduction in endogenous glucose production per unit serum insulin. After SXB treatment 
lipolysis increased, and body weight decreased in narcolepsy patients. Thus we show that 
narcolepsy patients are more insulin sensitive and may have a lower rate of lipolysis than 
matched controls. SXB stimulated lipolysis in narcolepsy patients, possibly accounting for 
the weight loss after treatment. While SXB tended to decrease systemic insulin sensitivity, 
it increased hepatic insulin sensitivity, suggesting tissue-specific effects.
the effects of sodium oxybate on core body and skin temperature regulation 
in narcolepsy
In chapter 7 we describe the study reported in part I of this thesis but now focus on its 
metabolic part. Sleep onset is usually preceded by an increase in (distal) skin temperature 
and a decline in core body temperature.97;221 When compared with controls, an increased 
Narcolepsy patients are more insulin sensitive than healthy matched controls.
SXB reduces weight in narcolepsy patients.
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distal skin temperature and a decreased proximal skin temperature during wake is observed in 
narcolepsy patients.23 In this study we established the effect of short term SXB administration 
on skin and core temperature. Skin temperature was measured using I-buttons and core 
body temperature using the Jonah capsule in eight male hypocretin-deficient narcolepsy with 
cataplexy patients and eight matched healthy controls. At baseline, patients had significantly 
lower daytime core body and proximal skin temperatures compared to controls. In patients, 
SXB increased the nocturnal amount of slow wave sleep (SWS), increased proximal skin 
temperature towards normal levels, but there was no difference in core temperature found 
after SXB. The finding of a decreased daytime proximal skin temperature in narcolepsy 
patients compared to controls was previously demonstrated.23 In contrast to our current 
findings, this previous study also revealed a higher distal skin temperature. The combination 
of the increased distal skin temperature and the decreased proximal skin temperature in that 
study led to a higher distal-proximal temperature gradient (DPG). Under controlled conditions, 
an increase in DPG is a reliable predictor for sleep onset in healthy controls. Furthermore, 
in narcolepsy, a shorter sleep onset latency was associated with an increase of proximal and 
distal skin temperatures and, to a lesser extent, an increase of the DPG.97 However, none 
of these studies concerned spontaneous daytime napping in narcolepsy patients. Analysis 
of spontaneous naps in (semi) supine position in the present study revealed an absence of 
predictive value for any of the temperature measurements in narcolepsy patients at baseline. 
Surprisingly, during SXB administration an increase in distal skin temperature and DPG did 
become predictive for subsequent daytime sleep onset. In conclusion, administration of SXB 
normalized the sleep wake pattern as well as the skin temperature profiles in narcolepsy 
patients. Furthermore, SXB restored the relationship between skin temperature profile and 
subsequent sleep onset in patients.
Narcolepsy patients had significantly lower daytime core body and proximal skin 
temperatures compared to controls. 
With SXB administration, DPG becomes predictive for subsequent daytime sleep onset’
SXB normalizes proximal skin temperature.
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Part III othEr asPEcts of narcolEPsy
month of birth is not a risk factor for narcolepsy with cataplexy in the netherlands
Chapter 9 describes changes in seasonal birth pattern of the entire Dutch population over 
a 79-year span and compared the monthly birth pattern of Dutch narcoleptics with the 
population data. Month and year of birth were noted for 307 patients with non-familial 
narcolepsy with cataplexy, born in the Netherlands between 1923 and 2001. The numbers of 
live births per month and per year from the entire Dutch population for the same period were 
used to calculate a virtual data set of expected births per month with exactly the number of 
narcolepsy with cataplexy cases, but with the birth pattern of the Dutch population. Observed 
and expected numbers per month were compared using the chi-square test. In contrast 
to earlier reports suggesting that narcolepsy patients are more often born during spring, 
we found a peak of narcolepsy births in August. This peak was not significantly different 
from expected birth numbers in the population. In addition, no other differences between 
observed and expected number of births was found. In conclusion: An effect of birth month 
on the occurrence of narcolepsy with cataplexy was not found in a study of 307 cases after 
adjusting for changing birth patterns in the general population. This in contrast to previous 
studies reporting a significantly different seasonality of birth month in narcolepsy patients 
compared to that of the general population, supporting the autoimmune hypothesis.248-251 
Our study is the first one to analyse births per year. Other studies pooled their births over ten 
years ignoring differences in birth patterns due to war or the introduction of birth control. In 
addition it was performed in a small country without large climate differences per region. In 
contrast to the largest study on birth months which was performed in a pooled population 
from the United States, France and Canada.249 
delusional confusion of dreaming and reality in narcolepsy
In chapter 8 we describe a study in 46 narcolepsy with cataplexy patients and age-matched 
controls. Participants completed a ~30-min structured telephone interview in which they 
were asked a series of questions pertaining to sleep, dreaming, and memory. Delusional 
episodes were defined as incidents in which a fully awake participant was uncertain if a 
Birth month in narcolepsy can not support the autoimmune hypothesis.
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memory was dreamed or real, or was convinced that a memory was real, only later to 
discover that it was actually dreamed. Fleeting feelings of confusion during the transition 
to wakefulness were excluded because brief confusion is a well-known consequence of the 
hypnagogic and hypnopompic hallucinations characterizing narcolepsy. Dream delusions were 
extremely common in narcolepsy. Overall, 83% of narcolepsy patients reported that they 
had confused dreams with reality, compared to only 15% of controls. All narcolepsy patients 
reporting dream delusions provided multiple examples of such occurrences. Two-thirds of 
patients (65%) reported experiencing dream delusions at least once a week, and all but two 
(95%) had the experience at least once a month. In contrast, of the 6 controls who reported 
delusions, only 2 (5% of all controls) had experienced this more than once in their lives. 
Confusion of dreams with reality is a prevailing symptom of narcolepsy.
future perspectives
The studies described in this thesis provide new grounds for future research and implications 
for clinical practice. First, as in almost any other study, these studies should be replicated, 
preferably in larger groups. Narcoleptic men and women are equally affected but the 
endocrine study was performed only in men. Future studies should focus on women and 
children as well. When these studies are performed in premenopausal women, the menstrual 
cycle should be taken into account and all women should be measured at the same day of 
their cycle. In children it will not be feasible to perform the same study mainly due to the 
amount of blood needed. However a less extensive protocol, with fewer samples and longer 
follow up would be quite important. Precocious puberty is highly prevalent in childhood 
narcolepsy,38 and it is conceivable that those children have other endocrine disturbances as 
well. Moreover, sodium oxybate (SXB), which is prescribed off-label in narcoleptic children, 
is proven to increase growth hormone (GH) and prolactin (PRL) release in adult men with 
narcolepsy. Although, the increase of these hormones always stayed within normal limits in 
adult men, it might go beyond these limits in children. Moreover the effect of this increase 
may very well be much different in the developing child. Therefore, and for safety reasons, 
a trial with SXB including endocrine measurements in children is needed.268 
The proportion of melatonin secreted during daytime was substantially higher in narcolepsy 
patients then controls. We hypothesised that reduced responsivity to light, as found in 
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hypocretin deficient mice198 could be the cause. Since light is the major suppressor of 
melatonin synthesis,177 it is conceivable that defects in hypocretin signalling might disrupt 
light-induced suppression of melatonin secretion. To test this hypothesis the protocol should 
be repeated in the dark. If disrupted light induced suppression is the cause of the altered 
pattern in narcolepsy, one should not find differences between patients and controls in a 
protocol performed in the dark.
The mechanism of action of sodium oxybate has not been elucidated. Apart from its effect 
through the GABAB receptor,
76 our data showed that SXB further strengthened the relation 
between SWS and GH secretion, so its effect may, at least in part, be mediated by an increase 
in GHRH activity. SXB increased the regularity of GH secretion as well. This may imply that 
SXB simultaneously promotes endogenous somatostatin release, since negative feedback 
has been shown to increase secretory regularity.148 Future studies should be undertaken to 
test this hypothesis.
We measured total ghrelin levels and not the biologically active, octanoylated-ghrelin fraction. 
While there is a high correlation between the total and octanoylated fraction ghrelin level 
it remains possible that the active fraction is altered.174 A future study measuring both total 
and octanoylated fraction ghrelin will have to prove that this high correlation also exists 
in narcolepsy. Mechanisms underlying increased BMI and altered ingestive behaviour in 
narcolepsy and the effects of SXB administration on GH release and weight loss are unlikely 
to involve changes in total plasma ghrelin or leptin concentrations. However, our study was 
done under strictly controlled lab circumstances with standardised meals at predetermined 
mealtimes. It is possible that in everyday life with different lifestyles and mealtimes alterations 
may be found. Therefore a study should be done under less controlled conditions with ad 
libitum food and bed times.  
With our hyperinsulinemic-euglycemic clamp study we proved that narcolepsy patients are 
more insulin sensitive than matched controls. Therefore it is less conceivable that narcolepsy 
patients are more prone to get type 2 diabetes than controls. It would be interesting to 
determine the cause of our finding of increased insulin sensitivity in narcoleptics, since 
this finding may have implications for diabetes treatment or even prevention. There was a 
trend towards lower lipolysis in narcolepsy patients, which could be part of the reason why 
they grow obese. Future studies in larger groups with enough power to clarify if this is a 
real difference are needed. So far, it remains unclear why narcolepsy patients gain weight, 
usually shortly after disease onset. A study using a 24 h respiration chamber in combination 
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with doubly labelled water and tri-axial accelerometer would provide interesting information 
as to whether altered energy expenditure explains obesity in narcolepsy.
The temperature differences found between narcolepsy patients and controls, and the 
normalisation of skin temperature under SXB, were obtained at a lab under strictly controlled 
circumstances in which subjects remained (semi)supine for 24 , a position known to influence 
skin temperature and a position that people usually do not keep for 24 h. It would be very 
interesting to measure skin and core temperature in an ambulatory situation in which 
subjects try to live their normal lives. In addition an increase in distal skin temperature and 
DPG became predictive for subsequent daytime sleep onset during SXB administration. 
If sleep onset is predictable from temperature differences in normal daily life one can 
think of developing practical solutions. It may be possible to prevent unwanted sleep by 
connecting temperature sensors to an alarm system while driving or performing monotonous 
tasks.
It is still unknown why people lose functioning hypocretin cells and develop narcolepsy. 
Although, support for an autoimmune cause is getting stronger and stronger, the modified 
Witebsky’s postulates should be met including direct evidence from transfer of pathogenic 
antibody or pathogenic T cells; indirect evidence based on reproduction of the autoimmune 
disease in experimental animals; and circumstantial evidence from clinical clues.269 Studies 
on birth month are an indirect way to make an autoimmune cause for the disease more 
likely. We could not confirm this with our study on birth months. Researchers are getting 
closer to the autoimmune origin of narcolepsy, but there is still a lot of work to do before 
the modified Witebsky’s postulates269 are fulfilled and autoimmunity is proven. 
Last but not least, with our study on dream delusions we reveal an underappreciated and 
very common symptom of narcolepsy. It may be helpful to mention these dream delusions 
when taking a patients history: because mentioning these delusions may help the patient to 
recognise this problem as a symptom of narcolepsy. Since the symptom is highly prevalent 
in narcolepsy patients it is important to establish the prevalence of this symptom in patients 
with other hypersomnias and estimate its specificity. Though the underlying mechanism 
of dream delusions is unknown, it is clear that many people with narcolepsy have a 
surprising and intense difficulty distinguishing the dreamed from the real. In concert, these 
patients perceive themselves as having more general difficulties with both retrospective 
and prospective memory. These observations highlight the possibility of source memory 
deficits in narcolepsy that have not yet been fully characterized and need more research. 
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Summary, conclusions and future perspectives
10
f-MRI studies might be helpful to clarify the underlying mechanisms by finding differences 
in activity of hippocampal, prefrontal or other brain regions during different memory 
tasks. Sleep should be recorded during f-MRI studies, and advanced neuropsychological 
testing may help to identify and tackle the specific memory problems described in 
narcolepsy which so far have not been detected with formal tests. In addition, narcolepsy 
patients with dream delusions should be compared with patients without delusions and 
controls.
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Algemene inleiding en doelstellingen vAn dit 
proefschrift
Een kort overzicht van de symptomen, de pathofysiologie en de behandeling van narcolepsie 
wordt gegeven in hoofdstuk 1. Narcolepsie wordt veroorzaakt door een tekort aan de 
neurotransmitter hypocretine in het brein en gekenmerkt door de volgende klassieke 
symptomen: overmatige slaperigheid overdag, kataplexie, hypnagoge hallucinaties, 
slaapverlamming en een verstoorde nachtelijke slaap. Daarnaast zijn er talrijke andere 
symptomen zoals overgewicht en endocriene stoornissen. Natriumoxybaat (sodium oxybate, 
SXB) is een medicament dat veel van de symptomen van narcolepsie kan verbeteren. 
Bovendien kan het de hormoonhuishouding en het metabolisme beïnvloeden zoals wordt 
beschreven in deel I en II van dit proefschrift.
Deel I enDocrIene onDerzoeken bIj narcolepsIe
In deel I beschrijven we een groot endocrienonderzoek bij narcolepsie, vóór en na 5 dagen 
gebruik van SXB. Acht mannelijke hypocretine-deficiënte narcolepsiepatiënten en acht 
controles gematcht voor geslacht, leeftijd, body mass index (BMI), waist-to-hip ratio en 
percentage lichaamsvet werden in dit onderzoek geïncludeerd. Alle narcolepsiepatiënten 
voldeden aan de ICSD II criteria118 en ze waren allemaal HLA DQB1 * 06:02 positief. Daarnaast 
waren alle patiënten ten minste 2 weken vóór aanvang van het onderzoek vrij van medicatie. 
Geen van de controles nam medicatie. Patiënten en controles ondergingen een 24 uur 
durend onderzoek waarbij bloed werd afgenomen voor de meting van prolactine (PRL) en 
groeihormoon (GH) (10 min interval), leptine (20 min interval), en ghreline en melatonine 
(1 uur interval). Dit werd gedaan tijdens de baselinemeting en op de vijfde dag van SXB-
toediening. Er werd twee keer per nacht 3 gram SXB ingenomen gedurende 5 opeenvolgende 
nachten. Proefpersonen bleven gedurende het hele onderzoek in (half)liggende positie, met 
uitzondering van toiletbezoek. Drie gestandaardiseerde maaltijden werden genuttigd, en 
cafeïnevrije thee en water werden naar behoefte verstrekt. Het was toegestaan overdag te 
slapen, en het licht werd uitgedaan tussen 23:00 en 7:30 de volgende ochtend. Slaap werd 
continue polygrafisch gemeten gedurende beide onderzoeksperiodes.
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natriumoxybaat verhoogt prolactinesecretie bij narcolepsiepatiënten en gezonde 
controles 
Hoofdstuk 2 behandelt de vraag of plasma prolactine (PRL) concentraties verschillen tussen 
hypocretine-deficiënte narcolepsiepatiënten en controles. Daarnaast hebben we gekeken 
naar het effect van SXB op PRL-afgifte in beide groepen. De PRL-concentratietijdreeksen 
werden geanalyseerd met een automatisch deconvolutieprogramma, approximate entropy 
(ApEn) en Cosinor-analyse. ApEn is een modelonafhankelijke statistiek die gebruikt wordt 
om de regulariteit van een tijdreeks te kwantificeren, hier PRL-afgifte. Zowel basale als 
pulsatiele PRL-secretie, pulsregulariteit en -frequentie, ApEn en 24-uurs parameters waren 
vergelijkbaar in patiënten en controles. SXB-toediening veroorzaakte een soortgelijke 
nachtelijke toename in PRL-secretie, een vervroeging van de acrophase, en een afname 
van de ApEn bij patiënten en controles. Het effect op de slaap van SXB bestond uit een 
toename in diepe slaap die vergelijkbaar was bij patiënten en controles. Bij dit gedetailleerde 
onderzoek werd op beide meetmomenten geen veranderde PRL-secretie vastgesteld bij 
hypocretine-deficiënte narcolepsiepatiënten. Daarom is het onwaarschijnlijk dat hypocretine 
een regulator van het lactotrofe systeem is. SXB-toediening resulteerde in een aanzienlijke 
toename van PRL-secretie in zowel narcolepsiepatiënten als controles. Deze bevinding is 
in overeenstemming met eerdere publicaties, en wordt mogelijk veroorzaakt door SXB 
geïnduceerde hyperpolarisatie van dopaminerge neuronen met een vermindering van 
dopamine-afgifte, door neuronen die de PRL-secretie reguleren.75
effect van sXb op groeihormoonsecretie bij narcolepsiepatiënten en gezonde 
controles
In hoofdstuk 3 wordt de groeihormoon (GH) secretie, en het effect van SXB-toediening op 
GH en slaap bij narcolepsiepatiënten en controles beschreven. Dit is relevant, omdat GH-
verlaging gewicht kan doen toenemen.153 De GH-concentratie tijdsreeksen zijn geanalyseerd 
met AutoDecon en ApEn. Basale en pulsatiele GH-secretie, pulseregulariteit en -frequentie, 
en ook ApEn waarden waren vergelijkbaar in patiënten en controles. Na SXB toediening 
werd in beide groepen een ruime verdubbeling gevonden van slow-wave sleep (SWS) 
PRL-secretie is niet veranderd bij hypocretine-deficiënte narcolepsiepatiënten ten 
opzichte van gezonde controles. 
SXB-toediening verhoogt PRL-secretie in narcolepsiepatiënten en controles.
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en, niet onbelangrijk, van de crosscorrelatie tussen GH-concentratie en SWS. Daarnaast 
veroorzaakte SXB-toediening een significante toename in het totale 24-uurs GH-secretie 
bij narcolepsiepatiënten, maar niet bij controles. GH heeft een sterk lipolytisch vermogen, 
terwijl GH-deficiëntie leidt tot vermindering van de lean body mass en toename van 
vetmassa.153;154 Deze data suggereren dat SXB, naast het consoliderend effect op nachtslaap in 
narcolepsiepatiënten, ook de somatotrofe tonus verandert. Het is dan ook verleidelijk om te 
speculeren dat het vermeende gewichtreducerende effect van SXB gedeeltelijk veroorzaakt 
wordt door het stimulerende effect op de somatotrofe as.  
Totale plasma ghreline- en leptineconcentraties bij narcolepsiepatiënten en 
gematchte controles: basale concentraties en respons op natriumoxybaat
In hoofdstuk 4 wordt onderzocht of het totale plasma ghreline- en/of leptineconcentraties 
veranderd zijn bij hypocretine-deficiënte narcolepsiepatiënten vergeleken met controles, 
en of ghreline- en leptineconcentraties beïnvloed worden door SXB. Er werd geen verschil 
waargenomen in 24-uurs totale ghrelineconcentraties of postprandiale suppressie van 
ghreline tussen patiënten en controles. Evenmin werd er een invloed van 5 dagen SXB-
toediening op de ghrelineconcentratie gevonden. Er was geen significant verschil tussen 
de 24-uurs totale leptineconcentratie en basale en pulsatiele secretie tussen beide 
groepen. De gemiddelde leptine pulsfrequentie was licht, maar significant verhoogd bij 
narcolepsiepatiënten in beide condities. De klinische relevantie van deze bevinding is 
onduidelijk. De resultaten maken het in ieder geval onwaarschijnlijk dat veranderingen in 
plasma ghreline- of leptineconcentraties een rol spelen bij de toegenomen BMI bij mensen 
narcolepsie. Ook is het niet aannemelijk dat plasma ghreline- of leptineconcentraties van 
invloed zijn op het effect van SXB-toediening op gewichtsverlies.
Leptinesecretie en ghrelineconcentraties zijn niet afwijkend bij narcolepsiepatiënten.
GH-secretiekarakteristieken zijn niet verschillend tussen patiënten en controles. 
SXB verhoogt de totale 24-h GH-secretie alleen bij narcolepsiepatiënten.
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Veranderd circadiaan ritme van melatonineconcentraties in hypocretine-
deficiënte mannen
In hoofdstuk 5 is onderzocht of melatonineconcentraties verschillen tussen narcolepsie-
patiënten en controles, en of SXB-toediening melatonine-afgifte beïnvloedt. 24-uurs 
melatonineconcentraties verschilden niet tussen narcolepsiepatiënten en controles, noch 
vóór, noch tijdens SXB-toediening. Echter, het percentage 24-uurs melatonineconcentratie 
dat overdag werd uitgescheiden was significant hoger in narcolepsiepatiënten, zowel vóór 
als tijdens SXB-toediening. Een recent onderzoek liet een verminderde reactie op licht zien 
in hypocretine-deficiënte muizen.198 Het is voorstelbaar dat hypocretine neurotransmissie 
betrokken is bij de licht-geïnduceerde suppressie van melatoninesecretie. Het effect van 
hypocretine op melatoninesecretie is bij mensen waarschijnlijk bescheiden, omdat men 
een groter verschil mag verwachten als er helemaal geen hypocretine aanwezig is. Onze 
bevindingen laten zien dat plasma-melatonineconcentraties overdag zijn toegenomen bij 
narcolepsiepatiënten (als percentage van de gemiddelde 24-uurs afgifte). SXB heeft geen 
effect op de gemiddelde melatonineconcentratie.
Deel II MeTabool onDerzoek bIj narcolepsIe
Glucose- en vetmetabolisme bij narcolepsie en het effect van natriumoxybaat: 
een hyperinsulinemische-euglycemische clampstudie
In hoofdstuk 6 werd onderzocht of narcolepsiepatiënten meer insuline-resistent zijn dan 
gezonde controles. Om deze vraag te beantwoorden hebben we negen hypocretine-deficiënte 
narcolepsie-met-kataplexie-patiënten, en negen leeftijd-, geslacht-, BMI- en vetpercentage-
gematchte controles geïncludeerd. Alle narcolepsiepatiënten voldeden aan de ICSD II 
criteria118 en ze waren allemaal HLA DQB1 * 06:02 positief. Geen van de controles gebruikte 
medicatie en als patiënten medicatie gebruikten, staakten ze deze ten minste twee weken 
voorafgaand aan het onderzoek. De onderzoeksdagen begonnen om 08:30 na gedurende 
de nacht gevast te hebben. Een hyperinsulinemische-euglycemische clamp gecombineerd 
met stabiele isotopen ([6,6-2 H 2] - glucose en [2H 5] - glycerol) werd uitgevoerd op baseline. 
Plasma-melatonineconcentraties overdag zijn toegenomen bij narcolepsiepatiënten 
(als percentage van de 24-uurs afgifte).
Samenvatting, conclusies en toekomstperspectieven
158
Daarnaast werd bij zeven patiënten een tweede clamp uitgevoerd na drie maanden van 
klinisch succesvolle SXB-behandeling. Glucose-omzetting per eenheid seruminsuline (GDR) 
was significant hoger bij narcolepsiepatiënten vergeleken met controles, terwijl β-cel-functie 
vergelijkbaar was. Er bestond een neiging tot lagere glycerolproductiesnelheid bij patiënten, 
wat kan duiden op een afgenomen lipolyse. SXB-behandeling induceerde een trend in 
de verlaging van de GDR en een afname van de endogene glucoseproductie per eenheid 
seruminsuline. Na SXB-behandeling was lipolyse toegenomen, en lichaamsgewicht gedaald 
bij narcolepsiepatiënten. Dit laat zien dat narcolepsiepatiënten meer insulinegevoelig zijn 
en wellicht een lagere lipolyse hebben dan gematchte controles. SXB stimuleert lipolyse 
bij narcolepsiepatiënten, wat mogelijk deels verantwoordelijk is voor het gewichtsverlies 
tijdens de behandeling. Hoewel SXB de neiging heeft om de systemische insulinegevoeligheid 
te verminderen, doet het de hepatische insulinegevoeligheid toenemen. Dit suggereert 
weefselspecifieke effecten van SXB.
De effecten van natriumoxybaat op kerntemperatuur- en huidtemperatuur-
regulatie bij narcolepsie
In hoofdstuk 7 worden metabole resultaten beschreven van het onderzoek wat beschreven 
is in deel I van dit proefschrift. Het begin van slaap wordt doorgaans voorafgegaan door 
een toename in (distale) huidtemperatuur en een afname in kerntemperatuur.97;221 Bij 
narcolepsiepatiënten wordt er tijdens waak een toegenomen distale huidtemperatuur 
en een afgenomen kern temperatuur gevonden ten opzichte van controles.23;25 In dit 
onderzoek hebben we gekeken naar het effect van korte termijn SXB-toediening op 
huid- en kerntemperatuur. Huidtemperatuur werd gemeten met gebruik van I-buttons, 
en kerntemperatuur door de Jonahcapsule, bij acht hypocretine-deficiënte mannelijke 
narcolepsiepatiënten en acht gematchte gezonde controles. Tijdens de baselinemeting 
hadden patiënten overdag een significant lagere kern temperatuur en proximale 
huidtemperatuur dan controles. SXB verhoogde bij patiënten de proximale huidtemperatuur 
tot normale waarden, maar er werd geen verschil in kerntemperatuur gevonden na SXB-
toediening. De verlaagde proximale huidtemperatuur overdag bij narcolepsiepatiënten ten 
opzichte van controles is eerder beschreven.23 Echter in tegenstelling tot onze bevindingen, 
Narcolepsiepatiënten zijn insulinegevoeliger dan gematchte controles.
SXB reduceert gewicht bij narcolepsiepatiënten.
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vond men bij het eerdere onderzoek ook een hogere distale huidtemperatuur. De combinatie 
van toegenomen distale huidtemperatuur en verlaagde proximale huidtemperatuur leidde in 
eerder onderzoek tot een hogere distale-proximale gradiënt (DPG). Een toegenomen DPG is 
onder gecontroleerde omstandigheden een goede voorspeller voor sleep onset bij gezonde 
controles.219 Bovendien werd bij narcolepsie een korte inslaaplatentie gevonden bij een 
toename van proximale en distale temperaturen en in mindere mate ook bij een toename 
van de DPG, hoewel geen van deze onderzoeken gekeken heeft naar spontaan indutten bij 
narcolepsiepatiënten. Baseline-analyse van temperatuurdata rondom spontane dutjes in 
(half)liggende positie uit het huidige onderzoek, leverde geen goed voorspellende waarden op 
bij narcolepsiepatiënten. Verrassend genoeg was een toename in distale huidtemperatuur en 
DPG wel voorspellend voor naderende slaap overdag tijdens SXB-toediening. We concluderen 
dat SXB-toediening het slaap-waakpatroon evenals de huidtemperatuurprofielen bij 
narcolepsiepatiënten normaliseert. Daarnaast herstelt SXB de relatie tussen huidtemperatuur 
en sleep onset bij narcolepsiepatiënten.
Deel III anDere aspecTen Van narcolepsIe
Geboortemaand is geen risicofactor voor narcolepsie met kataplexie in nederland
Hoofdstuk 9 beschrijft seizoensveranderingen in geboortepatronen van de hele Nederlandse 
bevolking over een periode van 79 jaar, vergeleken met het geboortepatroon van Nederlandse 
narcolepsiepatiënten. Onderzoek naar geboortepatronen wordt verricht om een auto-
immuun oorzaak voor ziekte aannemelijker te maken. Voor een auto-immuunaandoening 
geldt vaak een door het seizoen bepaalde verhoogde of verlaagde kans op het ontwikkelen 
van de aandoening. Geboortemaand- en jaar werden genoteerd van 307 patiënten met niet-
familiaire narcolepsie met kataplexie, die in Nederland geboren zijn tussen 1923 en 2001. 
Het aantal levendgeborenen per maand en per jaar van de gehele Nederlandse populatie 
voor dezelfde periode werd gebruikt om een virtuele dataset van verwachte geboorten per 
Narcolepsiepatiënten hebben overdag een lagere kerntemperatuur en proximale 
huidtemperatuur dan gematchte controles. 
Met SXB-toediening wordt DPG overdag voorspellend voor naderende slaap.
SXB normaliseert proximale huidtemperatuur.
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maand te creëren en dit te vergelijken met de geboortemaand van de narcolepsie-met-
kataplexie-patiënten in hetzelfde jaar. Waargenomen en verwachte aantallen per maand 
werden vergeleken met behulp van de Chi-kwadraattest. Eerdere publicaties247-250 vonden een 
geboortepiek in het voorjaar, wij vonden een piek van narcolepsiegeboorten in augustus. Deze 
piek was echter niet anders dan de verwachte geboortegetallen in de bevolking. Daarnaast 
werden er geen andere verschillen gevonden tussen de verwachte en de geobserveerde 
aantallen geboortes. Concluderend werd er geen effect van geboortemaand gevonden op 
het voorkomen van narcolepsie bij een onderzoek naar 307 patiënten als er gecorrigeerd 
werd voor geboortepatronen van de gehele bevolking. Dit in tegenstelling tot eerdere 
studies waarbij een aanzienlijk verschil in seizoensgebonden karakter van geboortemaand 
werd gevonden bij narcolepsiepatiënten vergeleken met die van de algemene populatie. 
Ons onderzoek is de eerste die geboortes per jaar bekeken heeft. Andere studies voegden 
geboortes per tien jaar samen en negeerden daarmee veranderingen in geboortepatronen 
door bijvoorbeeld oorlog of de introductie van hormonale anticonceptie. Daarnaast is 
ons onderzoek verricht in een klein land zonder grote klimaatveranderingen per regio in 
tegenstelling tot de grootste studie naar geboortemaand bij narcolepsie die een populatie 
samengevoegd heeft van de Verenigde Staten, Canada en Frankrijk.249 
Verwarring tussen dromen en realiteit bij narcolepsie
In hoofdstuk 8 beschrijven we een onderzoek bij 46 narcolepsie-met-kataplexie-patiënten 
en leeftijd-gematchte controles. Deelnemers voltooiden een ongeveer 30-mininuten durend 
gestructureerd telefonisch interview waarin zij een aantal vragen met betrekking tot slapen, 
dromen en geheugen beantwoordden. Delusionele episodes werden gedefinieerd als 
toestanden waarin de deelnemer volledig wakker was, maar onzeker of een herinnering 
gedroomd was of echt, of overtuigd was dat een herinnering echt was, en later ontdekte 
dat het toch gedroomd moest zijn. Kortstondige gevoelens van verwarring bij de overgang 
van slaap naar waak werden uitgesloten omdat korte verwarring een bekend gevolg is van 
hypnagoge en hypnopompe hallucinaties die karakteristiek zijn voor narcolepsie. Delusionele 
verwarring tussen droom en realiteit kwam erg veel voor bij narcolepsie. Al met al rapporteerde 
83% van de narcolepsiepatiënten dat zij dromen verwarden met realiteit, vergeleken met 
15% van de controles. Alle narcolepsiepatiënten die droomdelusies rapporteerden konden 
Geboortemaand bij narcolepsie kan de auto-immuunhypothese niet ondersteunen.
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meerdere voorbeelden van zulke gebeurtenissen noemen. Tweederde van de patiënten 
(65%) rapporteerde minstens één keer per week een droomdelusie te ervaren, en op twee 
na (95%) hadden ze allemaal minstens één keer per maand een dergelijke ervaring. Dit in 
tegenstelling tot zes controles die droomdelusies hadden, waarvan er slechts twee (5% van 
alle controles) dit meer dan eens hebben meegemaakt in hun leven. Kortom, delusionele 
verwarring tussen droom en realiteit komt veelvuldig voor bij narcolepsiepatiënten, maar 
zelden bij controles, en verdient daarom meer aandacht in de dagelijkse praktijk. 
ToekoMsTperspecTIeVIeVen
Het onderzoek beschreven in dit proefschrift levert nieuwe aanknopingspunten voor 
toekomstig onderzoek en heeft daarnaast implicaties voor de klinische praktijk. Ten eerste 
moeten de onderzoeken, net als bij bijna alle onderzoeken, worden gerepliceerd, bij voorkeur 
in grotere groepen. Mannen en vrouwen met narcolepsie zijn vergelijkbaar aangedaan, maar 
ons endocriene onderzoek werd alleen bij mannen uitgevoerd. Toekomstige onderzoeken 
zouden zich ook moeten richten op vrouwen en kinderen. Wanneer deze onderzoeken 
worden uitgevoerd in premenopauzale vrouwen, moet rekening worden gehouden met 
de menstruele cyclus, en dienen alle vrouwen te worden gemeten op dezelfde dag van 
hun cyclus. Bij kinderen zal het niet haalbaar zijn om hetzelfde onderzoek te herhalen, 
wat voornamelijk te wijten is aan de hoeveelheid bloed die afgenomen moet worden voor 
de analyses. Maar een minder uitgebreid protocol, met minder bloedmonsters en een 
langere follow-up is van groot belang. Pubertas praecox komt veel voor bij narcolepsie in de 
kinderjaren,38 en het is voorstelbaar dat deze kinderen ook andere endocriene afwijkingen 
hebben. Bovendien verhoogt SXB, dat off-label voorgeschreven wordt aan kinderen, bij 
volwassenen met narcolepsie groeihormoon- en prolactine-afgifte. Hoewel de toename 
van deze hormonen binnen normale grenzen bleef bij volwassen mannen, is het mogelijk 
dat bij kinderen deze grens overstegen wordt. Bovendien kunnen de gevolgen van een 
dergelijke toename in hormoonconcentraties heel anders zijn bij het zich ontwikkelende 
kind. Daarom, en om veiligheidsredenen, is een trial met SXB met inbegrip van hormonale 
controle bij kinderen nodig.268
Het percentage van melatonine dat overdag uitgescheiden wordt was aanzienlijk hoger bij 
narcolepsiepatiënten dan bij controles. We hadden de hypothese dat verlaagde responsiviteit 
Verwarring tussen droom en realiteit is een veelvoorkomend symptoom van narcolepsie.
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op licht, zoals gevonden werd bij hypocretine-deficiënte muizen,198 een oorzaak zou kunnen 
zijn. Omdat licht de grootste onderdrukker van melatoninesynthese is,177 is het denkbaar dat 
afwijkingen in hypocretinefunctie lichtgeïnduceerde onderdrukking van melatoninesecretie 
kunnen verstoren. Om deze hypothese te testen moet het protocol worden herhaald in het 
donker. Als een verstoorde lichtgeïnduceerde onderdrukking de oorzaak is van het veranderde 
afgiftepatroon bij narcolepsiepatiënten, zou men geen verschillen tussen patiënten en 
controles vinden bij een protocol uitgevoerd in het donker.
Afgezien van het effect van SXB op de GABAB-receptor is het werkingsmechanisme vooralsnog 
niet opgehelderd.76 Uit onze data is gebleken dat SXB de relatie tussen SWS- en GH-secretie 
versterkt, zodat het effect ervan, op zijn minst gedeeltelijk, zou kunnen worden veroorzaakt 
door een verhoging van de GHRH activiteit. SXB verhoogt ook de regulariteit van de GH-
secretie. Dit kan betekenen dat SXB gelijktijdig endogene somatostatinerelease bevordert, 
omdat is aangetoond dat negatieve feedback secretoire regulariteit verhoogt.148 Toekomstig 
onderzoek zou deze hypothese moeten bevestigen.
We hebben totale ghrelineconcentraties en niet het biologisch actieve hexatropine (met een 
octanoylgroep) gemeten. Hoewel er een hoge correlatie bestaat tussen het totale ghreline 
en hexatropine,174 blijft de mogelijkheid bestaan dat er een verandering bestaat in de 
actieve vorm. Een toekomstig onderzoek zou moeten uitwijzen of er ook een hoge correlatie 
bestaat tussen beide vormen van ghreline bij narcolepsiepatiënten. Het is onwaarschijnlijk 
dat leptine en ghreline betrokken zijn bij de mechanismen die ten grondslag liggen aan een 
verhoogde BMI bij mensen met narcolepsie. Ook lijken leptine en ghreline niet betrokken 
te zijn bij de effecten van SXB op GH-secretie en gewichtsverlies. Echter, ons onderzoek is 
onder strikte laboratoriumomstandigheden uitgevoerd met gestandaardiseerde maaltijden 
op vooraf bepaalde tijden. Het is mogelijk dat er in het dagelijks leven, met andere leefstijlen 
en etenstijden, toch veranderingen gevonden worden. Om dit vast te stellen zou er een 
studie gedaan kunnen worden onder minder gecontroleerde condities met zelfgekozen 
voedings- en bedtijden.  
Met de hyperinsulinemische-euglycemische clampstudie werd aangetoond dat narcolepsie-
patiënten insulinegevoeliger zijn dan gematchte controles. Daarom is het minder aannemelijk 
dat narcolepsiepatiënten meer vatbaar zijn voor het krijgen van diabetes type 2. Het is van 
belang om de oorzaak hiervan te achterhalen omdat het implicaties kan hebben voor de 
behandeling van diabetes of zelfs preventie hiervan. Er was een trend in de richting van een 
lagere lipolyse bij narcolepsiepatiënten, wat voor een deel zou kunnen verklaren waarom ze 
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overgewicht krijgen. Toekomstig onderzoek in grotere groepen met genoeg power is nodig 
om op te helderen of er een daadwerkelijk verschil in lipolyse bestaat. Tot nu toe blijft het 
onduidelijk waarom narcolepsiepatiënten in gewicht toenemen, doorgaans kort na het 
begin van de ziekte. Onderzoek in een respiratiekamer, waarbij energiegebruik berekend 
wordt op basis van de uitgeademde lucht tijdens het verblijf in de kamer, in combinatie met 
dubbel gelabeld water, waarmee energiegebruik over langere perioden bepaald kan worden 
middels isotopen in de urine, en meting van de fysieke activiteit zou kunnen helpen de vraag 
te beantwoorden of een veranderd energiegebruik en/of lichamelijke activiteit een oorzaak 
is voor het overgewicht bij narcolepsie.
De temperatuurverschillen die gevonden werden tussen narcolepsiepatiënten en controles, 
en de normalisatie van huidtemperatuur onder SXB, werden verkregen onder strikt 
gecontroleerde laboratoriumomstandigheden waarbij de deelnemers gedurende 24 h in 
(half)liggende positie bleven. Een houding waarvan bekend is dat het de huidtemperatuur 
beïnvloedt en een houding waarin mensen doorgaans niet 24 uur in blijven. Het zou 
interessant zijn om huid- en kerntemperatuur te meten in een ambulante toestand, waarbij 
de deelnemers zoveel mogelijk proberen hun normale dagelijkse bezigheden vol te houden. 
Daarnaast bleken onder SXB een toegenomen distale huidtemperatuur en DPG voorspellend 
voor een opkomende slaapperiode overdag. Wanneer slaapperiodes voorspeld kunnen 
worden door temperatuurwisselingen in het dagelijkse leven, komen wellicht praktische 
toepassingen in zicht. Het zou mogelijk kunnen zijn om ongewenste slaap te voorkomen 
door temperatuursensors te koppelen aan een alarmsysteem tijdens autorijden of monotone 
taken. 
Het is nog altijd onbekend waarom sommige mensen goed functionerende hypocretinecellen 
verliezen en daarmee narcolepsie krijgen. Hoewel er steeds meer aanwijzingen komen 
voor een auto-immuunoorzaak, is het bewijs nog steeds niet geleverd. Om een auto-
immuunoorzaak te bewijzen moet voldaan zijn aan de gemodificeerde Witebskycriteria,269 
inclusief direct bewijs uit overdracht van pathogeen antilichaam of pathogene T-cellen; 
indirect bewijs gebaseerd op overbrenging van de auto-immuunaandoening in proefdieren, 
en indirect bewijs vanuit klinische aanwijzingen. Onderzoeken naar geboortemaanden zijn 
een heel indirecte manier om een auto-immuunoorzaak voor een aandoening aannemelijker 
te maken. Wij konden dit niet bevestigen met ons onderzoek naar geboortemaand. 
Onderzoekers komen steeds dichter bij het bewijs voor een auto-immuunoorzaak van 
narcolepsie, maar er is nog steeds veel werk te verzetten voordat aan de gemodificeerde 
Witebskycriteria voldaan wordt en auto-immuniteit is bewezen. 
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Tot slot hebben we met ons onderzoek naar delusionele verwarring tussen droom en 
realiteit een ondergewaardeerd, maar veel voorkomend probleem bij narcolepsie onthuld. 
Het kan nuttig zijn om deze verwarringen te benoemen bij de anamnese omdat het op 
deze manier herkend kan worden als symptoom van de aandoening. Gezien de hoge 
prevalentie van dit probleem bij narcolepsie is het van belang om uit te zoeken of dit ook 
veel voorkomt bij andere hypersomnieën en daarbij zijn specificiteit te bepalen. Hoewel 
het onderliggende mechanisme van de droomdelusies niet duidelijk is, is het duidelijk 
dat mensen met narcolepsie vaak moeilijkheden hebben met het onderscheiden van het 
gedroomde met de realiteit. Hiermee samenhangend hebben patiënten het idee dat ze in 
het algemeen meer moeite hebben met zowel retrospectief als prospectief geheugen. Deze 
observaties onderstrepen de mogelijkheid dat er iets mis kan zijn met het brongeheugen 
bij narcolepsiepatiënten wat vooralsnog nog niet opgehelderd is. F-MRI-onderzoeken 
kunnen behulpzaam zijn om onderliggende mechanismen op te helderen door tijdens 
geheugentaken verschillen in activiteit aan te tonen in de hippocampus, prefrontale of in 
andere hersengebieden. Slaap zou tijdens f-MRI-onderzoeken geregistreerd moeten worden 
en geavanceerde neuropsychologische tests zijn nodig om de specifieke geheugenproblemen 
die bij narcolepsie beschreven worden, maar nooit aangetoond zijn met gangbare tests, te 
detecteren. Daarnaast zou het interessant zijn om narcolepsiepatiënten met droomdelusies 
te vergelijken met narcolepsiepatiënten zonder droomdelusies om een betere verklaring 
voor het probleem te vinden. 
Er wordt veel onderzoek naar narcolepsie verricht en ik heb daar mijn steentje aan bijgedra-
gen, en hoop dat in de toekomst te blijven doen totdat het niet meer nodig is.
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